BIT LATE THIS MORNING BUT WE NOW
HAVE QUORUM SO WE WILL GO AHEAD
AND GET STARTED.
SO GOOD MORNING.
WELCOME TO SECOND DAY OF COUNCIL
OF COUNCILS FOR THIS SEPTEMBER
MEETING.
I NEED TO BANG MY GAVEL.
WE'RE NOW BACK IN SESSION.
SO YESTERDAY WHAT WAS A REALLY
GREAT DAY, I THINK WE HAD SOME
REALLY THOUGHTFUL DISCUSSION
THAT WAS REEL KEEPSAKESLY ROBUST
AND RICH AND WE HEARD ABOUT SOME
UPDATES FROM NOT JUST DPC PSI,
AND THE WORK WE'RE DOING BUT
FROM LARRY TARK BAK OUR
PRINCIPAL DEPUTY DIRECTOR,
ACROSS NIH, HEARD ABOUT ALL OF
US ABOUT 2 DIFFERENT
PRESENTATIONS ABOUT 2 GENERAL
UPDATES AND THE UPCOMING GENERAL
DATA RELEASE AS WELL AS THE
WORKING GROUP REPORT WHICH WAS
ACCEPTED BY COUNCIL AND THEN WE
HAD A COUPLE CONCEPT CLEARANCES
THAT WERE ALL APPROVED.
SO THAT'S GREAT.
SO TODAY IS CONCEPT CLEARANCE
DAY.
WE HAVE 4 CONCEPTS THAT WE'RE
TALKING ABOUT TO GET HOPEFULLY
CLEARED.
IT'S AMBITIOUS BUT WE'RE STILL
TRYING TO GET EVERYONE OUT OF
HERE BY 12:35 BECAUSE I KNOW
PEOPLE HAVE PLANES AND TRAINS
THAT THEY NEAD TO CATCH.
IF WE COULD GO TO THE NEXT SLIDE
REALLY QUICKLY, 1 THING I WANT
TO MENTION AND WE WILL TALK
ABOUT IT THEA THE END OF THE
MEETING BUT WE HAVE A SLIDE UP
THAT WE WOULD APPRECIATE YOUR
FEEDBACK ON, SO I THINK THERE
WERE--ARE THERE PRINT OUTS, YES,
YOU SHOULD HAVE PRINT OUTS OF
THE QR CODE IF YOU COULD SCAN
THAT OR GO TO THE
SLIDO.COMWEBSITE AND ENTER THE
CODE.
TWO QUESTIONS JUST ABOUT THE
IN-PERSON MEETING, JUST WHETHER
OR NOT THERE'S A DESIRE FOR
FOLKS TO HAVE MORE THAN 1 PER
YEAR AND IF SO WHICH 1S BECAUSE
WE ALWAYS HAVE 3, SO TRYING TO
GET MORE INFORMATION ON YOU ALL
AND WHAT YOUR PREFERENCES ARE
AND THEN WE WILL CIRCLE BACK AT
THE END OF THE DAY.
SO IF YOU CAN COMPLETE THAT,
THAT WOULD BE REALLY HELPFUL.
YEAH, THE FOLKS ONLINE, YEAH, IF
YOU CAN JUST TAKE A QUICK SHOT
OR WE'LL MAKE SURE THAT YOU HAVE
THE LINK.
OKAY, GREAT.
THANK YOU.
ALL RIGHT, NOW, WITH THAT
BECAUSE WE LEFT A LOT OF TIME
FOR WELCOMING REMARKS AND WE HAD
VERY FEW THAT ALLOWED US TO
BASICALLY CATCH UP ON TIME.
SO WE'LL DIVE INTO OUR FIRST
CONCEPT CLEARANCE FOR THE TAME
WHICH IS FROM THE ENVIRONMENTAL
INFLUENCES ON CHILD HEALTH
OUTCOMES OR ECHO PROGRAM.
DR. LESLIE THOMPSON HEALTH
SCIENCE POLICY ANALYST IN ECHO,
WILL PRECEPT THE CONCEPT
ENTITLED EXPANDING ACCESS TO
ECHO COHORT DATA AND
BIOSPECIMENS THROUGH AN XO1.
AND THEN THE PRESENTATION WILL
BE FOLLOWED BY COMMENTS FROM 2
OF THIS WITH COUNCIL MEMBERS FOR
DISCUSSION, SO DICK AND ANNA
MARIA, SO WHILE I GUESS
THROUGHOUT THE DAY, WHILE A LOT
OF PEOPLE ARE FILLING IN, WE'LL
HAVE THESE PRESENTATIONS GET
GOING.
SO IF WE CAN GET LESLIE'S
PRESENTATION PULLED UP AND
STARTED THAT WOULD BE GREAT.
YOU CAN DO IT NOW.
WE'LL GET BACK TO IT LATER.
SO NO RUSH IN THE IMMEDIATE
FUTURE SO CAN WE GET--THANK YOU.
>> GOOD MORNING.
I HOPE YOU CAN HEAR ME OKAY,
ONLINE, COUNCIL, IT'S A PRIVATE
SECTOR LEM AND HONOR TO BE HERE
TODAY, MY NAME IS LESLIE
THOMPSON, I'M A HEALTH SCIENCE
POLICY ANALYST IN THE
ENVIRONMENTAL INFLUENCES ON
CHILDHOOD HEALTH OUTCOMES
PROGRAM.
ON BEHALF OF THE WHOLE TEAM IT'S
A YOI TO BRING THIS CONCEPT TO
YOU TODAY TITLED EXPANDING
ACCESS TO COHORT DATA AND
BIOSPECIMENS THROUGH XO1.
SO THE COMPLEX TEMPLATE IS ABOUT
ISSUING A P. A. R. FOR ACCESS TO
OUR DATA AND BIOSPECIMENS IN
ECHO THROUGH XO1 EMPLOY OUR
PURPOSE IS REALLY TO ENHANCE
ECHO'S IMPACT AND VALUE WHILE
FOSTERING COLLABORATION AND
EQUITY OF OPPORTUNITY THROUGH
EXPANDED ACCESS TO ECHO DATA AND
BIOSPECIMENS, IN TERMS OF
FUNDING AND AVAILABILITY,
FUNDING AVAILABILITY AND THE
NUMBER OF AWARDS, THE XO1
ACTUALLY REQUIRES NO FUNDING
FROM ECHO AND WE ANTICIPATE UP
TO 20 AWARDS PER YEAR.
AND FOR PROJECT PERIODS RANGING
FROM 1-3 YEARS DEPENDING ON THE
PROJECT AND OUR COUNCIL ACTION,
WE'RE ASKING TODAY AS A MOTION
AND VOTE TO PROVIDE CONCEPT
CLEARANCE TO ISSUE THE P. A. R.
NEXT SLIDE, PLEASE.
SO AN OUTLINE OF MY PRESENTATION
SO YOU CAN SEE HOW IT ALL WORKS
TOGETHER.
I REALLY WANT TO FRAME THE
OPPORTUNITY THAT WE HAVE IN ECHO
TO MAKE THESE DATA AND
BIOSPECIMENS BROADLY AVAILABLE.
AS A NATIONAL RESOURCE, THE
BROADER SCIENTIFIC COMMUNITY AND
NOT ONLY TO OUR INVESTIGATORS.
AND SO RAPIDLY EXPANDING
RESOURCE AND WITH THAT WE THINK
THE OPPORTUNITY IS RAPIDLY
EXPANDING.
I WILL DIVE BO THE DETAILS OF
THE CONCEPT WHICH ARE REALLY
ABOUT A P. A. R. FOR RESOURCE
ACCESS VIA XO1.
I WILL TELL YOU A LITTLE BIT
ABOUT HOW WE WILL FACAS SIT TAIL
ACCESS FOR XO1 AND OUR PLANS FOR
XO1 APPLICATIONS AND THEN I WANT
TO TAKE A STEP BACK BY SHOWING
YOU HOW THE P. A. R.'S FITS INTO
THE APPROACH FOR ANCILLARY
TOEVERYS WHICH IS A REALLY
IMPORTANT PART OF THE DISCUSSION
SAYS WE MAKE EMPLOY I WILL GIVE
YOU THE DEFINITION ABOUT HOW WE
THINK ABOUT ANCILLARY STUDIES
AND WALK YOU THROUGH A PROGRAM
OF ANCILLARY STUDIES WHERE YOU
SEE WHERE THIS PERFORM A. R.
FITS IN THE BROADER NARRATIVE
AND THEN WE'LLCROSE BY
REQUESTING ACTION EMPLOY NEXT
SLIDE, PLEASE.
SO IT JUST STARTED, I WANT TO
FRAME FOR YOU HOW WE THINK ABOUT
ACCESS TO ECHO'S DATA AND
BIOSPECIMEN RESOURCES.
SO STARTING ON THE LEFT, WE HAVE
OUR PROGRAM WHERE WE HAVE
INVESTIGATORS NATIONALLY
DISTRIBUTED AND THEY, THROUGH
THEIR STUDY SITES CONTRIBUTE AND
COLLABORATIVELY ACCESS IESHES
DENTIFIABLE DATA AND
BIOSPECIMENS ON ECHO'S PLATPORM
AND BIOREPOSITORY.
WE HAVE FAILITATE THROUGH THAT
UGH3 AWARS THAT ARE ALREADY IN
PLACE.
THE CONCEPT TODAY IS ABOUT
ANCILLARY STUDIES, AND THIS IS
PARTICULARLY FOR ECHO
INVESTIGATORS IN ADDITION TO
NONECHO VERY LONGS, SO THOSE
INVESTIGATOR WHO IS ARE OUTSIDE
OF THE PROGRAM AND TRYING TO
FACILITATE ACCESS FOR THEM TO BE
THE IDENTIFIABLE DATA AND
BIOSPECIMENS IN OUR PLATFORM AND
REPOSITORY AND WE WANT TO
FACILITATE THAT ACCESS ON THE
RO-1.
AND THEN ON THE FAR RIGHT YOU
WILL HEAR FROM DR. CLAY MASH
JUST AFTER MY PRESENTATION AND
HE WILL TALK TO YOU ABOUT
NOFOOTWORK Os FOR POST
DOCTORAL STUDENT RAM AND
PREDOCTORAL TRAINEES AND
FACILITATING ACCESS TO ECHOES
DEIDENTIFIED DAT SET THAT WE
CURRENTLY HOUSE ON NICHD'S PUB,
AND FACILITATING THAT THROUGH
F32 AND R36.
SO THESE ARE THE 3 WAYS WE THINK
ABOUT ACCESS TO DATA AND
BIOSPECIMENS IN ECHO AND SO, THE
FOCUS OF THIS CONCEPT IS ON
ANCILLARY STUDIES IN XO1.
NEXT SLIDE, PLEASE.
SO I WANT TO FRAME UP THE
OPPORTUNITY THAT ECHO PRESENTS
TO THE BROADER SCIENTIFIC
COMMUNITY.
NEXT SLIDE.
SO THAT OPPORTUNITY EMERGES FROM
A MISSION DRIVEN PROGRAM IN
ECHO, AND THAT MISSION IS TO
ENHANCE THE HEALTH OF CHILDREN
FOR GENERATIONS TO COME AND WE
DO RESEARCH ADDRESSING 5 KEY
AREAS OF CHILD HEALTH WITH HIGH
PUBLIC HEALTH IMPACT AND THESE
INCLUDE PRE, PERRY AND POST
NODAL OUTCOMES, THIS INCLUDES
UPPER AND LOWER AIR WAY,
OBESITY, NEUROTWEPMENT AND
POSITIVE HEALTH.
SO IN ECHO IT REALLY IS ALL
ABOUT THE KIDS.
NEXT SLIDE.
WE DO OBSERVATIONAL AND
INTERVENTION RESEARCH IN ECHO.
FOR OUR OBSERVATIONAL RESEARCH
THIS HAPPENS IN OUR ECHO COHORT
CONSORTIUM, DEPICTED ON THE LEFT
AND THE STATES COLORED PURPLE
WHERE THE STUDY SITE DRIEWBTED
AND THEN OUR INTERVENTION
RESEARCH HAPPENS IN OUR ECHO
IDEA STATES PEDIATRIC CLINICAL
TRIALS NETWORK, AS LOCATED ON
THE RIGHT IN THE STATES COLORED
GREEN AND TOGETHER WE HAVE
REPRESENTATION FROM RESEARCH
SITES IN 42 STATES, WASHINGTON
D. C. AND PUERTO RICO, OVER 180
HEALTH INSTITUTIONS AND OVER
1200 INVESTIGATORS CONTRIBUTING
TO THE RESEARCH WITHIN THE ECHO
PROGRAM.
NEXT SLIDE, PLEASE.
SO A MAJOR GOAL OF ECHO IN OUR
STRATEGIC PLAN HAS BEEN TO
ESTABLISH ECHO AS A NATIONAL
RESOURCE BY MAKING OUR ECHO
COHORT DATA AND BIOSPECIMENS
AVAILABLE TO THE BROADER
SCIENTIFIC COMMUNITY.
SO FAR WE'VE MADE MAJOR STEPS
TOWARD ACCOMPLISHING THAT GOAL
BY MAKING DEIDENTIFIED DATA
AVAILABLE THROUGH CONTROLLED
ACCESS ON THE NICHD'S DATA AND
SPECIMEN'S HUB AND THESE ARE
DATA THAT EMERGE FRIDAY OUR
OBSERVATIONAL COHORT STUDY.
NEXT SLIDE.
SO WHAT'S THE FUTURE LOOK LIKE
IN SO OUR NEXT STEPS, WE WANT TO
EXPAND ECHO'S ROLE AS A NATIONAL
RESOURCE BY MAKING OUR ECHO
COHORT DAT AND BIOSPECIMENS
AVAILABLE TO THE BLUEDER
COMMUNITY PARTICULARLY WITH OUR
SECURE IDENTIFIABLE DATA AND
BIOSPECIMENS AND WE WANT TO DO
THAT THROUGH ANCILLARY STUDIES
AND IT'S THROUGH THE ANCILLARY
STUDIES THAT THIS CONCEPT
FOCUSES ON TODAY.
NEXT SLIDE.
SO WHAT DOES THE RESOURCE LOOK
LIKE AFTER 8 YEARS OF ECHO.
SO WE LAUNCHED IN 2016 AND OUR
FIRST CYCLE RAN THROUGH AUGUST
OF 2023.
DURING THAT TIME WE AMASSED HARM
ANISEED DATA FROM OVER 107,000
PARTICIPANTS FROM AROUND 70
PREEXISTING ONGOING LONGITUDINAL
MATERNAL CHILDHOOD STUDIES
INCLUDING DATA FROM AROUND
65,000 CHILDREN, A HOST OF ASSAY
DAILY BASIS THEA AND UPWARDS OF
A HUNDRED THOUSAND BIOSPECIMENS
CURRENTLY LOCATED IN OUR
BIOREPOSITORY AND OUR SECOND
CYCLE START NOTHING SEPTEMBER OF
2023, AND CONTINUING THROUGH MAY
OF 2030 WE ARE PLANNING TO
FOLLOW UP OVER 30,000 KIDS FROM
SEEKLE --CYCLE 1 AND RECRUIT OVR
30,000 FEW PREGNANCIES DURING
CYCLE 2.
IN ADDITION TO FOLLOWING UP THE
CHILDREN DURING THESE STUDIES,
WE WANT TO FOLLOW THE MOTHER
DURING POSTPARTUM AND
PRECONCEPTION INCLUDING PARTNERS
WITH POSSIBLE.
SO TOGETHER WE HAVE A RAPIDLYKS
PANNING BIODATA REPOSITORY AND A
HOST OF NEW BUSINESS PROGRAMS O
PESMENS IN THE WORKS.
NEXT SLIDE.
SO PARTICULARLY WITH THE
BIOSPECIMENS I WANT TO EMPHASIZE
THE OPPORTUNITY THAT WE HAVE.
AND SO, WHAT WE SEE AS DEPICTED
ON THE LEFT IN MANY
BIOREPOSITORYS, SPECIMENS GET
STORED WITH THE HOPE OF USING
THEM FOR FUTURE ASSAYS AND WHAT
CAN HAPPEN IN THOSE CASES IS
THAT SPECIMENS CAN BE STORED
INDEFINITELY AT GREAT COST.
AND SO WE'RE TRYING TO BALANCE
THAT AND ECHO AS YOU SEE ON THE
RIGHT, WITH STORAGE AND SO WE
HAVE OUR LABORATORY CORE TO DO
ASSAYS OF THOSE BIOSPECIMENS BUT
THERE WILL BE MANY, MANY
BIOSPECIMENS LEFT OVER AND WE
WANT TO PROTECT FOR FOR
ANCILLARY STUDIES.
NEXT SLIDE.
SO TODAY'S CONCEPT IS ABOUT
THAT.
IT'S ABOUT HOW DO WE FACILITATE
THE ACCESS FOR THOSE ANCILLARY
STUDIES.
NEXT SLIDE.
SO WHY, XO1?
ESPECIALLY GIVEN THAT XO1
REQUIRES NO FUNDING FROM ECHO
BUT IT DOES--IT'S A RESOURCE
ACCESS MECHANISM.
MANY AWARDS OFFER FUNDING TO
SUPPORT RESEARCH, XO1 IS ABOUT
FACILITATING ACCESS SO IT MAKES
AN ADEAL TREATMENT FOR US TO DO
THAT WITH ANCILLARY STUDIES OF
THE SO IT WOULD ARK LOW
INVESTIGATORS FROM INSIDE AND
OUTSIDE ECHO TO ASK IMPORTANT
QUESTIONS FOR RESEARCH THAT
WOULD REQUIRE PERSONALLY
IDENTIFIABLE INFORMATION ON THE
PLATFORM OR ASSAYS OF
BIOSPECIMENS LOCATED IN THE BI
BIOSPECIMEN LABORATORY.
IT WOULD ALLOW THE OFFICE OF NIH
TO OVERSEE THOSE PROJECTS WITH
CLOSE OVERSIGHT AND FACILITATE
ACCESS WITH OUR CORES AND
CENTERS IN ECHO.
IT WOULD ALLOW US TO PROTECT THE
INTEREST OF OUR ECHO COHORT
STUDIATES WHO ARE DEEP LE
INVESTED IN THE INTERESTS OF
THEIR PARTICIPANTS THAT THEY
FOLLOW, AS WELL AS CORES AND
CENTERS WORKING DILIGENTLY TO
CONTINUE TO SUPPORT AND EXPAND
OUR CAPABILITIES IN ECHO WITH
REGARDS TO OUR INFRASTRUCTURE,
WOULD ALSO ALLOW US TO PROTECT
THE INTEREST OF ANCILLARY TODAY
INVESTIGATORS AND TO MONITOR
THOSE INVESTIGATORS CAREER
DEVELOPMENT IN FUTURE YEARS BY
HAVING THOSE XO1 TAGS AND WE CAN
LOOK IN NIH SYSTEMS AND TRACK
THEM OVERTIME.
NOW THE XO1 ALSO BENEFIT HERE IS
THAT IT ALLOWS OTHER INSTITUTES,
CENTERS, OFFICES, EVEN AGENCIES
OR INSTITUTIONS, TO SUPPLY THE
FUNDING.
IN MANY CASES INSTITUTE ANDS
CENTERS OR EVEN OTHER AGENCIES
HAVE FINANCIAL RESOURCES THAT
THEY WANT TO SPEND FOR THIS KIND
OF RESEARCH FOR THE AIR MISSIONS
AND SO BY,A LOWING AND USING
THIS, SO ONCE I WILL ALLOW THEM
TO USE THAT FUNDING TO ADVANCE
THEIR MISSIONS WE CAN ALSO
CONTINUE TO ADVANCE ECHOES
MENTION AND IT WOULD PREVENT
THEM FROM HAVING TO EXPEND
ADDITIONAL RESOURCES TO COLLECT
THAT DATA OR BIOSPECIMENS
THEMSELVES AND SO LEVERAGE THEN
ECHOES DATA AND BIOSPECIMEN
RESOURCES.
NEXT SLIDE.
SO THE PLANS FOR THE P. A. R.
FOR XO1 AND THE APPLICATIONS TO
THEM, WE ANTICIPATE USING
STANDARD DUE DATES IN FEBRUARY,
MAY, OCTOBER, AND WE WANT TO DO
THAT BECAUSE, FUNDING
OPPORTUNITIES THAT ARE NOT
RELATED TO ECHO THAT
INVESTIGATORS FROM INSIDE AN
ECHO, THEY MAY BE ABLE TO USE,
WE'RE NOT SURE WHEN THOSE COME
UP SO WE WANT TO MAKE SURE WE
ARE HAVE AN XO1 APPLICATION
PROCESS THAT IS VERY FLEXIBLE
FOR THEM AND WE ANTICIPATE USING
A FEDERAL REVIEW PANEL APPROACH
FOR SCIENTIFIC AND TECHNICAL
MERIT REVIEW.
NEXT SLIDE, SO LET'S TAKE A STEP
BACK NOW WITH THOSE DETAILS OF
THE CONCEPT, HOW DOES THE P. A.
R. FIT WITH THE APPROACH TO
ANCILLARY STUDIES.
NEXT SLIDE.
SO THE DEFINITION OF ANCILLARY
STUDIES IN ECHO IS A TODAY THAT
DERIVES FUNDING FROM A NONECHO
SOURCE AND USES ECHOES
NONPUBLICLY AVAILABLE DATA OR
BIOSPECIMENS.
NEXT SLIDE.
SO TO WALK YOU THROUGH THE
PROCESS, I WILL PRESENT A FLOW
CHART HERE IN 3 STEPS, FOR THIS
FIRST STEP, IT'S REALLY ABOUT
DETERMINING WHETHER A STUDY FROM
AN INVESTIGATOR EITHER INSIDE OF
ECHO OR OUTSIDE MAY BE ANCILLARY
SO THE FIRST QUESTION WE HAVE IN
THE TOP LEFT CORN SERIES POINTS
WHETHER THE STUDY REQUIRES
NONECHO FUNDING AND IF SO THE
NEXT QUESTION IS WHETHER IT
REQUIRES THE USE OF ECO'S
BIOREPOSITTORY AND/OR WHETHER IT
REQUIRES THE USE OF A PLATFORM
FOR DATA THAT REQUIRES
INFORMATION EMPLOY IF THEERGT OF
THOSE ARE NECESSARY THAT'S WHAT
WE HAVE OUR DEIESHES DENTIFIED
AVAILABLE ACCESS DATA AVAILABLE
TOEM THIS FOR IF THEY DO NEED
RESEARCH AND IF THEY NEED
BIOSPECIMENS WITH PLATFORM DATA,
THEN THE STUDY MAY BE ANCILLARY.
NEXT SLIDE.
SO IN THE SECOND STEP, IF A
STUDY MAY BE ANCILLARY, WE WILL
CAN THOSE INVESTIGATORS,
POTENTIAL ANCILLARY STUDIES TO
REQUEST SUPPORT PRACTICES OUR
STEERING COMMITTEE AND THEN WITH
THAT SUPPORT IF THEY DON'T
ALREADY HAVE THEIR NONECHO FUND
NOTHING HAND, THEY WOULD APPLY
TO A NONECHO FUNDING SOURCE AND
SIMULTANEOUSLY AMRI FOR AN ECHO
1 WHICH IS TODAY'S CONCEPT IN P.
A. R. ARE ABOUT.
NEXT SLIDE.
IF THEY HAVE BOTH THE NONECHO
FUNDING IN HAND AND AN XO1 WITH
ECHO, THEY CAN PROCEED WITH
ANCILLARY STUDY AND IF NOT THEY
MAY REVISE AND BRING THEIR
PROPOSAL BACK TO THE STEERING
COMMITTEE WITH THE AMENDMENTS
AND THEN GO FORWARD AGAIN.
SO TO SUMMARIZE THE ECHO COHORT
HAS ALREADY MADE DEIESHES
DENTIFIABLE DATA AVAILABLE
THROUGH THE BROADER SCIENTIFIC
COMMUNITY THROUGH THE SPECIMEN
HUB AND INTENDS TO FOLLOW SUIT
WITH IDENTIFIABLE DATA ON THE
PLATFORM AND IN THE REPOSITORY.
THE ANCILLARY STUDIES AND THAT'S
WHAT THIS CONCEPT IS ABOUT, IS
USING A P. A. RMPLET FOR XO1 TO
ALLOW US TO OVERSEE CONDUCT OF
ANCILLARY STUDIES FROM THE
OFFICE AND THAT BRINGS US TO OUR
REQUEST FOR COUNCIL TO APPROVE
THE CONCEPT OR TO--NEXT SLIDE,
PLEASE--TO VOTE AND POTENTIALLY
APPROVE THE CONCEPT CLEARANCE.
AND THAT'S IT, THANK YOU.
I WILL TAKE ANY QUESTIONS OR
DISCUSSION.
>> GREAT.
THANK YOU LESLIE.
WE WILL TART WITH DICK EMPLOY IF
YOU WANT TO RUN THROUGH ANY
COMMENTS OR FEEDBACK FOR THE
COUNCIL.
>> THIS IS OBVIOUSLY AN
IMPORTANT PROJECT AND AS I SAID
YESTERDAY, RELATED TO ALL OF US,
ANYTHING THAT'S LONGITUDINAL
WITH CHILDREN AND ADULTS IS
REALLY IMPORTANT.
I ACTUALLY HAD A SPECIFIC
QUESTION TO ASK ABOUT THIS AND I
DISCLOSED THIS ON MY CONFLICT OF
INTEREST, BUT I HAVE A
FOUNDATION THAT SUPPORTS
RESEARCH IN THE AREA OF CHILD
ABUSE AND NEGLECT THAT A
COLLEAGUE AND I STARTED SEVERAL
YEARS -ING AND WHAT I WAS TRYING
TO UNDERSTAND THROUGH THIS WAS
CAN WE IN FACT STIMULATE PEOPLE
TO APPLY FOR THESE WITH THE
FOUNDATION.
JUST SO IT'S CLEAR WHAT I'M
TALKING ABOUT, I'VE BEEN
CONCERNED FOR ABOUT 10 YEARS
THAT THE SUBSPECIALTY AREA OF
CHILD ABUSE PEDIATRICS WHICH WAS
DEVELOPED BACK IN 2009 WAS
PREMATURE BECAUSE THERE WAS NO
FUNDING PRACTICALLY ANYWHERE TO
SUPPORT RESEARCH OR NO RESEARCH
INFRASTRUCTURE FOR THE TRAINEES
IN THE CHILD ABUSE PEDIATRICS,
TO ACTUALLY DO ACADEMIC WORK.
IT'S 15 YEARS LATER AND IT TURNS
OUT THAT THAT'S TRUE.
THERE'S VERY LITTLE ACADEMIC
WORK AND MOST OF THE PEOPLE IN
THAT FIELD ARE TRYING TO FIGURE
OUT HOW TO DO STUDIES THAT WILL
HELP PROSECUTORS WITH THEIR
LEGAL CASES.
SO THE WHOLE FOCUS HAS BEEN ON
FORENSIC AND LEGAL INSTEAD OF ON
THE OUTCOMES AND WHAT HAPPENS TO
CHILDREN IN A POPULATION.
SO THAT WAS 1 QUESTION I HAD IS
IF WE CAME TO THAT FEEL AND
SAID, WE WILL LIKE TO HAVE YOU
FOCUS IN THIS AREA INSTEAD OF
THE FORENSIC LEGAL AREA, WHAT IS
THE WHAT IS THE COST FOR THIS?
IN THE SENSE THAT--BECAUSE I
HAVE NO IDEA WHENNA A GRANT SIZE
WOULD BE FOR THIS TYPE OF
APPROACH.
>> SO THE QUESTION IS REALLY
ABOUT HOW WOULD AN INVESTIGATOR
KNOW HOW MANY--WHAT SIZE
NONACCURATE FUNDING SOURCE THEY
MIGHT NEED.
NTHAT'S RIGHT NTHAT'S A REALLY
GOOD QUESTION.
I DON'T HAVE A SPECIFIC ANSWER
FOR YOU ON THAT.
I THINK PART OF THAT YOU KNOW WE
WILL HAVE TO LOOK INTO HOW WE
MAKE THAT KIND OF INFORMATION
AVAILABLE AS PART OF THIS SO
THAT THEY HAVE A MEANS OF
ASSESSING THAT BUT I DON'T HAVE
A SPECIFIC ANSWER AND I WOULD
LOVE TO HEAR ANY THOUGHTS YOU
MIGHT HAVE ABOUT THAT, TOO.
>> WELL, I CAN TURN IT THE OTHER
WAY.
WE GIVE 2-3 GRANTS, UP TO
$25,000 A YEAR FOR 2 YEARS TO
TRAINEES TO TRY TO STIMULATE
THEIR RESEARCH CAREER.
AND I DON'T KNOW WHETHER THAT'S
OUT OF THE BALLPARK OR NOT EVEN
CLOSE TO THE BALLPARK.
>> YEAH, I WON'T BE ABLE TO TELL
YOU ABOUT HOW CLOSE IT IS TO THE
BALLPARK ISSUE THE KINDS OF
THINGS I CAN TELL YOU, WHICH IS
THE KINDS OF COSTS THEY'LL HAVE
TO CONSIDER, 1 IS THEIR OWN
INVESTIGATOR TIME TO SUPPORT
THEIR TIME, WE ALSO HAVE OUR
CORES AND TRUSTEESS THAT THEY
WILL HAVE TO CONSIDER MAKING
SURE THEY'RE PROVIDING SUPPORT
FOR, SO WE HAVE A DATA,AINAL SIS
CENTER THAT WOULD FACILITATE
SOME OF THE ACCESS AND TRAINING
SO THAT THEY HAVE THE
CREDENTIALS NECESSARY TO SECURE
THAT PLATFORM AS WELL AS ECHO
LAB RATRY CORE WHO HOUSES THE
BIOSPECIMENS AND IF THEY DON'T
DO AN ASSAY THEMSELVES THEY
WOULD HAVE TO FACILITATE THE
SHIPPING EMPLOY SO THEY WILL
HAVE TO AT LEAST FACTOR THOSE
KINDS OF THINGS IN, SO IT HAS TO
DO WITH HOW LONG THEY ANTICIPATE
THE PROJECT LASTING, HOW MUCH
TIME THEY NEED AND HOW MUCH TIME
THEY NEED TO PROVIDE ADDITIONAL
SUPPORT TO OUR CORES AND CENTERS
IN ADDITION TO OTHER COSTS THEY
MAY HAVE WITH REGARDS TO STAFF,
TIME, AND THINGS LIKE THAT.
NI WILL FOLLOW UP LATER AND
EDUCATE MYSELF MORE ON THAT.
I WILL SAY THAT THIS IS
SOMETHING THAT WE CLEARLY, IN MY
VIEW SHOULD SUPPORT.
IT'S AN IMPORTANT EFFORT AND
WELL, WE ALSO HAVE THE NEXT 1
WE'RE GOING TO TALK ABOUT WITH
THE DISSERTATIONS THERE AS WELL.
I WILL HAVE COMMENTS THERE.
CAN I CAN THOUGH, WITH THE
700,000 CHILDREN YOU'VE GOT AND
I SUSPECT AT LEAST 1000 OF THOSE
HAVE EXPERIENCED ABUSE SO FAR.
HOW ARE YOU FACTORING THAT IN OR
FINDING THAT IF YOU ARE?
>> YES, SO OUR INVESTIGATORS ARE
REALLY THE EXPERTS OF OUR
PROTOCOL, WE HAVE A DETAILED
COMPLEX ECHO COHORT DATA
COLLECTION PROTOCOL.
WHAT I CAN TELL YOU IS THAT WE
THINK VERY BROADLY ABOUT
ENVIRONMENT, WE DON'T JUST THINK
ABOUT AIR, WATER AND SOIL, WE
THINK ABOUT EVERYTHING FROM THE
PSYCHOSOCIAL AND SOCIETAL
ENVIRONMENT ALL THE WAY DOWN TO
THINGS BENEEG THE SKIN LIKE
GENETICS AND SO WE THINK THAT
THOSE ARE IMPORTANT EXPOSURES
AND THEY ARE ON OUR RADAR AND
QUITE SURE TO SOME EXTENT OUR
INVESTIGATORS HAVE MEASURES THAT
GET AT SOME OF THOSE THINGS IN
THE PROTOCOL TO SOME EXTENT, THE
QUESTION IS HOW MUCH AND HOW
DIRECTLY, BUT IT IS A REALLY
GREAT QUESTION AND IT IS, PART
OF OUR PARADIGM, WE THINK VERY
BROADLY ABOUT THE ENVIRONMENT
FROM SOCIETY TO BIOLOGY.
>> SO, I'VE HAD THE PRIVILEGE OF
SERVING AS THE COUNCIL OF
COUNCIL'S LIAISON WITH ECHO, I
HAVE BEEN INVOLVED WITH ALL OF
THEIR MEETING FOR THE LAST 6
YEARS AND AS PART OF THAT, I
HAVE TO SAY, I'VE BEEN EXTREMELY
IMPRESSED THE AMOUNT OF WORK
THAT ECHO HAS BEEN ABLE TO BE
ACCOMPLISHED.
FOR THOSE THAT DON'T KNOW IT
STARTED OUT AS THE NATIONAL
CHILDREN'S STUDY AND THEN IT GOT
REORGANIZED INTO THIS FRAMEWORK
AND THROUGH THE LEADERSHIP OF
MATT GILLMAN AND HIS WHOLE TEAM
HAVE DONE AN AMAZING JOB.
AND SO WHILE THERE'S--IT LOOK A
LONG TIME TO DO DATA
HARMONIZATION AND RIGHT NOW
ACCORDING TO LATEST
DOCUMENTATION THAT WE HAVE,
THERE HAS BEEN OVER CLOSE TO 400
PROPOSALS FOR ANALYSIS HAVE BEEN
ACCEPTED AND ALREADY 109 PAPERS
THAT HAVE BEEN PUBLISHED SO
THERE'S MORE DATA THAT'S FIGURE
TO BE COMING OUT FROM THIS
PARTICULAR COHORT AND THE--I
THINK IT'S VERY IMPORTANT FOR US
WHOM WE HEARD THIS YESTERDAY TO
BE AS PROACTIVE AS WE CAN AND BE
COST EFFICIENT IN USING
TAXPAYER'S MONEY AND THIS IS
CLEARLY A MECHANISM FOR BEING
MORE COST EFFECTIVE AND USING
TAXPAYER'S MONEY.
SO THE REQUEST TO ACTUALLY HAVE
THESE ANCILLARY PROPOSALS FOR
USING THE BIOSPECIMENS AND USING
THE BIOSPECIMENS TIMELY BECAUSE
WE KNOW YOU CAN'T PRESERVE THESE
BIOSPECIMENS FOR EVERYTHING YOU
WANT, IS REALLY I THINK NOVEL
AND IMPORTANT AND WE TOTALLY
SUPPORTIVE OF IT AND I THINK THE
OTHER THING THAT IS IMPORTANT TO
KEEP IN MIND IS, WE WANT TO MAKE
SURE THAT THERE'S PEOPLE OUTSIDE
OF THE INVESTIGATORS INVOLVED IN
ECHO COHORT TO BECOME MORE AWARE
AND USE THESE DATA.
AND THAT INCLUDES NOT ONLY
ALREADY ESTABLISHED SCIENTIFIC
INVESTIGATORS BUT YOUNG
INVESTIGATORS AS WELL.
SO I'M--YOU KNOW THAT SORT OF
ANSWERS A COUPLE QUESTIONS IN
TERMS WHERE ECHO HAS BEEN, WHERE
THEY SEE THEMSELVES GOING, BUT,
YOU BROUGHT UP SOMETHING VERY
INTERESTING THAT I WOULD HOPE
THAT AS PART OF THE PROCESS FOR
ALLOWING PEOPLE TO GET LETTERS
OF SUPPORT FROM THE STEERING
COMMITTEE AND WHEN YOU WRITE UP
THIS XO1 THAT MAKE PEOPLE AWARE
OF THIS OPPORTUNITY THAT YOU
ACTUALLY INCLUDE THE COST OF
WHAT IT'S GOING TO TAKE TO
WITHDRAW THE SPECIMENS FROM THE
BIOBANKS ISSUES RIGHT?
AND ANY OTHER OF THAT INTERNAL
COST SO THAT PEOPLE CAN COME UP
WITH MORE REALISTIC PROPOSALS
WHEN THEY ACTUALLY DO SUBMIT
THEM.
SO THAT WOULD BE REALLY
IMPORTANT TO ACTUALLY HAVE THAT
TRANSPARENT SO THAT IT'S NOT
HIDDEN.
>> TOTALLY ADPREE.
THANK YOU FOR THAT AND YEAH, WE
WANT TO BE DILIGENT IN NAAREA AS
WELL BECAUSE WE WANT TO SET
PEOPLE UP FOR SUCCESS.
>> GREAT.
ARE THERE ANY QUESTIONS--OKAY.
RUSS BARELY BEAT YOU WITH
PUTTING THE TENT CARD UP SO WE
WILL GO RUSS AND THEN LINDA AND
THEN RHONDA AND MONICA.
THAT'S THE ORDER.
>> SO I COULDN'T AGREE MORE THIS
IS A REALLY VALUABLE RESOURCE,
I'M NOT SO FAMILIAR WITH THE XO1
MECHANISM AND IF AN INVESTIGATOR
WHO IS SAY NOT A CORE ECHO
INVESTIGATOR WANTED TO PUT IN AN
RO-1 OR AN R21 TO DO A STUDY,
I'M TRYING TO UNDERSTAND THE
MECHANICS OF THIS, WOULD THEY
NEED TO HAVE THE XO1 IN HAND TO
PUT THE R21 OR RO-1 IN AND
CONVERSELY, IF THE TODAY SECTION
LOOKEDDA THE RO-1 OR R21 PROGRAM
OFFICER, THEY MIGHT SAY, WELL
YOU DON'T HAVE ACCESS AT THIS
POINT, SO HOW DOES THIS
INTERDIGITATE WITH OTHER FUNDING
MECHANISMS--POSSIBLY BE FUNDED
BECAUSE YOU'RE DENIED XO1 FOR
EXAMPLE.
>> YEAH, THAT'S 1 REASON WE WANT
TO TO DO SIMULTANEOUS XO1 OF THE
APPLICATION SO THOSE CAN WORK
TOGETHER, SPECIALLY WITHIN NIH
AT LEAST.
>> THERE'S A LITTLE BIT OF A
DOUBLE JEOPARDY THERE BECAUSE
HAVE YOU 2 STUDY SECTIONS OR
PANELS THAT ARE EVALUATING THE
SAME WORK AND BASICALLY 1 COULD
SAY THAT'S WORTH WHILE AND THE
OTHER 1 COULD SAY NOT SO MUCH
AND THAT MIGHT DISCOURAGE USE OF
THIS BECAUSE OF THE RISK THAT
YOU ARE SORT OF TAKING DOUBLE
THE--I DON'T KNOW THERE'S A WAY
TO MITIGATE THAT NECESSARILY OR
COMBINE THE PROCESSES, SO THAT
IT COULD BASICALLY BE A
HARMONIZED DECISION.
>> YEAH, I CAN AT LEAST TELL YOU
ABOUT THE RATIONAL, WE
DEFINITELY WRESTLED WITH THAT
SPECIFIC ISSUE AND OUR RATIONAL
FOR DOING SIMULTANEOUS
APPLICATION IS REALLY TO SUPPORT
THE SPEED WITH WHICH THEY GO
THROUGH INSTEAD OF HAVING TO
WAIT FOR 2 SEQUENTIAL REVIEWS TO
AT LEAST HAVE THOSE REVIEWS
HAPPEN AT THE SAME TIME SO THAT
ESPECIALLY FOR PEOPLE WHO ARE
EARLIER IN THEIR CAREERS ARE NOT
MISSING VALUABLE TIME SO YEAH,
WE RECOGNIZE THAT TENSION THAT
YOU'RE POINTING OUT AND
WE'RE--WE WOULD LOVE TO HEAR
MORE IDEAS ABOUT HOW WE CAN
MITIGATE THE DIFFICULTY YOU'RE
POINTING TOO BECAUSE WE SEE THAT
AS A CHALLENGE AND WE REALLY
HAVE IN MIND, ESPECIALLY FOR
EARLIER STAGE INVESTIGATORS THE
TIME WITH WHICH IT WOULD TAKE
THEM TO GO THROUGH A REPEAT
PROCESS WHEN THERE'S SEQUENTIAL,
TOO, SO YEAH, HEAR YOU.
>> ONE POSSIBILITY MIGHT BE TO
HAVE A SPECIAL EMPHASIS PANEL
THAT WOULD SPECIFICALLY LOOK AT
ECHO GRANTS AND BE ABLE TO LOOK
AT BOTH SIMULTANEOUSLY WITH THE
SAME STUDY SECTION AND I DON'T
KNOW IF THE CSR CAN ACCOMMODATE
THAT BUT THAT MIGHT BE 1 POINT
TO AVOID THE DOUBLE JEOPARDY
ISSUE.
>> I LIKE THAT A LOT.
I WILL BRING IT BACK TO OUR
TEAM.
>> LINDA?
>> OKAY, I HAD A QUICK QUESTION
ABOUT 1 OF YOUR SLIDE, ABOUT
WHAT'S REQUIRED ABOUT THE XO1.
IT'S THE SLIDE WHERE YOU MENTION
INVESTIGATORS INSIDE ECHO TO ASK
FOR RESEARCH QUESTIONS THAT
WOULD REQUIRE PERSONAL
IDENTIFYING INFORMATION ON THE
ECHO DATA PLATFORM, SO I JUST
WASN'T SURE WHY THEY NEED TO
HAVE ACCESS ON THE PII DATABASE
BECAUSE THAT WOULD VIOLATE
CONFIDENTIALITY?
>> YEAH, I CAN'T GIVE YOU AN
EXHAUSTIVE LIST THERE YOU 1
EXAMPLE OF THAT TO THINK ABOUT
IS GEOCODING AND TIME STAMPING
SO SAY IF THEY WANT TO CONNECT
TO A DATABASE THAT'S OUTSIDE OF
ECHO WE THINK ABOUT
INTEROPERABILITY O MAYBE THEY'RE
INTERESTED IN A DATABASE THAT'S
ON HUD'S PLATFORM OR EPA'S AIR
POLLUTION RESOURCES SO THERE MAY
BE GEOCODING AND TIME CODING
THAT ARE IMPORTANT PARTS OF
UNDERSTANDING EXPOSURE AND
OUTCOME AND SOPHISTICATED SO
THAT'S 1 EXAMPLE THAT I FEEL
CONFIDENT TO GIVE AND ARE
PROBABLY, MANY, MANY MORE THAT
ARE BEYOND MY EXPERTISE TO
SHARE, BUT THAT'S 1 OF THEM
EMPLOY NI WORK WITH ABCD DATA
SET AND WE HAVE THAT SAME ISSUE
AND WE RELEASE DATA TO THE
PUBLIC ALL OVER THE WORLD
ACTUALLY, WE WOULD NEVER RELEASE
THE PIE DATABASE AND WE DO
ACTUALLY--WE HAVE SPECIAL WORK
GROUP THAT WORK SPECIFICALLY TO
LINK THE ABC DATA SET TO ALL THE
EXTERNAL DATA BY THE GEOCODING,
BECAUSE IF YOU ONLY HAVE THE ZIP
CODE, YOU WILL ALREADY BE ABLE
TO LINK THE DEIESHES DENTIFIED
DATA OF THE INDIVIDUAL
PARTICIPANT TO WHERE THEY LIVE,
HOW MUCH AIR PARTICULATE,
WHATEVER, POLLUTION AND YOU
KNOW, THERE WAS A PAPER THAT
ABCDPUBLISHED ININATE AND YOU
ARE MEDICINE WHERE THEY LINK IT
TO THE SOIL LEAD CONTENT TO SHOW
IF SOME KIDS IN CERTAIN
REGIONS--AND HOW THAT MIGHT
AFFECT THE COGNITIVE AND BRAIN
MEASURES THAT WE COLLECTED.
SO I THINK THERE'S WAYS OF
LINKING ALL THE GEOCODING AND
ALL OF THE SOCIOLOGICAL ECONOM
INCREASE IN BODY DATA PUBLICLY
AVAILABLE WITHOUT REQUIRING THE
PIOOH, TO ME IT'S A MAJOR
CONCERN.
>> UNDERSTAND.
LET ME CLARIFY A COUPLE THINGS,
1, WE DO GEOCODING AND TIME
STAMPING WITH OUR DEIDENTIFIED
DATA SET, THE QUESTION THERE IS
GRANULARITY, BUT I WANT TO BE
CLEAR, WE'RE NOT TALKING ABOUT
RELEASING PUBLICLY IDENTIFIA
INFORMATION, IN THIS CASE WE ARE
TALKING ABOUT HAVING OUR
DATA,AINAL SIS TRAIN OUR
INVESTIGATORS WHO ARE PART OF
ECHO OR WHO ARE ASSOCIATED WITH
ECHO AND THEN HAVE THE SECURITY
CREDENTIALS TO ENTER INTEREST
THE DATA PLATFORM ANALYSIS IN
THAT SECURE ENVIRONMENT AND NOT
HAVE DATA GO OUT OF THAT
ENVIRONMENT, I DON'T KNOW IF
THAT'S PART OF THE QUESTION OR
NOT BUT I WANT TO BE SURE THIS
IS NOT ABOUT RELEASING DATA BUT
ABOUT INVITING INVESTIGATORS IN
TO USE THAT DATA THAT ARE AT A
FINER GRANULARITY.
BUT THE WAY IT'S WRITTEN IS
LIKE, YOU KNOW, THE INVESTIGATOR
WHO ARE IN AND OUTSIDE ECHO
WOULD HAVE ACCESS TO THE
PII DATABASE BECAUSE OF COURSE
THE INVESTIGATORS OR THE
CLINICIANS WHO ARE COLLECTING
THE DATA HAVE THE
PIOOH DATABASE, LIKE IN ABCD, WE
HAVE 12,000 SUBJECTS AND 21
SITES AND NOBODY OUTSIDE OF THE
GROUP THAT THE LOCAL SITE THAT'S
COLLECTING THE DATA WOULD HAVE
ACCESS TO THE PII DATABASE SO
EVEN WITHIN THE WHOLE ABCD
CONSORTIUM, YOU WILL NOT BE ABLE
TO ACCESS THE PII OF ANY OTHER
SITES.
SO JUST, TO ME IT'S A REAL
IMPORTANT POINT TO SECURE THE
PII DATABASE.
>> YES, AND WE DO HAVE A DEEP
DISCUSSION ABOUT THE POTENTIAL
MEASURES THAT OUR DATA ANALYSIS
CENTER WILL GO THROUGH, SO IT'S
NOT THAT AN INVESTIGATOR OUTSIDE
OF ECHO WILL HAVE ACCESS TO ALL
THE DATA, THE DATA THEY HAVE
ACCESS TO WITHIN THAT SECURE
SPACE WOULD BE RELATED TO THE
RESEARCH QUESTION, OUR
DATA,AINAL SIS CENTER WILL HAVE
MEANS.
BUT I HEAR THAT.
>> HAVE A LAYER WHERE ONLY
PEOPLE WHO ARE MANAGING THE DATA
CAN ARE HAVE ACCESS TO THAT BUT
THEN, LIKE IF SOMEBODY'S WRITING
A PROPOSAL, SAY I WANT TO ACCESS
THIS DATA, I JUST THINK THAT
POINT REALLY NEEDS TO BE CLEAR.
>> THANK YOU.
>> OKAY, WE HAVE RHONDA, MONICA,
YEEN THEN MAYBE KENT, YOU WILL
BE THE LAST WORD JUST IN THE
INTEREST OF TIME.
>> THANK YOU SO MUCH.
I DO AGREE THIS IS A VERY, VERY
IMPORTANT PROJECT AND I THINK
EXPANSION OF YOUR CAPABILITIES
AND EXCEPTIONALLY IMPORTANT.
I HAVE SOME QUESTIONS AROUND
THAT.
ONE, PRIMARILY AROUND THE
CONCEPT OF COMPARABILITY OF
DATA, DATA SPECIFICATIONS AND
PROCESSES.
SUCH THAT IT CAN BE, HOW WOULD
YOU SAY WORK IN ALIGNMENT WITH
OTHER PROGRAMS WITHIN NIH THAT
ARE COLLECTING DATA.
ALL OF US IS 1 OF THEM WHETHER
OR NOT THERE'S ANY COMMUNICATION
OR DISCUSSIONS IN TERMS OF
ALIGNMENT ACROSS THAT, I'M SURE
THERE'S A LOT OF OTHER STUDIES
THAT I HAVE NO KNOWLEDGE OF
THAT, HAVE SOME COMPARABLE--NIES
TO HAVE SOME COMPARABILITY, ALSO
IN TERMS OF LONG-TERM STORAGE,
YOU KNOW, DEALING WITH CHILDREN,
THAT'S A LONG-TERM TYPE OF
PROJECT WHERE THERE'S SO MUCH
THAT CAN BE LEARNED THROUGH THAT
AND I GET CONCERNED WHEN I
THOUGHT I HEARD YOU TALK ABOUT A
SHORT-TERM PROCESS AS IT RELATES
TO SAMPLE STORAGE AND I
UNDERSTAND THAT'S A VERY, VERY
EXPENSIVE PROCESS, AND I'M JUST
WONDERING WHETHER OR NOT IT IS
ON THE PRIORITY LIST FOR NIH TO
REALLY FOCUS IN ON HOW TO FIND A
WAY TO PRESERVE, MAY ALREADY DO
THAT, I JUST DON'T KNOW, THESE
TYPES OF SAMPLES PARTICULARLY IN
THESE TYPES OF STUDIES WHERE
THERE'S SO MUCH THAT CAN BE
GARNERED FROM IT.
THERE'S SO MUCH WE DON'T
UNDERSTAND ABOUT CHILDREN, SO
MUCH WE DON'T UNDERSTAND ABOUT
THE LONG-TERM CENTER FOR
EXCELLENCE ON AGINGS,
PARTICULARLY OF THE ENVIRONMENT
ON THEM AS WE'RE SEEING THE
PREVALENCE OF GROWING PREVALENCE
OF ALL KINDS OF CONDITIONS,
AUTOIMMUNE CONDITIONS, ALLERGIES
TO THE THINGS THAT WHEN I WAS A
KID NUT ALLERGY WAS NOT A THING
AND NOW IT IS DEFINITELY A
THING.
SO I BRING THAT UP EMPLOY THE
OTHER THING IN TERMS OF THERE
WAS NOTHING MENTIONED ABOUT A
BI-DIRECTIONAL EXPANSION OF
DATA, IN OTHER WORDS GOING OUT
TO OTHER DATABASES THAT MIGHT BE
HELPFUL IN TERMS OF BRINGING IN
A MORE COMPREHENSIVE PICTURE OF
WHAT'S GOING ON, I'M SURE THAT'S
PORT --PART OF IT BUT IT WASN'T
STATED HERE SO I'M WONDERING
ABOUT THAT.
PARTICULARLY HOSPITAL IS THE
SYSTEMS THAT HAVE GRANTS TO LOOK
AT GENOMICS, [INDISCERNIBLE]
HEALTH IN SAN DIEGO IS 1 OF THEM
AS WELL AS IN NEW YORK THEY'RE
DOING THIS.
AND WHETHERRER NOT THAT WOULD
INCLUDE OTHER TYPES OF DATABASE
IN EMERGINGS OF LIKE SOCIAL
DETERMINANTS OF HEALTH AND
EDUCATIONAL LEVELS.
SO I LOOK AT THIS AND THIS IS
EXPRESSIONALLY IMPORTANT XI WILL
BRING IT FROM A STANDPOINT OF
VIEW, I WORK FOR UNITED HEALTH
GROUP AND SO WE'RE ALWAYS
LOOKING AT COST AND WHAT IS A
COST BURDEN ACROSS STATES.
ONE OF THE NUMBER 1 THINGS THAT
COMES ACROSS IN THEIR RFPs IN
TERMS OF TRYING TO ADDRESS IS
CHILD ABUSE, CHILD WELFARE
SYSTEMS THAT ARE COSTING A LOT
OF MONEY AND THEY DON'T HAVE
ANSWERS FOR THAT.
I BRING THAT UP BECAUSE FROM A
POLITICAL STANDPOINT, THAT'S
SOMETHING THAT IS OF GREAT
INTEREST AND IT'S SOMETHING THAT
COULD VERY WELL HELP TO SOLIDIFY
INVESTMENTS IN THIS TYPE OF
WORK.
THANK YOU SO MUCH.
>> YEAH, THANK YOU.
THE FIRST QUESTION I WILL TRY TO
ADDRESS THERE IF I BED IT
CORRECTLY, HOW IS ECHO WORKING
ACROSS NIH TO MAKE SURE OUR DATA
CAN CO KNOW NECT WITH OTHER
DATABASES AND OTHER STUDIES THAT
ARE ONGOING.
AND THE FIRST PART OF THAT
APPROACH FOR ECHO AT LEAST IS
THAT WE MAKE OUR PROTOCOL
PUBLICLY AVAILABLE FOR 1 AND WE
ENGAGE REGULARLY WITH ALL OF US,
ABCD,A HBCD, SO WE CAN HAVE SOME
COORDINATION TO THE EXTENT
POSSIBLE BUT WE REALLY TRY TO
MAKE SURE THAT OUR PROTOCOL IS
AVAILABLE AND WE'VE SEEN PEOPLE
ASK ABOUT THAT FOR THAT EXACT
PURPOSE AND WHAT'S ECHO DOING,
CAN WE LOOK AT THE PROTOCOL AND
MAKE IT AVAILABLE SO THERE CAN
BE SOME STANDARDIZATION.
MANY MEMBERS FROM OUR OFFICE
ALSO SIT ON VARIOUS COUNCILS AND
WORKING GROUPS AT NIH THAT DEAL
WITH THIS KIND OF THING WHETHER
IT'S SORT OF STANDARDIZED
MEASURES OR THINK ABOUT THE DATA
POLICY COUNCIL, THOSE KINDS OF
THINGS TO MAKE SURE WE'RE AWAER
OF WHAT INSTITUTES, CENTERS AND
OFFICES ARE DOING IN THAT SPACE
SO WE HAVE SITUATIONAL AWARENESS
TO HELP OUR INVESTIGATORS THINK
THROUGH SOME OF THOSE KINDS OF
ISSUES SO WE SEE THAT AS REALLY
IMPORTANT.
ANOTHER THING IS, WE HIGHLY
PRIORITIZE INTEROPERABILITY OF
OUR DATA TO MAKE SURE, SO WITH
THINGS THAT WE MENTIONED,
WHETHER IT'S GEOCODING, TIME
STAMPING TO MAKE SURE THAT OUR
DATA CAN CONNECT AS EASILY AS
POSSIBLE WITH OTHER DATABASES
AND DATA SOURCES, WE HIGHLY
PRIORITIZE THAT AND OUR DATA
ANALYSIS CONSIDERS THAT IN THE
IMPORTANT WORK THEY DO WITH
MAKING THE DAILY BASIS AT READY
FOR USE.
YOU MAYBE HAD ANOTHER QUESTION
THERE.
CAN I CLARIFY OR DID I THAT
ANSWER YOUR QUESTIONS?
NMOSTLY STATEMENTS AROUND
BI-DIRECTIONAL DATA OTHER
SOURCES OUTSIDE OF NIH THAT
MIGHT HAVE DATA THAT WOULD BE
HELPFUL TO YOU AND THE LAST 1
IS, THIS AREA IS A VERY HIGH
COST AREA FOR THE STATES
PARTICULARLY AROUND MEDICAID.
>> YEAH, YEAH, 1 OF THE BENEFITS
WE HAVE IS INVESTIGATORS WHO ARE
NATIONALLY DISTRIBUTED AND
STATES IN VERY DIFFERENT
CONNECTICUT TEXT AND POLITICAL
CONTEXT AND WE REALLY ASK THEM
TO WORK TOGETHER COLLABORATIVELY
BUT THINK THROUGH A LOT OF WHAT
ECHO CAN DO SO THAT IT'S WELL
POISED TO SUPPORT AN ARRAY OF
ISSUES.
I DON'T--I DON'T KNOW MORE
SPECIFICS THAT THAN THAT.
I DON'T KNOW IF HOW MUCH MORE I
CAN GET INTO BUT IT'S SOMETHING
IMPORTANT.
WE THINK ABOUT POSTURES BROADLY
AGAIN FROM SCIENCE TO BIOLOGY
AND WE TRY TO ADDRESS THE
VARIOUS DOMAINS OF THOSE 2
EPPEDS OF THE SPECTRUM IN TERMS
OF CHILD HEALTH.
>> MONICA?
>> JUST QUICKLY, THIS IS AN
IMPORTANT INITIATIVE.
THE BIOSPECIMEN ISSUE, HOWEVER,
I WANT TO THINK ABOUT COST
SAVINGS SO I THINK YESTERDAY WE
DIDN'T REALLY TOUCH UPON THE
FACT THAT PART OF THE REASON
THAT--I KNOW THAT THE NIH HAD
UNPRECEDENTED BUDGET ATTACKS
FROM CONGRESS BUT 1 QUESTION IS
ABOUT BEING REALLY STREAMLINED
IN TERMS OF ABOUT I O SPECIMEN
BANKING BECAUSE ANYTHING WE CAN
DO TO DO COST SAVINGS WOULD
ADDRESS HEAD ON THE QUESTION
PEOPLE HAVE ABOUT EFFICIENCY AND
THE PROBLEM IS THAT COHORTS LIKE
THIS, THEY GATHER SO MUCH
BIOSPECIMENS AND THEY'RE NOT
USED AND THEY'RE NOT
CONSOLIDATED AND PLASMA ISN'T
PUT TOGETHER AND DO YOU REALLY
NEED EVERY X-MONTHS THAT MANY
SPECIMENS.
YOU ONLY NEED TO DO GENETIC
TESTING ONCE FOR EXAMPLE,
BECAUSE A HOST ROAMSOME DOESN'T
CHANGE SO HOW CAN YOU USE BEST
PRACTICES AND BIOSPECIMEN
BANKING I THINK TO CONSOLIDATE
AND TO STREAM LINEUP AND MAKE
SMALLER THE BIOSPECIMEN BANK
BECAUSE THIS WOULD JUST GO OUT
OF CONTROL AND THIS IS TRUE OUT
OF ANY COHORTS OR ANY NIH FUND
ANDS SO MUCH FUNDING THAT GOES
INTO PRESERVING SPECIMENS THAT
WE DON'T END UP USING.
SO I WOULD THINK ABOUT A
BIOSPECIMEN BEST PRACTICES, BUT
NOT BEST PRACTICES BUT
CONSOLIDATION, STREAMLINING AND
MAKING THINGS CHEAPER BECAUSE
SPACE IS AT A HUGE PREMIUM.
>> YES, THANK YOU SO MUCH THAT
REALLY TOUCHES ON THE IMPETUS
FOR WHY WE'RE BRING THANKSGIVING
CONCEPT TO YOU TODAY IS 1 OF
THOSE MEASURES NOT NECESSARILY
COST SAVINGS BUT VALUE, VALUE OF
DOLLARS SPENT USING THOSE
RESOURCES.
AND WE DO CONSIDER OUR PROTOCOL
LARGE AND COMPLEX IN TERMS OF
THE DATA AND BIOSPECIMENS THEY
COLLECT AND WE'RE CONSTANTLY
THINKING THROUGH HOW TO
STREAMLINE THINGS AND HOW THEY
MAKE THATENTIOUS FICIENT AND
THAT'S IMPORTANT WORK WE DO
EVERY DAY AND THE GOVERNANCE
COMMITTEE AND STEERING COMMITTEE
THEY MENTION ON A DAILY BASIS,
YOU KNOW SO THANK YOU WE REALLY
APPRECIATE THAT CONCERN, IT'S 1
THAT'S PARAMOUNT FOR US FRONT
AND CENTER.
>> GENE?
>> THANK YOU FOR ALL THIS WORK.
OBVIOUSLY, I THINK HAVING A
BIOSPECIMEN BANK LIKE YOURS IS
AMAZING.
I HAVE TO SAY I'M WITH LINDA I'M
FEELING UNCOMFORT WITH PPI,
BECAUSE I'M FROM A COMMUNITY WHO
THINKS ABOUT HOW YOU CAN USE OUR
DATA AGAINST US SO I WILL GO TO
A PLACE THAT I IMAGINE AND
PROBABLY WOULDN'T GO TO BUT
INSTEAD OF GEOCODE AND UPDATE
DATA, LET'S SAY WE'RE LOOKING AT
CHILD ABUSE AND RACE AND WE'RE
LOOKING AT THE DIFFERENCE IN THE
PREVALENCE OF CHILD ABUSE, I'M
MAKING THIS UP, BUT LET'S SAY
SOMEBODY COMING UP WITH THAT AND
THAT'S THEIR STUDY AND THE
ANSWER I'M HEARING IS THAT WE
HAVE A SECURE PLATFORM IN WHICH
THIS HAPPENS.
WELL BEING THAT I HAVE A LOT OF
DATA CENTERS I WORK WITH AND I
HAVE A LOT OF CYBERSECURITY
PEOPLE I WORK WITH, THEY CAN
BREAK INTO ANY SYSTEM AND I'M
NOT JOKING ABOUT ANY SYSTEM, SO
MY WORRY IS A SECURE PLATFORM IS
ONLY AS SECURE AS WE THINK ABOUT
IT IN 1 WAY BUT UNDERSTANDING
THAT PEOPLE CAN THROUGH
CYBERSECURITY ACCESS WE SEE IT
ALL AROUND THE WORLD GET BO THAT
DATA.
SO PEOPLE'S PERSONAL INFORMATION
THAT'S IN THE DATABASE IS TRUTH,
IT'S TALKING ABOUT MY CHILDREN
RIGHT NOW, I'M CONCERNED ABOUT
THAT.
SO I'M IN WITH DEIESHES DENT
IDENTIFIABLE DATA, I'M IN, I'M
TOTALLY IN.
THIS NOW ARE THERE CASES WHERE
THIS MAY ARISE AND IT'S A RARE
DISEASE AND YOU NEED TO TELL AND
YOU NEED TO TELL THE PERSON BY
THE WAY YOU HAVE THIS, I KNOW
THERE WILL BE OCCASIONS FOR THIS
TO HAPPEN, I DON'T LIKE IT AS A
POSSIBILITY FOR MOST THINGS TO
HAPPEN IN A PARTICULAR WAY AND
I'M IMAGINING IT'S GOING TO BE
LESS OF THIS, BUT I DON'T WANT
IT TO BE ANY OF IT UNLESS THERE
IS A REAP A LIFE AND DEATH
REASON TO KNOW THE ANSWER THAT
MY PPI SHOULD BE OUT.
SO I'M CONCERNED ABOUT THAT, I'M
CONCERNED ABOUT THE ANSWER TO
HOW WE'RE GOING TO PROTECT
PEOPLE.
I KNOW WE WANT TO, AND I KNOW
POSSIBLY WE CAN IF THEY'RE NOT
PEOPLE WHO UNDERSTAND
CYBERSECURITY BETTER THAN ANY
PLATFORM WE COULD PREVEBT,
CREATE, AND IN THE FUTURE WILL
BE WORSE SO THAT IS A MAJOR
CONCERN, LIKE A SICK IN MY
STOMACH CONCERN.
>> [INDISCERNIBLE].
N.
>> WHAT SPECIFICALLY ABOUT THIS
PROJECT CONCERNS YOU, IT SEEMS A
CONCERN ABOUT ANY DATA BEING
STORED IN.
>> YES IT DOES BUT BIOSPECIMENS
IS DIFFERENT TO ME, IT'S MY
GENETICS IT'S MY SOCIOECONOMIC
STATUS, IT'S EVERYTHING, IT'S
LIKE MY EVERYTHING.
I AGREE WITH LITTLE PIECES HERE
AND THEY PROBABLY CAN PUT THE
STORY TOGETHER BUT WITH MY PPI,
YOU COULD PUT MY ENTIRE STORY
TOGETHER, IT JUST FEELS LIKE I
DON'T KNOW I'M FEELING THAT
CONCERN.
>> WOULD YOU BE COMFORTABLE IF
THEY WERE USING THE SAME LEVEL
OF ANON MYSELFATION AS ALL OF
US?
NYES.
>> SO MAYBE THAT WOULD BE OUR
KECK MENDATION.
>> ALL OF US USES A THIRD PARTY
MODEL SO IT'S PRETTY SAFE.
>> AND THAT LEVEL OF
SOPHISTICATION IS ALWAYS BETTER
THAN WHAT WE PROVIDE.
I MAY BE TOTALLY WRONG WITH
BEING THIS UNCOMFORTABLE BUT I
AM UNCOMFORTABLE.
>> IT'S REASONABLE.
NJUST TO FOLLOW UP, IN THE
ABCD STUDY I SAID WE USE A VERY
LONG STRING OF DEIDENTIFIED ID
FOR EACH PARTICIPANT, THERE'S NO
NEED TO SHARE THE PII DATABASE
WITH ANYONE BECAUSE WE CAN DO
EVERYTHING YOU NEED TO DO WITH
DEIDENTIFIED DATA.
>> I THINK THIS IS SOMETHING WE
CAN ASK THE ECHO FOLKS TO GO
BACK AND LOOK AT A LITTLE BIT
MORE CLOSELY AS A TWEP OUT THE
FUNDING OPPORTUNITY ANNOUNCE
EXPMENT FURTHER DEVELOP OUT THE
PLAN, AS I MENTIONED THIS
YESTERDAY, THIS IS WHY WE HAVE
THESE CONVERSATIONS BECAUSE IT'S
HELPFUL FOR US TO HEAR SOME OF
THE FEEDBACK, RELATED TO THESE
THINGS SO WE CAN CONNECT WITH
THE ALL OF US FOLKS TO SEE, YOU
KNOW BETTER UNDERSTAND THEIR
STRUCTURE AND WHAT WOULD BE
POSSIBLE HERE FOR THIS PROGRAM,
AS WELL AS WE HAVE OBVIOUSLY OUR
OFFICE OF SCIENCE AND STRATEGY
ACROSS OTHER DPC PSI AND NIH YOU
CAN CONSULT WITH.
YOU CAN DO THAT.
KEN I SAW YOUR HAND WAS UP AT 1,
DO YOU HAVE A QUESTION?
>> YEAH, VERY QUICKLY
DR. THOMPSON THANK YOU VERY
MUCH.
I DON'T THINK YOU MENTIONED THE
ESSENCE OF WHY THIS ISSUE OF THE
XO1.
WHAT OF DEMAND?
HAVE YOU SURVEY THE COMMUNITY TO
INDICATE THERE'S A LOT DEMAND
FROM THE UH3, UG3 ACCESS FUNDED
COMMUNITY THAT SAID THEY NEED
ACCESS TO THIS DATA AND WHAT
KIND OF THINGS THEY WANT THE
DATA FOR WHICH ALOUDS TO LINDA
AND GENE'S COMMENTS.
THANK YOU.
>> THANK YOU, DOCTOR, THAT'S A
GREAT QUESTION, AND WE DON'T
HAVE SPECIFIC DATA SOURCES LIKE
THAT TO BRING TO YOU TODAY.
YEAH, AND I WOULD JUST SAY THAT
JUST TO ADDRESS THE CONCERN, YOU
KNOW, IT'S A REALLY IMPORTANT
CONCERN TO ECHO TOO AND OUR
INVESTIGATORS WRESTLE WITH IT
REGULARLY AND HOW TO BALANCE
RISK VERSUS THE ABILITY TO
ANSWER IMPORTANT SCIENTIFIC
QUESTIONS AND WE APPRECIATE THE
DISCUSSIONS AND CONCERNS YOU'RE
RAISING AND YES WE DO, WE ARE
HAPPY TO BRING THAT BACK TO THE
PROGRAM OFFICE AND TO CONNECT
WITH OUR PEERS ACROSS NIH TO
THINK ABOUT HOW WE CAN ADDRESS
THOSE CONCERNS BECAUSE THEY'RE
CRITICALLY IMPORTANT,
DEFINITELY.
>> SO JUST QUICK FOLLOW UP, IF
YOU DON'T HAVE EVIDENT OF DEMAND
THEN WHAT'S THE JUSTIFICATION
FOR THE XO1.
>> I GUESS THE ANSWER TO YOUR
QUESTION CANY DID MANDATORY
OUTSIDE OF ECHO, WE KNOW THERE'S
A LOT OF DEMAND WITH OUR OPENING
REMARKS INVESTIGATOR WHO IS ARE
SUPPORTING EARLY STAGE
INVESTIGATORS AND KNOWA ARRAY OF
POTENTIAL POSSIBILITIES, WE'RE
VERY FAMILIAR WITH THAT.
I REALLY APPRECIATE YOUR
QUESTION ABOUT YOU KNOW VOICES
OUTSIDE OF THE PROGRAM AND YEAH,
THAT'S 1 WE NEED TO THINK ABOUT
CAREFULLY IN TERMS OF PROVIDING
DATA TO BACK UP THAT CLAIM, BUT
YEAH.
>> CAN I SAY THAT I DISAGREE
THAT WE NEED [INDISCERNIBLE].
WE CREATE DATA AND THERE'S SO
MANY POSSIBILITIES OF LEARNING
MORE FROM IT.
IT'S SOMETHING I THINK THE NIH
HAS BEEN TALKING ABOUT FOR A
LONG TIME.
WE HEAR IT OVER AND OVER AGAIN
THAT WE WANT TO MAKE DATA
PUBLIC, WE WANT TO GET THE MOST
OUT OF IT AND I DON'T THINK WE
HAVE TO JUSTIFY IT--WE'VE BEEN
JUSTIFYING IT FOR 10 YEARS OR
MORE.
>> OUR
>> [INDISCERNIBLE] OTHER THAN
WHAT YOU JUST SAID, I WAS JUST
CURIOUS THAT YOU HAVE AN
ANNOUNCEMENT FOR A NEW CONCEPT
AND YET NO EVIDENCE TO SHOW
THERE'S DEMAND FOR THIS DATA
BECAUSE IT FEEDS INTO THEN WHY
DO YOU WANT THE DATA WHICH FEEDS
BACK TO WHAT LINDA AND YEEN WERE
TALKING ABOUT WHICH IS
PROTECTION FOR PERSONAL
INFORMATION.
THANKS.
>> AND THE IMPETUS ABOUT THE WHY
IS THE LONG-TERM PLANNING AND
GOAL SETTING IF ARE ECHO AND
EXACTLY WHAT WE JUST INSURED
THAT WE WANT TO MAKE, WE WANT
ECHO TO BE A RESOURCE FOR THE
BROADER SCIENTIFIC COMMUNITY AND
YEAH, SO WE'RE ALWAYS THINKING
HOW CAN WE BALANCE RISK WITH THE
SCIENTIFIC BENEFIT AND THAT'S 1
OF THE THINGS WE WRESTLE WITH
DAILY.
BUT THE IMPETUS HERE IS MOVING
MORE TOWARDS ACCOMPLISHING
THINGS THAT NIH IS INTERESTED IN
THIS TERMS OF ECHO AND DATA
AVAILABILITY AND THINGS LIKE
THAT.
>> SO I JUST WANT TO ADD
2-POINTS, 1 IS THE FACT THAT YOU
KNOW, ECHO IS CONGRESSALLY
FUNDED.
SO THEY DO HAVE INVESTIGATORS
INVOLVE WIDE --INVOLVED WITH ITS
I SAID THERE ARE 387 PROPOSALS +
OF WHICH 180 PAPERS HAVE BEEN
PUBLISHED BUT IN ORDER FOR THEM
TO CONTINUE TO BE PRODUCTIVE,
THEY NEED TO GET THE WORD OUT TO
HAVE OTHER PEOPLE USE AND MAKE
USE OF THIS DATA.
SO THERE'S JUST NO QUESTION THAT
I DON'T THINK YOU NEED TO GO
SURVEY, THOSE OF US IN ACADEMIA
OR IN MEDICINE PER SE TO
ACTUALLY HOW CAN YOU USE THIS
DATA.
THERE'S LOTS OF AVENUES TO USE
THIS DATA AND TO YOUR POINT THEY
PROBABLY HAVEN'T EVEN LOOKED AT
THE REQUESTY THAT YOU AND RHONDA
HAVE PROPOSED BUT EASY LE COULD
DO THAT AND I THINK THE OTHER
THING ABOUT THE ANCILLARY
STUDIES IS THE FACT THAT YOU CAN
BRING OTHER DATA SETS NOW FROM
OUTSIDE OF WHAT ECHOES ALREADY
COLLECTING AND MERGING IN TO BE
ABLE TO ANSWER SOME NEW
QUESTIONS AND THAT KIND OF
CREATIVITY IS ONLY GOING TO COME
THROUGH THESE TYPES OF EFFORTS
OF GETTING THE WORD OUT.
AND IF THEY DON'T GET THE WORD
OUT AND ARE NOT PRODUCTIVE THEY
WILL NOT GET CONGRESSIONAL
APPROVAL FOR CONTINUING FUNDING
AND SO THAT'S KEY.
AND THEN THE ONLY OTHER THING,
YOU KNOW I DID NOT PICK UP THE
PII STUFF BUT I KNOW IN OTHER
COHORT STUDIES THERE'S ONLY A
LIMITED AMOUNT OF DATA AVAILABLE
ON THE DASHBOARD AND IF YOU WANT
MORE GRANULARITY AND THAT'S NOT
COMPLETE PIOOH, AND THAT'S
SOMETHING TO LOOK INTO BUT
THAT'S ONLY AVAILABLE IF YOU
ACTUALLY HAVE AN APPROVED
ANCILLARY STUDY THAT YOU THEN
GET, YOU KNOW ACCESS TO BEING
ABLE TO HANDLE THE DATA IN A
SPECIAL WAY.
>> ALL RIGHT, SUSAN FINAL WORD
BECAUSE WE DO NEED TO MOVE ON TO
THE NEXT NYEAH, I WILL NOT ADD
TO THE DISCUSSION BUT I WANT TO
TALK ABOUT BIOSPECIMEN ANDS THIS
IS A DISCUSSION WE ALSO HAD WITH
THE ALL OF US PROGRAM, HOW
COSTLY THEY ARE AND YOU HAVE TO
HAVE THEM LONG-TERM.
I APPRECIATE THAT WE WANT TO
TEST THEM QUICKLY BUT THE
TECHNOLOGIES WE HAVE FOR TESTING
RIGHT NOW ARE LIMITED AND THEY
WILL IMPROVE OVER THE YEARS AS
WELL AS NEW CONDITIONS THAT WE
NEVER THOUGHT OF LIKE ALLERGIES,
A LOT OF THINGS SO WHAT I WANT
TO CONSIDER WITH THIS PROBLEM,
THE OVERARCHING PROBLEM THAT
MAYBE WE NEED SOME FUNDING TO
LOOK AT HOW TO PRESERVE OUR
SPECIMENS THAT DON'T REQUIRE
CRYOPRESERVATION, THAT ARE
CHEAPER TO MAINTAIN, BUT WILL
ALLOW FOR TESTING IN THE LONG
RUN.
AND THIS WILL BE SEPARATE FROM
ALL OF THIS PROGRAMS, BUT IT
MIGHT REQUIRE INFORMATION,
INDUSTRY, MIND, SOMETHING LIKE
THAT BUT THIS IS A CRUCIAL POINT
BY WHICH WE, I BELIEVE WE NEED
TO INVEST INTO FIGURING OUT HOW
WE CAN DO THIS BETTER BECAUSE WE
WANT TO HAVE THIS PROGRAMS
EVENTUALLY WE WILL BE ABLE TO
TELL OUR POLITICIANS THAT WE ARE
WORKING TOWARDS CUTTING OUR
COSTS BY DOING MORE SCIENCE AND
I THINK THAT MIGHT MAKE SENSE.
THATYA JUST MY COMMENT.
THANK YOU NI THINK THAT'S A
REALLY IMPORTANT POINT THAT
REQUIRES A LOT MORE DISTHAN WE
HAVE TIME FOR RIGHT NOW.
SO WE WILL TABLE THAT 1 BUT WE
WILL GET BACK TO THIS 1 FOR
SURE.
FRANCISK,A, WHEN WE SAY
SOMETHING ABOUT CONCERNS ABOUT
PRIVACY AND CLARIFY, WHO HAS
ACCESS, WHO REALLY HAS ACCESS TO
PIOOH, LIKE HOW DO WE MAKE SURE
WE CLOSE THAT LOOP HERE BECAUSE
I WOULD SAY OKAY I'LL VOTE WITH
THE UNDERSTANDING THAT THAT
ISSUE WILL BE ADDRESSED.
YEAH, WE CAN COME BACK, JUST
LIKE WE MENTIONED YESTERDAY, FOR
SOME OF THE OTHER CONCEPTS, WE
CAN COME BACK, CIRCLE BACK TO
THE GROUP, WHETHER THAT IS--IT'S
GOING TO DEPEND ON, YOU KNOW THE
NATURE OF DISCUSSION AND NATURE
OF THE CHANGES WHETHER OR NOT WE
HAVE A FULL PRESENTATION FROM
THE OFFICE ABOUT THE PROGRAM,
AND KIND OF HOW IT HAS EVOLVED
OR IF WE JUST KIND OF DO A
GENERAL TOUCH BASE REALLY
QUICKLY EITHER BY E-MAIL OR YOU
KNOW PUBLICLY HERE, WE WILL HAVE
A SLID OR SOMETHING JUST TO
SHOW.
I THINK IT'S JUST GOING TO
DEPEND ON HOW SUBSTANTIVE THE
CHANGES ARE BUT WE WILL MAKE
SURE WE CIRCLE BACK ON SOME OF
THESE CRITICAL ISSUES, AS I
THINK I SAID, I THINK THE
BIOSPECIMEN DISCUSSION PROBABLY
IS GOING TO REQUIRE A MUCH
DEEPER THOUGHT HERE, AND IT'S
SOMETHING I THINK GENERALLY
ACROSS ALL OF THE BIOMEDICAL
RESEARCH COMMUNITY THAT WE'RE
STRUGGLING WITH, BIOSPECIMEN AND
THEN WE HAVE SOME OF THE SAME
TYPES OF CHALLENGES WITH DATA
TOO, THEY'RE DIFFERENT IN NATURE
BUT SIMILAR IN A LOT OF WAYS.
>> SO LET ME TRY TO DO THIS TO
ADDRESS ALL THE ISSUES OR AT
LEAST MOST OF THE ISSUES THAT
WERE RAISED.
THIS LAST DISCUSSION WILL
ADDRESS THIS.
SO I WILL ASK FOR A MOTION FOR
APPROVAL OF THE ECHO CONCEPT
CLEARANCE ENTITLED: EXPANDING
ACCESS TO ECHO COHORT DATA AND
BIOSPECIMENS THROUGH XO1, AND
USE THE ALL OF US MODEL CALLED
EXPORT CERTIFICATION AND
CONSIDER OTHER ISSUES RAISED.
IS THERE A MOTION FOR SUCH A
PROPOSAL?
NYES, THERE IS SUCH A MOTION.
>> THANK YOU.
SECOND?
>> SECOND.
>> ALL THOSE IN FAVOR SAY AYE.
>> AYE.
>> ANYBODY OPPOSED SAY NAY.
ABSTENTIONS?
SO WE HAVE 3 ABSTENTIONS, COULD
YOU PLEASE RAISE YOUR HANDS
AGAIN.
OKAY, THANK YOU.
THE MOTION CARRIES.
>> OKAY, THANK YOU LESLIE.
NTHANK YOU.
>> OKAY, SO WE'RE GOING TO
CONTINUE ON ECHO FOR ANOTHER
PRESENTATION FROM DR. CLAY MASH
WHO IS A PROGRAM COHORT OFFICER
IN ECHO TO PRESENT ON A
DISSERTATION POST DOC FELLOWSHIP
GRANTS FOR THE ANALYSIS OF
PUBLICLY ACCESSIBLE DATA SO I
IMAGINE THERE WILL BE SOME
SIMILAR COMMENTS THAT WE CAN
CARRY OVER SOME OF THAT
DISCUSSION WE JUST HAD INTO THIS
1 AFTER THE PRESENTATION DOCTORS
YENS AND [INDISCERNIBLE] ARE
ALSO GOING TO HELP LEAD THE
FEEDBACK AND DISCUSSION
QUESTION.
SO CLAY, THE FLOOR IS YOURS.
NDPRAIT.
THANK YOU.
I'M CLAY MASH FROM THE ECHO
PROGRAM OFFICE AND I WILL
PRESENT DISSERTATION POST
DOCTORAL FELLOWSHIP GRANTS FOR
THE ANALYSIS OF PUBLICLY
EXCESSIBLE DATA COHORT.
NEXT SLIDE, PLEASE.
ECHO IS REQUESTING REISSUE
APPROVED IN 2023 FOR INFLUENCES
IN THE CHILDHOOD HEALTH OUTCOME.
THE PURPOSE OF THE FUNDING IS TO
PANNED RESEARCH IN HIGH PRIORITY
AREAS BY STIMULATING ANALYSIS BY
INVESTIGATOR TRAINEES USING 2
COMPANION OPPORTUNITIES 1 FOR
R36 DISSERTATION GRANT ANDS THE
OTHER FOR F32 POST DOCTORAL
FELLOWSHIP AWARDS, ECHO PLANS TO
COMMIT UP TO $1.26 MILLION IN
TOTAL COST OVER FISCAL YEARS
2026-28 FOR UP TO 8 2-3 YEAR
AWARDS.
THE COUNCIL ACTION WE REQUEST IS
THE VOTE FOR APPROVE WILL TO
REISSUE THE 2 RFAs.
NEXT SLIDE, PLEASE.
AS MY COLLEAGUE DR. THOMPSON
JUST DESCRIBED, THE MISSION OF
ECHO IS TO ENHANCE HEALTH FOR
CHILDREN GENERATIONS TO COME, IT
FOCUSES ON THESE 5 KEY OUTCOMES
THAT ARE STUDIED FROM BEFORE
BIRTH TO AGE 21.
NEXT SLIDE, PLEASE.
ECHO RESEARCH EXAMINES A VERY
BROAD ARRAY OF EARLY EXPOSURES
THAT RANGE FROM SOCIETY ALL THE
WAY TO BIOLOGY AND THAT ARE
STUDIED FROM PRECONCEPTION TO
AGE 5 YEARS.
WE FOCUS ON THIS TIMELINE
BECAUSE EARLIER EXPERIENCE CAN
HAVE A LIFE LONG IMPLICATION.
NEXT SLIDE, PLEASE.
SO AS YOU HEARD THE FIRST 8
YEARS OF ECHO HAVE BEEN VERY
SUCK SUCCESSFUL FROM THE
ACCOMPLISH AMS FROM THE FIRST
AWARD PERIOD INCLUDING
HARMONIZED DATA FROM 70 LONG
NUDEINAL CHILD MATERNAL STUDIES
THAT REFLECT VERY MANY CHILDREN,
MANY BIOSPECIMENS AND ASSAYS.
IN THE SECOND 7 YEAR AWARD
PERIOD WHICH BEGAN IN 2023, WE
ARE ACTIVELY FOLLOWING OVER
30,000 CHILDREN WHILE RECRUITING
30,000 NEW PREGNANCIES.
THE SECOND CYCLE INCLUDES
PROTOCOL TO STUDY EFFECTS OF
EXPOSURES BEFORE CONCEPTION THAT
INCLUDES CONCEIVING PARTNER ANDS
RAPIDLY EXPANDING DATA PLATFORM
AND BIOREPOSITORY.
NEXT SLIDE PLEASE.
SO WITH RESPECT TO THE 2 ECHO
CONCEPTS THAT WE ARE PROPOSING
TODAY, A CENTRAL FACTOR IN BOTH,
IS THE MANNER OF ACCESS TO THE
DATA
BY INTERESTED INVESTIGATORS.
THE CLARIFICATION ABOUT PATHWAYS
TO ACCESS AGAIN, THIS SHOWS ECHO
AS A WHOLE ON THE LEFT AND
DR. PRESENT CONCEPT AND
REPRESENTED IN THE MIDDLE PANEL
AND WHAT I'M TALKING ABOUT NOW
IS ON THE RIGHT IN THE RIGHT
PANEL.
THE FIRST PANEL REPRESENTS WORK
OF CURRENTLY FUNDED ECHO
INVESTIGATOR WHO IS ACTUALLY
COLLECT THE DATA USING THEIR
UH3/UG3 MECHANISMS AND AWARDS.
THEY HAVE ACCESS TO THE INTERNAL
PLATFORM WHERE DATA WITH
PERSONAL IDENTIFIERS ARE STORED
AND ALSO HAVE ACCESS TO THE
BIOSPECIMENS IN AND THE
BIOREPOSITORY.
SO THE MIDDLE PANEL, REPRESENTS
HOW WE PROPOSE TO ENABLE
INVESTIGATORS ACCESS TO INTERNAL
PLATFORM DATA AND BIOSPECIMENS
FOR RESEARCH HA IS BEYOND THE
SCOPE OF THE EXISTING FUNDED
APPLICATIONS.
AND RESEARCH THAT IS FUNDED BY
NONECHO AWARDS.
SO IT'S THIS THIRD PANEL ON THE
RIGHT THAT REPRESENTS THE
PRESENT CONCEPT WHICH AIMS TO
FUND DISSERTATION STUDENTS AND
POST DOCS WHO AREN'T ALREADY
FUNDED ON AN ECHO AWARD, FOR
WERE RESEARCH USING THE DEIESHES
DEBTIFIED DATA SPECIMEN HUB OR
DASH.
NEXT SLIDE ISSUE PLEASE.
THE PURPOSE OF THIS CONCEPT IS
TO ADVANCE RESEARCH AND HIGH
PRIORITY AREAS OF CHILD HEALTH
BY STIMMULING USE OF ECHO DATAOT
PUBLICLY ACCESSIBLE DATA DASH
REPOSITORY BY THE BROAD
SCIENTIFIC COMMUNITY.
PROPOSED FUNDING SUPPORTS
TRAINING OF NEW INVESTIGATORS IN
ANALYSIS OF LARGE LONGITUDINAL
DATA SETS FOR CHILDHOOD HEALTH
OUTCOMES.
THESE OPPORTUNITIES COINCIDE
WITH ECHO GOALS WHICH IS TO
FACILITATE THE NEXT GENERATION
OF RESEARCHERS AND TO MAKE THIS
INCREDIBLY RICH NATIONWIDE
LONGITUDINAL DATA SET TO
QUALIFIED AND INVESTIGATORS ON A
NATIONAL SCALE EMPLOY NEXT
SLIDE, PLEASE.
SO HARMONIZED DEIDENTIFIED DATA
IS AVAILABLE ON DASH.
IT CONTAINS DATA ON OVER 30,000
EACH OF PREGNANT AND CHILD
PARTICIPANT ANDS ECHO DATA
ANALYSIS CENTER POSTS NEW DATA
AT REGULAR INTERVALS.
NEXT SLIDE, PLEASE.
SO THIS SLIDE HAS EXAMPLES OF
SOME OF THE KINDS OF ECHO DATA
THAT ARE AVAILABLE ON DASH THIS
INCLUDES DATA ON CHILDREN'S
EARLY DEVELOPMENT, DEMOGRAPHIC
INFORMATION, AND MEASURES OF
MANY ENVIRONMENTAL EXPOSURES
SUCH AS PHYSICAL, CHEMICAL,
PSYCHOSOCIAL, NATURAL, AND BUILT
ENVIRONMENTS.
IT ALSO INCLUDES PREGNANCY AND
BIRTH INFORMATION, DATA ON
ECHOES 5 PRIMARY CHILD HEALTH
OUTCOMES AND DATA RELATED TO
PUBLIC HEALTH CRISIS SUCH AS
COVID PANDEMIC.
NEXT SLIDE, PLEASE.
IN 2023 WE PUBLISHED THE INITIAL
ROUND OF DASH DATA ANALYSIS
NOFOs, TITLED MAXIMIZING
SCIENTIFIC DATA GENERATED BYEC O
PROGRAM.
THERE WAS 1 OF THE DISSERTATION
GRANTS USING THE R36 MECHANISM
AND 1 FOR POST DOCTORAL
FELLOWSHIPS USING THE F32.
NEXT SLIDE.
THE APPLICATIONS WERE RECEIVED
BY A CSR SPECIAL EMPHASIS PANEL
AND THEY FOCUSED ON A BROAD
RAINCHL OF CHILDHOOD AND
CHILDHOOD HEALTH OUTCOMES.
NEXT SLIDE.
TO ELEVATE THE RANGE OF
QUESTIONS I LIST THEM HIRE.
THEY ARE EARLY EXPOSURE TO
READING ABILITY, EARLY EXPOSURE
TO CO PACK O AND CANNABIS SMOKE
AND DEVELOPMENT LATER IN
CHILDHOOD AND RELATIONSHIPS OF
PARENTS OF DISCRIMINATION,
CHILDREN'S EARLY PHYSICAL AND
PSYCHOSOCIAL EXPOSURES AND
DEPRESSION OUTCOMES IN RACIAL
MINORITY ADOLESCENTS.
NEXT SLIDE, PLEASE.
THE OTHERS ARE EXAMINING
ASSOCIATIONS OF PFOS EXPOSURE
WITH CHILDHOOD AND ALLERGIES,
AND OBESITY RELATED TO DIETARY
FACTORS AND MEDIATION BY DNA
METHYLATION BETWEEN PRENATAL
EXPOSURE TO CHEMICALS AND CHILD
DEVELOPMENT OUTCOMES.
NEXT SLIDE, PLEASE.
AND IMPORTANT CONSIDERATION IN
SUPPORTING GRANTEES SUCCESS IS
BRIDGING THEIR NEW AND EMERGING
DATA ANALYTICS SKILLS WITH THE
SUBSTANTIAL SIZE AND COMPLEXITY
OF THE DATA SET.
SO TO FACILITATE STUDENTS AND
POST DOCS WITH GETTING STARTED
AND EFFECTIVELY USING THE DATA.
WE CONDUCT ANNUAL MEETINGS TO
THE GRAPEDEES TO PROVIDE
ORIENTATION TO THE DAILY BASIS
AT AND PREPARE IT FOR ANALYSIS.
WE ALSO SERVE AS A LIAISON WITH
THE ECHO MEASUREMENT CORE AND
DATA ANALYSIS CENTER AND THAT
MIGHT BE NECESSARY TO ACHIEVE
AIMS.
NEXT SLIDE, PLEASE.
AS WE EVALUATE GRANTEE PROGRESS,
WITH THEIR AWARDS, WE WILL TRACK
COMPLETION OF DEGREE OR
FELLOWSHIP, PRESENTATIONS OF
PROFESSIONAL MEETINGS,
AUTHORSHIP ON PUBLICATIONS, AND
TRANSITION TO EMPLOYMENT AND
THEIR FIELD OF TRAINING.
NEXT SLIDE, PLEASE.
WE ARE NOW REQUESTING APPROVAL
TO REISSUE THE SAME 2 FUNDING
OPPORTUNITIES.
R36 DISSERTATION GRANTS WHICH
CAN BE PURSUED BY STUDENTS WOWHO
WILL HAVE AN APPROVED
DISSERTATION PROPOSAL BY THE
START OF THEIR AWARD, AWARD
BUDGETS COVER STIPENDS AND
BUDGET COSTS OF A DURATION OF
1-2 YEARS.
ALSO F32 FELLOWSHIP AWARDS WHICH
CAN BE PERCEIVED BY RECENT
GRADUATES OF DOCTORAL PROGRAMS
AND FEELS RELEVANT TO PATHWAY
GIVES AMERICANAL AND CHILD
HEALTH.
AWARD THESE WITH YEAST COVERED
STIPENDS AND TRAINING SEARCH
WITH THE WAY THEY COST FOR UP TO
2-3 YEARS.
NEXT SLIDE, PLEASE.
AMONG MANY POSSIBLE DIRECTIONS,
A FEW POTENTIAL KIND OF RESEARCH
AIMS INCLUDE EXPOSURE OUTCOME
SUCH AS MATERNAL WEIGHT
TRAJECTORY IN RELATION TO
CHILDHOOD OBESITY, INFANT SLEEP
HEALTH IN RELATION TO ASTHMA AND
OBESITY AND OTHER OUTCOMES, AND
MENTAL HEALTH OUTCOMES AMONG
OTHERS LISTED HERE WITH MEDIA
USE.
AND GIVEN THE SIZE,
LONGITUDINALLITY OF THE DATA
SET, AWARDEES HAVE THE POTENTIAL
TO DEVELOP NEW METHODOLOGIES FOR
ETIOLOGY AND PREDICTION IN
STUDIES IN MATERNAL AND CHILD
HEALTH.
NEXT SLIDE, PLEASE.
WITH RESPECT TO FUNDING WE
ANTICIPATE A LEVEL OF UP TO
$1.26 MILLION WHICH MAY BE
PARTLY SHARED AS WE INVITE OTHER
INSTITUTES, CENTERS AND OFFICES
TO SIGN ON TO THESE
OPPORTUNITIES.
THIS TOTAL INCLUDES PLANNING FOR
UP TO 8 AWARDS WITH R36 GRANTS
COSTING $45,000 PER YEAR FOR 2
YEARS AND F32 AWARDS COSTING
$75,000 PER YEAR FOR 3 YEARS.
NEXT SLIDE, PLEASE.
TO SUMMARIZE THIS QUESTION FOR
APPROVAL OF ISSUE FOR THESE
FOFOs, WE HAVE HAD GOOD
RESPONSE INITIAL TIEWPTS AND
REISSUE THESE OPPORTUNITIES WILL
STIMULATE WIDER USE OF ECHO DATA
WHILE INCREASE RESEARCH ON HIGH
PRIORITY AREAS OF MATERNAL AND
CHILD HEALTH AND WILL ENHANCE
RESEARCH EXPERIENCE AND CAREER
ENTRY FOR INVESTIGATOR TRAINEES.
NEXT SLIDE PLEASE.
WE REQUEST A VOTE FOR COUNCIL OF
COUNCILS FOR APPROVING THE
CONCEPT FOR MAXIMIZING THE
SCIENTIFIC VALUE DATA GENERATED
BY THE ECHO PROGRAM.
>> OKAY, KEVIN WANT TO KICK IT
OFF.
>> GREAT SLIDES AND GREAT
PRESENTATION, THIS WE'VE ALREADY
HAD EXCITING CONVERSATIONS ABOUT
THIS, I WON'T REHASH ANYTHING, I
HAVE A FEW QUESTIONS, I LOVE THE
DPOAL OF THE PROJECT AND I WAS
PLEASED TO SEE THE SICK AWARDEES
THAT ARE THERE THEY OBVIOUSLY
REPRESENT A FAIRLY DIVERSE GROUP
OF INSTITUTIONS, THERE'S CLEARLY
SOME WORK DONE THERE BUT 1 OF MY
QUESTIONS WILL RELATE TO THAT.
FIRST, YOU KNOW THERE'S ALWAYS A
BIG CHALLENGE WITH THIS PLETHORA
OF NEW RESOURCES IS HOW THEY GET
THROUGH THE NOISE TO HAVE
AUDIENCES UNDERSTAND THEIR
IMPACT OR THEIR AVAILABILITY.
I ACTUALLY NOTE NONE OF THESE AS
FAR AS I CAN TELL GOING TO THE
NIH REPORTER ARE SPECIFICALLY
FROM MAJOR CHILDREN'S HOSPITALS
THEY'RE ALL FROM PLACES LIKE
HOPKINS MAY OR MAY NOT HAVE BEEN
I CAN'T TELL BUT THE OTHERS I'M
JUST NOT SURE SO IT MAKES ME
WONDER TO WHAT EXTENT THERE
NEEDS TO BE CONCOMITANT WITH
THIS EFFORT MORE ADVERTISING AS
SORT OF THE RESEARCH 1
CHILDREN'S HOSPITALS WHO WOULD
THEORETICALLY BE IDEAL FOR BOTH
THE FIRST PROPOSAL AS WELL AS
THIS PROPOSAL.
JUST FRANKLY I KNOW ABOUT ONLY
BECAUSE OF COUNCIL.
THERE'S NOT 1 PERSON AT EITHER
VANDERBILT OR PENN, BOTH OF WHOM
HAD FUNDING THAT ACTUALLY SAID
ANYTHING TO METRICS.
SO IT'S KIND OF A SIGN.
THE SECOND THING IS I'M NOT
COMPLETELY CLEAR ABOUT THE
NUMBERS AND THIS IS PROBABLY
RELEVANT TO BOTH WHICH HEAD H TO
DO WITH THE FIRST SLIDE SAYS
THEIR, THERE'S 170,000 MATERNAL
CHILD PARTICIPANT PAIRS, THERE'S
A HARMONIZATION STEP AND I THINK
YOU'RE AT 67,000 IN THE LAST
SLIDE BUT I'M CURIOUS IF THERE'S
SOMETHING WE SHOULD KNOW ABOUT
THE DATA HARMONIZATION STEP THAT
COULD BE IMPACING IN SOME WAY
THE DATA AS WE'RE MOVING FORWARD
WITH THESE ADDITIONAL PROPOSALS.
>> LET ME ANSWER THIS FIRST, SO
65,000 ARE CHILD PARTICIPANTS
AND THEN, OTHER NUMBERS ARE THAT
IN THE CURRENT--SO WE'RE STILL
CATCHING UP WITH UPLOADING ALL
OF THOSE ON TO DASH SO THEY FEEL
IT'S GOING CANNED WHAT OVER THE
COUPLE MONTHS BUT THEN THERE'S
ALSO RELEVANT SET OF NUMBERS AS
THE KIDS THAT WE ARE TRACKING
NOW, IN THE SECOND CYCLE IN THE
SECOND FUNDING PERIOD, THAT'S
30,000 CONTINUING KID ANDS THEN
INCLUDING 30,000 NEW
PREGNANCIES.
SO IT'S A LOT OF DIFFERENT
MEMBERS, JUST DEPENDS ON HOW YOU
SLICE IT.
SO IS THAT MORE CLEAR.
>> IT DID AND I MEANT TO ALSO
ASK YOU THERE'S LONGITUDINAL
ONGOING CONNECTIONS TO ALL OF
THE COHORT.
>> YEAH, THAT'S RIGHT.
NUP TO 21.
INTERESTING.
>> AND IN RELATION TO YOUR FIRST
QUESTION, YEAH, WE DEVELOPED A
COMMUNICATIONS PLAN FOR THIS
INITIAL ROUND OF OPPORTUNITIES
AND WE ARE IN THE PROCESS
OF--WE'RE PLANNING TO EXPAND
THAT AND SO I TAKE THAT WELL AND
I TAKE QUALITY OF REVIEW POINT
CAREFULLY THAT WE WILL MAKE AN
EFFORT TO COMMUNICATE WITH
HOSPITALS AS WELL AS MORE KIND
OF CONVENTIONAL ACADEMICS, IN
THE FUTURE.
YEAH, THANK YOU.
>> THAT'S IT.
>> I WILL BE VERY BRIEF.
I HAVE THE SAME QUESTION THAT
DEVIN DID ACTUALLY ABOUT HOW
THIS IS GETTING ADVERTISED
BECAUSE--AND RELATIVE TO WHAT I
SAID BEFORE, THERE ARE FOAL
OSHIP PROGRAMS IN PEDIATRICS
AROUND THE COUNTRY AND CHILD
DEVELOPMENT, AND CHILD ABUSE AND
OTHERS THAT DON'T HAVE THE
INFRASTRUCTURE AND I AM SURE
THEY WOULD WELCOME THE
OPPORTUNITY TO GET SOMETHING
LIKE THIS FOR THEIR FELLOWS.
I MADE THIS COMMENT EARLIER ON
THE BUS TO ANNA MARIA BUT
THEY'RE NOT EXACTLY DIVING IN
WITH US.
IT LOOKS TO ME LIKE YOU'RE
PUTTING YOUR FOOT IN THE WATER
TO FIND THIS NUMBER.
IS IT BECAUSE YOU'RE NOT GETTING
ENOUGH APPLICANTS TO FEEL
COMFORTABLE CHOOSING?
OR CAN WE EXPECT AS TIME COMES
IF MORE AND MORE APPLICATIONS
COME THAT THIS COULD GROW?
>> YEAH, YEAH, THANKS FOR THAT
QUESTION.
WE DID--WITH THE FIRST, WITH THE
INITIAL ROUND WE DID
INTENTIONALLY PLAN TO START
SMALL BECAUSE WE WANTED TO SEE
HOW WELL IT WOULD WORK TO HAVE
TRAINEES ACCESSING THIS GIGANTIC
DATA SET.
HOW WELL WILL THAT WORK?
ARE THEY GOING TO NEED MORE
RESOURCES THAN WE ARE EMBASSYING
IN ARE THEY GOING TO BE ABLE TO
DO IT UNDER THE SUPER VISION OF
THEIR DOCTORAL THESIS ADVISORS
AND POST DOC MENTORS AND WE
WANTED TO START SMALL AND ASSESS
THAT AND WE NOW ARE SEEING THAT
THEY SEEM TO BE DOING GREAT.
SO THEY'RE DOING FINE.
WE DO MEET WITH THEM AS I
MENTIONED TO HELP YOU KNOW
ANSWER A FEW QUICK QUESTIONS AND
THEN GET BACK TO WORK AND WITH
FIGURE IT OUT.
THAT'S 1 REASON WE START SMALL
AND PLAN TO EXPAND.
THAT'S WHY WE'RE DOING IT RIGHT
AWAY, JUST WAITING A FEW MORE
YEARS WE WOULD LIKE TO EXPAND AS
QUICKLY WITH THESE OPPORTUNITIES
AS RESOURCES WILL PERMIT.
>> IMRAIT.
SO CAN WE OPEN IT UP FOR
ADDITIONAL QUESTIONS FROM THE
COUNCIL?
RHONDA IS YOURS UP?
WE WILL START WITH YOU.
>> THANK YOU SO MUCH I JUST WANT
TO PIGGYBACK OFF WHAT KEVIN WAS
TALKING ABOUT IN THIS TERMS OF
OTHER SOURCES, KIND OF THE
DEFINITION OF RESEARCHERS.
OBVIOUSLY THERE IS QUITE AN
EXTENSIVE NOTEBOOK WORK WITHIN
NIH AND I AM ARK SOUPING THAT
YOU'RE GOING TO LOOK AT
RESEARCHERS WHO HAVE ALREADY
BEEN IN THIS FIELD AND MAKING
SURE THEY KNOW ABOUT ACCESS TO
THIS DATA.
I WOULD REALLY ENCOURAGE YOU TO
LOOK OUTSIDE OF YOUR CLASSIC NIH
RESEARCHERS FROM WHAT YOU'RE
SAYING, KEVIN IS TRUE, THERE ARE
HOSPITAL SYSTEMS THAT ARE
COLLECTING GENETIC MATERIAL AND
THE REASON WHY THAT'S IMPORTANT
IS THAT THEY'RE DOING THEIR OWN
RESEARCH BUT THEY'RE ALSO WHAT I
WOULD SAY ON THE GROUND IN TERMS
OF DEALING WITH INDIVIDUALS
BECAUSE THEY'RE PATIENTS ARE
COMING THROUGH MUCH IT'S NOT
ONLY HOSPITAL SYSTEMS BUT THERE
ARE ALSO PROVOIDER
ORGANIZATIONS, LARGE
ORGANIZATIONS AS YOU HEARD ME
MENTION YESTERDAY THAT ARE
ACCOUNTABLE FOR THEIR
POPULATION, NOT ONLY FROM A
CLINICAL OUTCOME PER SPECTIVE
BUT ALSO FOR COST.
SO IT BEHOOVES THEM TO HAVE
ACCESS TO DATA THAT THEY CAN
BLEND WITH THEIR OWN THAT THEY
CAN UNDERSTAND WHERE ARE YOUR
HOT SPOTS AS IT RELATES TO COST,
PARTICULARLY COST THAT'S
UNNECESSARY OF THE LET ME GIVE
YOU AN EXAMPLE, IT'S NOT
PARTICULARLY TO PEDIATRICS BUT
IT IS A GOOD EXAMPLE.
AUTOIMMUNE TEASE.
WE HAVE OVER 21 DIAGNOSIS THAT
ARE ASSOCIATE WIDE AUTOIMMUNE
DISEASE.
WHEN YOU LOOK AT THE JOURNEY FOR
INDIVIDUALS WITH AUTOIMMUNE DEC,
THERE'S A LONG TRAJECTORY IN
TERPS OF GETTING DIAGNOSED.
THERE'S MULTIPLE TESTS THAT ARE
BEING DONE OVER A PERIOD OF
TIME, THEN ONCE DIAGNOSED, THE
TREATMENT GOES ALL OVER WHERE
TIMES IT LOOKS LIKE TRIAL AND
ERROR, ALL OF THESE THINGS ARE
BURDENS TO THE PATIENT, IT'S A
BURDEN TO THE PROVIDER AND IT'S
ALSO A BURDEN TO THE SYSTEM IN
TERMS OF IN MEDICAL COST WHICH
ALL AFFECTS OUR PREMIUMS IN THE
LONG RUN.
I'M SUGGESTING THIS FOR THE
PURPOSE OF EXPANDING YOUR SCOPE,
GETTING CLOSER TO THOSE WHO ARE
ACTUALLY ON THE GROUND,
DELIVERING CARE BECAUSE THEY
KNOW BETTER WHAT THEY'RE FACED
WITH AND THEY NEED TO, THEY
HAVEN'T DONE THIS MAYBE AND TO
COMMUNICATE BACK TO YOU, WHAT
THOSE HOT SPOTS ARE AND WHAT
REALLY WOULD LIKE YOU TO HELP
COMMUNICATE THAT TO YOUR
RESEARCHERS SO THEY PICK UP
THOSE THEMES.
THAT IS A DIFFERENT TYPE OF HOW
WILL YOU SAY, IT'S A DIFFERENT
APPROACH THAN WHAT HAS BEEN DONE
BY THE CDC WHICH IS LOOKING AT
DECS OF PREVALENCE AND DEATH,
HERE WE'RE TALKING ABOUT
UNNECESSARY COST THAT'S NOT BEEN
A PILLAR IN THE PAST AND I'M
SUGGESTING TO TAKE A LOOK AT
THAT BECAUSE THAT'S VERY, VERY
IMPORTANT AS IT RELATES TO OUR
ECONOMIC HEALTH AS IT RELATES TO
HEALTHCARE.
>> YEAH, THANKS SO MUCH.
THAT'S HELPFUL FOR US TO THINK
ABOUT AND YOU'RE RIGHT, YOU
KNOW, IF WE HAD THAT KIND OF A
BACK AND FOURTH, THEY COULD--YOU
KNOW IF YOU'RE ACCESSING THE
PUBLICLY ACCESSIBLE DATA WITH
SOMEONE ON THEIR STAFF, THEY
COULD SEE, YOU KNOW FROM MEDICAL
HEALTH RECORDS AND THEY WOULD
HAVE A WHOLE LONGITUDINAL SET
OF, YOU KNOW, CORRESPONDING, YOU
KNOW HEALTH OUTCOMES FOR THOSE
CHILDREN AND THAT COULD BE
REALLY--THAT COULD BE REALLY
POWERFUL, YEAH, THANK YOU FOR
THAT.
LIPPEDDA DID YOU HAVE--LINDA DID
YOU HAVE--OKAY, GREAT.
OH, SORRY ANNA, MARIE?
>> SO JUST A QUICK FOLLOW UP,
THESE 2 MECHANISMS FOR
DISSERTATION GRANTS AND T32S
WHICH ARE USUALLY POST DOCS, MY
EXPERIENCE OF HAVING BEEN BOTH
WITHIN A UNIVERSITY THAT HAS IN
A HOSPITAL SETTING AS WELL AS 1
THAT DOES NOT MOST YOUNG
CLINICIANS WHO ARE STARTING
THEIR RESIDENCY AND EVEN IF
THEY'RE IN ON AT32 WITHIN A
FELLOWSHIP PROGRAM THEY'RE NOT
ENCOURAGED TO APPLY FOR THESE
KINDS OF THINGS.
UNFORTUNATELY, THEY CAN ACTUALLY
DOWNLOAD THE DATA FROM THE DATA
BANK, THE DASHBOARD, AND GO
AHEAD AND DO AN ANALYSIS THAT
MIGHT FIT THE RESEARCH INTERESTS
FOR THAT PARTICULAR FELLOWSHIP
BUT THEY'RE NEVER GIVEN THE TIME
SO I THINK THAT'S A WHOLE
DIFFERENT TOPIC OF THE FACT THAT
IF WE WANT TO HAVE MORE MDs TO
ACTUALLY ANSWER RESEARCH
QUESTIONS, THEY NEED TO BE GIIVE
MORE TIME TO BE ABLE TO DO THAT
KIND OF STUFF.
AND SO WHERE THESE GRANTS BECOME
REALLY CRITICAL FOR, ARE THOSE
OF US WHO ARE TRAINING FUTURE
DOCTORAL STUDENTS OR POST DAK
PRESCOTTS TO BE ABLE TO DO--POST
DOCS TO BE ABLE TO DO SOME OF
THIS STUFF, IT'S THE WAY OF THE
WORLD, IT'S HARD.
YOU HAVE CLINICIANS TO BE ABLE
TO COMPLETE THESE TYPES OF
RESEARCH PROJECTS IN ORDER THAT
THEY CAN GAIN SKILL SET.
>> WELL SAID.
FOOTWORK RANCISKA.
WHY KOANT WE MOVE FORWARD.
>> GOOD DISCUSSION EMPLOY I WILL
MOVE FORWARD AS THE VOTE THAT'S
ORIGINALLY POST UNLESS SOMEBODY
WANTS ME TO ASK FOR SOMETHING
ELSE?
NOT SEEING ANY HANDS.
MAY I HAVE A MOTION FOR APPROVAL
OF THE ECHO CONCEPT CLEARANCE
ENTITLED: DISSERTATION AND POST
DOCTORAL FELLOWSHIP GRANTS FOR
THE ANALYSIS OF PUBLICLY
ACCESSIBLE ECHO DATA.
IS THERE SUCH A MOTION?
SO MOVED.
SECOND.
ANY DISCUSSION?
ALL THOSE IN FAVOR A AYE PLEASE.
I SEE LOTS OF HANDS.
ALL THOSE AGAINST SAY NAY.
ANY ABSTENTIONS?
THE MOTION CARRIES.
THANK YOU VERY MUCH.
>> THANK YOU VERY MUCH.
>> THANK YOU CLAY.
>> ALL RIGHT, WELL, WE'RE NOW
GOING TO SWITCH INTO A BREAK
VERY QUICKLY, SO WE ASK KAREN
AND KENT TO STAY ON AND MUTED
AND WE WILL SEE EVERYONE
BACK--WE WILL KEEP THE ORIGINAL
TIME AT 10:35.
SO IF FOLKS CAN COME BACK AT
10:35, THAT WOULD BE GREAT.
>> I THINK MOST PEOPLE ARE BACK
ON THEIR WAY TO THEIR SEAT IF
NOT AT THEIR SEAT SO WELCOME
BACK, WE TOOK A LITTLE BIT
LONGER BREAK THAN PLANNED BUT I
THINK PROBABLY WAS NEEDED
SPECIAL SO WE'LL JUMP INTO OUR
NEXT CONCEPT CLEARANCE FROM THE
OFFICE OF BEHAVIORIAL AND SOCIAL
SCIENCES RESEARCH DR. ERICA
SPOTTS, HEALTH SCIENCE
ADMINISTRATOR WILL PRESENT ON
THIS CONCEPT, SHORT COURSES ON
INNOVATIVE METHODOLOGIES AND
APPROACHES IN THE BEHAVIORIAL
AND SOCIAL SCIENCES.
IT IS A REISSUE.
WE WILL HAVE DISCUSSION
AFTERWARD TAC WILL BE LED BY
MONICA AND RHONDA SO WITH THAT,
ERICA ?
>> SURE.
THANK YOU SO MUCH.
THANK YOU FOR THE OPPORTUNITY TO
PRESENT THIS TODAY ISSUES AS
TARA SAID THIS IS A CONCEPT FOR
REISSUE APPROVE WILL OF OUR R25
SHORT COURSE PROGRAM.
NEXT SLIDE.
THE OBJECTIVE IS TO SUPPORT
EDUCATIONAL ACTIVITIES THAT
DEVELOP CROSS CUTTING
METHODOLOGIES AND ANALYTICS THAT
ARE RAPIDLY NEEDED TO ADVANCE
BEHAVIORIA WILL AND SOCIAL
SCIENCE AND NOT ALREADY
ADDRESSED BY EDUCATIONAL
PROGRAMS WIDELY AVAILABLE TO THE
RESEARCH COMMUNITY.
OBVIOUSLY THIS IS CONTINGENT
UPON NIH APPROPRIATIONS AND THE
SUBMISSIONS AND MERITORIOUS
AWARDS AND HISTORICALLY FOR THE
OBSSR FUNDED 8 APPLICATION WITH
EACH RFA AND THE ASHES WARD
PROJECT PERIOD IS FOR YEARS AND
THE COUNCIL ACTION WE'RE ASKING
FOR IS TO VOTE FOR CONTINUED
SUPPORT FOR THIS PROGRAM.
NEXT SLIDE.
THIS PROGRAM WAS FIRST STARTED
IN 2013.
WE MOST RECENTLY REISSUED IT IN
2023.
THIS PROGRAM INTENDS TO FILL
GAPS IN BEHAVIORIAL AND SOCIAL
SCIENCE EDUCATION NOT PROVIDED
BY MOST STANDARD [INDISCERNIBLE]
PROGRAMS AND ENCOURAGE
INTEGRATION OF BEHAVIORIAL AND
SOCIAL SCIENCE AND
NONBEHAVIORIAL AND SOCIAL
SCIENCES TO REACH AS BROAD AN
AUDIENCE AS POSSIBLE.
THE TARGET POPULATION IS THE
CHOICE OF THE APPLICANT BUT IS
TYPICALLY ALL CAREER STAGES
STARTING IN GRADUATE SCHOOL.
NEXT SLIDE, PLEASE.
THIS INITIATIVE PROVIDES 4 YEAR
SUPPORT FOR THE DEVELOPMENT OF
EDUCATIONAL OPPORTUNITIES FOR
SKILLS DEVELOPMENT.
THE COURSES ARE OFFERED AT LEAST
ONCE EACH OF 4 YEARS OF FUNDING
THE COURSE IS ADDRESSES TOPICS
NOT COMMONLY OFFERED IN TYPICAL
VIERPTS, THEY INCLUDE BUT ARE
NOT EMILY THED TO NEUROIMAGING
METHODS RELATED TO BEHAVIORIAL
AND SOCIAL SCIENCES, APPROACHES
TO MAKE BETTER USE OF BIG DATA,
OPEN SCIENCE PARADIEPS FOR
BEHAVIORIAL AND SOCIAL SCIENCES,
COMPUTATIONAL AND AI APPROACHES
FOR MULTILEVEL DATA, APPROACHES
FOR TRANSLATING BS S INTO THE
BEP DEVELOPMENT AND TESTING OF
PREVENTION AND INTERVENTION
PROGRAMS.
IN TERMS OF THE FACULTY, MENTORS
ARE ENCOURAGED TO BE FROM
DIVERSE BACKGROUNDS, SHOULD HAVE
EXPERTISE AND EXPERIENCE
RELEVANT TO THE PROPOSED PROGRAM
AND MUST BE COMMITTED TO
CONTINUE THEIR INVOLVEMENT
THROUGHOUT THE TOTAL PERIOD OF
THE AWARD.
IN 2023, APPLICATION BUDGETS
WERE LIMITED TO 200,000 THERE IS
DIRECT COSTS PER YEAR.
NEXT SLIDE.
JUST IN TERMS OF PROGRESS AND
IMPACTS IN 2013, 8 AWARDS WERE
MADE.
TOPICS INCLUDE CAUSAL ANALYSIS,
MIXED METHODS, COMMUNITY BASED
AND PARTICIPATORY RESEARCH,
DYNAMIC SYSTEMS MODELING, POWER
ANALYSIS FOR MULTILEVEL AND
LONGITUDINAL STUDIES AND MOBILE
HEALTH.
ALL MADE IMPROVES TO THE COURSES
OVER TIME IN RESPONSE TO
CHANGING NEEDS.
IN 1019, 10 AWARDS WERE MADE,
THESE WERE MHEALTH, DATA
MANAGEMENT, DISSEMINATION
IMPLEMENTATION, RANDOMIZED
CONTROL TRIALS AND RANDOMIZATION
OPTIMIZATION.
YOU WILL NOTICE THE DATA OF
THESE, THEY WERE MADE IN THE
FALL OF 2019 AND SUCCESSFULLY
AAMENDED TO CHANGE THE NATURE OF
THEIR PROGRAMS, IN 2026 DATA WAS
MADE MHEALTH DATA MANAGEMENT FOR
DATA SHARING, COMMUNITY BASED
PARTICIPATORY RESEARCH, HALF
WERE RENEWALS AND HALF WERE NEW
PROGRAMS.
NEXT SLIDE PLEASE.
SOME EXAMPLES OF THE SOME OF THE
COURSES AND THEIR REACH, SO
CAUSAL ANALYSIS COURSE HAS
TAUGHT AN AVERAGE OF 90 STUDENTS
PER YEAR WITH 53 AHNIQUE FACULTY
AND EPIDEMIOLOGY AND PUBLIC
HEALTH PROGRAM HAS TAUGHT 19
COURSES AND ONLINE OPTIONS,
CONTINUED INTERACTIONS AMONG
STUDENTS AND STAFF WERE
FACILITATE THE POST-COURSE IN
2017 ALONE THE COURSE HAD
PARTICIPANTS FROM 29 DIFFERENT
COUNTRIES.
MOBILE HEALTH COURSE REACHES
175-213 PARTICIPANTS PER YEAR.
THE COURSE IS AVAILABLE IN AN
ONLINE FORUM THAT IN 3 YEARS
LOGGED 66,005 HELPED SICK PAGE
VIEWS WITH MORE THAN 14,000
YIEWSERS AND 1 TWOWRT COUNTRIES.
IT TOOK THE COURSE TO INTERESTED
IENS TUITIONS RATHER THAN HAVING
STUDENTS CAN AM TO THEM.
THE 3 DAY COURSE WAS ALSO
OFFERED ROUTINELY ONLINE, I'M
SORRY, ENTIRELY ONLINE, IT WAS
DEVELOPED BY THE INVESTIGATORS,
WITHIN 3 YEARS, SCIENTISTS FROM
MORE THAN 100 SPECIALTIESS HAD
ATTENDED THIS COURSE.
NEXT SLIDE PLEASE AND OUR
REQUEST NOW IS FOR CONTINUED
SUPPORT FOR THIS PROGRAM,
SPECIFICALLY WE WOULD LOVE TO
REISSUE IT THIS YEAR AND IN 2
YEARS SO WOULD IT BE 2025 AND
2027 IN TOTAL.
NGREAT.
SORRY.
THANK YOU, ERICA.
I WAS ENGROSSED IN SOMETHING.
ALL RIGHT WITH THIS WE HAVE THE
DISCUSSION NOW FROM I THINK
MONICA, YOU ARE GOING TO KICK IT
OFF AND THEN WE WILL SHIFT TO
RHONDA.
>> SO THIS IS REALLY GREAT
BECAUSE WHAT I LIKE ABOUT THIS
IS THAT WE HAVE TO FIGURE OUT
CHEAPER WAYS, MORE EFFICIENT
WAYS TO SUPPORT RECALL STAGE
INVESTIGATOR AND I WANT TO GET
INTO THAT IN A MINUTE SO WHEN WE
THINK ABOUT NIH PRIORITIES GOING
FORWARD, THERE ARE 2 WAYS TO
SUPPORT EARLY STAGE
INVESTIGATORS.
ONE IS TRAINING AND COURSES AND
WEBINARS AND HOW TO WRITE GRANTS
AND HOW TO DO METHODOLOGY AND
RESEARCH VEHICLE SCIENCE AND THE
OTHER IS, I WILL SAY IT AGAIN
DECIDING WHAT WE DECIDE ABOUT
PAY LINES FOR K-AWARDS WHICH I
THINK ARE RIGHT NOW TOO LOW
ACROSS THE INSTITUTES.
SO R25 MICANISMS ARE WAYS TO
REACH A LARGE NUMBER OF PEOPLE
IN A RELATIVELY ECOST EFFECT WAY
TO TO DEVELOP EDUCATIONAL
ACTIVITIES AND R25S ARE
DIFFERENT.
WE HAVE AN R25 UCSF WHERE WE ARE
ACTUALLY BRINGING PEOPLE TO
TRAIN THEM OVER A SUMMER.
IT'S CALLED THE VISITING
PROFESSOR'S PROGRAM AND IT'S
MUCH MORE EXPENSIVE THAN THAT
BECAUSE WE'RE SUPPORTING THEIR
TUITION AND THEIR AT A AND AND
WE'RE SUPPORTING THEM OVER 2
YORES THIS, IS $200,000 A YEAR
FOR 4 YEARS.
SO THAT'S ACTUALLY RELATIVELY
COST EFFICIENT AND EACH YEAR,
THERE'S A DIFFERENT MEETING AND
EACH MEETING IS REALLY
BEHAVIORIAL--A BEHAVIORIAL AND
SOCIAL SCIENCES TOPIC THAT'S
EITHER IN METHODOLOGY OR IN
EPIDEMIOLOGY OR A MOBILE HEALTH
COURSE OR POWER CALCULATIONS
THAT'S MEANT FOR EACH AUDIENCE,
I THINK THIS IS COST EFFICIENT,
THIS SHOULD BE CONTINUED BUT 1
THING I WILL SAY THAT I
DEPARTMENT SEE THE FOCUS ON
EARLY STAGE INVESTIGATORS IN THE
RFA AS MUCH AS JUST TRAINING
PEOPLE ACROSS THE BOARD.
AND THAT WE PUT A SPECIFIC FOCUS
ON SOME BENEFIT FOR EARLY STAGE
INVESTIGATORS OR INSURING
THAT--I NEED TO SEE THE BREAK
DOWN FOR EXAMPLE, IN THE SLIDES
IT SAID WE HAD 29 DIFFERENT
COUNTRIES AND PARTICIPANTS IN
FROM THE EPIDEMIOLOGY PUBLIC
HEALTH PROGRAM BUT NOT BROKEN
DOWN BY EARLY STAGE VERSUS LATER
STAGE INVESTIGATORS SO I WOULD
MAKE ANY R25 BE FOCUSED AS MUCH
AS POSSIBLE AND ENCOURAGING
INVESTIGATORS TO ENTER NIH
RESEARCH AND HOW THEY USE THEIR
METHODOLOGY, HOW THEY CAN USE
THE PROGRAM AND POWER
CALCULATIONS AND THEN HAVE
OUTCOMES DEMAND OUTCOMES OF HOW
DID THAT COURSE HELP YOU IN
PUTTING IN A GRANT THAT USED
THESE POWER CALCULATIONS ON
MULTILEVEL AND LONGITUDINAL
STUDIES WHERE THE EARLY STAGE
INVESTIGATOR, WE HAD TO DO THIS
IN THE CFAR WHERE ANY ESI
PROGRAM WE HAVE TO REPORT
OUTCOMES, WHAT R21S, WHAT Ks
CAME OUT OF THAT TRAINING.
SO THAT'S THE ONLY SUGGESTION I
HAVE.
I THINK THIS IS VERY COST
EFFICIENT, I THINK THESE
EDUCATIONAL ACTIVITIES ARE
REALLY CROSS CUTTING AND I THINK
R25S ARE REALLY COST EFFICIENT
EFFICIENT
WAYS TO GET A LOT MORE METHOD O
LOGIC TRAINING SO I REALLY
APPROVE THIS CONCEPT.
>> THANK YOU MONICA.
I CAN'T COMMENT ON THAT
PERSPECTIVE, SO I WILL GO FROM A
DIFFERENT PERSPECTIVE.
I ALSO TOO THINK THE IDEA OF
THIS IS VERY, VERY IMPORTANT
PARTICULARLY AS PART OF YOUR
GOAL IS THE INTEGRATION OF
SOCIAL AND BEHAVIORIAL SCIENCES
AND TO THE BROADER BIOMEDICAL
RESEARCH EFFORTS IN OTHER WORDS
YOU'RE LOOKING AT COORDINATING
ACROSS MANY DIVISIONS AND
INTRODUCING BEHAVIORIAL AND
HEALTH SCIENCES INTO THOSE
VARIOUS AREAS AND TO STIMULATE
RESEARCH FROM THAT PERSPECTIVE,
SPOT ON WELL SAID.
THAT IS VERY, VERY IMPORTANT BUT
IT IS ALSO A VERY DIFFICULT JOB
FROM THE STANDPOINT AND VIEW OF
NOT ONLY THE AREAS THAT YOU
IDENTIFIED BUT JUST THE LACK OF
CONTINUITY AND STANDARDIZATION
IN THE BEHAVIORIAL HEALTH FIELD,
AND THE TREMENDOUS NEED AS WE
ALL KNOW THAT THE PREVALENCE, I
WON'T SAY MENTAL HEALTH
CONDITIONS, ALTHOUGH THAT'S TRUE
BUT PEOPLE FEELING EMOTIONAL
DISTRAUGHT HAS INCREASED
TREMENDOUSLY IN THE LAST 3 YEARS
AND SO FROM THAT PERSPECTIVE
THERE IS A GREAT NEED
PARTICULARLY ARK ROUND THE WHYED
OF HAVING A BETTER UNDERSTANDING
AS WELL AS HOW TO BETTER TREAT.
SO TRAINING ACROSS THIS
PARTICULAR AREA IS A REAL
IMPORTANT 1.
I WOULD ADVISE YOU TO LOOK
OUTSIDE AGAIN OUT OF YOUR NORMAL
PLACES WITHIN NIH.
THE REASON BE BEING THERE'S A
LOT OF ORGANIZATIONS THAT ARE
MOTIVATED BY ADVOCATES THAT HAVE
ACCUMULATED A LOT OF MONEY TO
TRY AND CONDUCT THEIR OWN
RESEARCH AND THIS MIGHT BE A
GOOD COLLABORATION TO HAVE.
MANY OF THEM ARE IN TOUCH WITH
CERTAIN POCKETS OF THE
POPULATION THAT HAS SPECIFIC
INTERESTS AND I THINK THIS COULD
HELP NOT ONLY FROM THE
STANDPOINT OF VIEW OF HELPING
THEM BECAUSE THEY MAY NOT KNOW
HOW TO DO THIS BUT ALSO HELP
FUELING THE EMPHASIS ON THE
DIRECT DIRECT APPLICATION OF THE
RESEARCH INTO A REAL WORLD,
MAYBE NOT IN TERMS OF PRACTICE
BUT IN TERMS OF UNDERSTANDING
AND HAVING THOSE AS A PREMISE BY
WHICH 1 APPROACHES POPULATIONS
AND INTERVENING WITH THOSE
POPULATIONS.
SO I THINK THIS IS EXCEPTIONAL
IMPORTANT.
I THINK IN THIS IT BROUGHT UP
COMMON THEMES, THE COMMON THEMES
WAS TRAINING AROUND NEW
METHODOLOGIES OR I WOULD SAY
IMPORTING DIFFERENT
METHODOLOGIES FROM DIFFERENT
AREAS AND DIFFERENT INSTITUTES,
BEING ABLE TO WORK WITH LARGE
DATA SETS AND BEING ABLE TO
PERFORM ANALYSIS, THIS IS A
THEME THAT'S BEEN BROUGHT FORTH
IN OTHER CONCEPTS AND SO I WANT
TO TAKE A STEP BACK TO SAY, IS
THERE A COMMONALITY IN THIS NEED
THAT'S GOING ACROSS SEVERAL
DIFFERENT ORGANIZATIONS AND
WOULD THERE BE A PROTOCOL OR A
PLAY BOOK FOR THIS THAT WOULD
ALLOW PROBABLY BEING REALLY
POLYANNISH HERE SO PLEASE EXCUSE
ME SOME LEVEL OF BASIC TRAINING
IN THESE DIFFERENT
METHODOLOGIES, DATA ANALYSIS AND
SO FORTH THAT GOES ACROSS ALL
INSTITUTIONS.
SO THEREFORE THERE WOULD BE
SOME--HOW WOULD YOU SAY--A
COMMON WAY THIS IS DONE.
I THINK THIS IS PARTICULARLY
DIFFICULT IN THE BEHAVIORIAL
HELT AREA AS I MENTIONED BEFORE,
THERE'S A LACK OF
STANDARDIZATION PARTICULARLY
AROUND HOW YOU LABEL THINGS WHAT
YOU CALL THINGS, EVEN THE
UNDERSTANDING OF WHAT A
METROPOLITANNAL ILLNESS IS NOT
ALWAYS CLEAR EXCEPT DEFINED BY
DSM5 BUT WE HAVE OTHER
SUBCATEGORIES OF THINGS THAT ARE
GOING ON NOW BECAUSE MAIORITY OF
PEOPLE SEEKING MENTAL HEGHT
TREATMENT DO NOT HAVE A CLASSIC
DIAGNOSIS, IT'S MOSTLY
TRANSITION, ANXIETY AT THIS
POINT.
SO THE FIELD IS 1 THAT HAS A LOT
OF LACK OF CLARITY MUCH SO
THAT'S GOING TO MAKE THE JOB OF
TRAINING AS IT RELATES TO DATA
AND METHODOLOGIES VERY
DIFFICULT.
SO I JUST WANT TO MAKE SURE THAT
THAT'S ACKNOWLEDGE AND THAT IT'S
ADDRESSED IN HOW YOU'RE
APPROACHING THIS.
SO THANK YOU SO MUCH, I
APPRECIATE THE OPPORTUNITY TO
COME IN.
>> THANK YOU.
I JUST WANT TO MENTION, I DID
NOT SAY THIS YEAR BUT OVER THE
COURSE OF THE DECADE THAT WE'VE
HAD THIS PROGRAM, WE'VE HAD
INVOLVEMENT FROM SOMEWHERE IN
THE VICINITY OF 10 OTHER
INSTITUTES AND CENTERS WITH THIS
PROGRAM.
SO IT IS A CROSS CUTTING
NIH-WIDE PROGRAM AND 1 OF THE
BENEFITS OF IT IS THAT WE HAVE
FUNDED THINGS THAT WOULD NOT NOT
OTHERWISE GOTTEN FUNDED IF THEY
HAD JUST GONE TO AN INSTITUTE IN
PARTICULAR.
SO I THINK THERE A LOT OF THAT
COST NIH INVOLVEMENT ALREADY.
WE'VE HAD A NUMBER OF
APPLICATIONS COME IN BOTH FROM
THE COMMUNITY BASED
ORGANIZATIONS BUT ALSO WE'VE
FUNDED WHETHER THERE'S SEVERAL
PARTNERSHIPS AND RESEARCHERS
FROM COMMUNITY BASED
ORGANIZATIONS SO THERE'S THAT TO
SPECIAL DEGREE, NOT IN ALL THE
PROGRAMS BUT THEY DO INVOLVE
COMMUNITY ORGANIZATIONS.
>> OKAY, SO CAN WE OPEN IT UP
FOR QUESTIONS FROM THE BROADER
COUNCIL.
>> ANNA MARIA AND THEN RAFAEL.
>> I WANTED TO FOLLOW UP BECAUSE
WHAT I DIDN'T SEE AND WOULD LOVE
TO HEAR IS WHO'S GETTING THESE
GRANTS AND ARE THEY GOING INTO
STATES WHERE THERE MIGHT NOT BE
A STRONG YOU KNOW ACADEMIC
INSTITUTION THAT IS ALREADY
PROVIDING THAT KIND OF TRAINING
SO THAT YOU GET INDIVIDUALS WHO
MIGHT NOT HAVE ACCESS TO THAT
KIND OF TRAINING, BE ABLE TO
PARTICIPATE AND I KNOW YOU SAID
SOME OF IT WAS DONE ONLINE, BUT
ARE THEY REQUIRED TO REPORT SO
THAT YOU CAN UNDERSTAND SORT OF
THE GEOGRAPHIC GRIEWKS AND SORT
OF THE IMPACT THAT IT'S ACTUALLY
MAKING ACROSS MANY DIFFERENT
FIELDS LIKE RHONDA BROUGHT UP?
>> I MUST ADMIT IT DIDN'T OCCUR
TO ME TO DO KIND OF ANALYSIS WHO
WHO HAS GOTTEN THESE GRANTS.
WHAT I WILL SAY IS THAT WE
STRONGLY ENCOURAGE THE RECIPIENT
OF THE AWARDS TO AS FAR AND
BROADER REACH IN RECRUITING
PARTICIPANTS AS FAR AS POSSIBLE.
SO BY SAYING THEY'RE GOING TO
BRING IT THEIR UNIVERSITY,
THAT'S NOT GOOD ENOUGH.
WE WANT THEM TO BRING IN PEOPLE
FROM A BROAD RANGE OF
BACKGROUNDS, GEOGRAPHIC
LOCATIONS, ET CETERA AND I'VE
FORGOTTEN WHAT THE NEXT PART OF
YOUR QUESTION WAS, SORRY.
>> NO, I MEAN WITH THAT IS
UNDERSTANDING WHAT FIELDS THESE
DIFFERENT FIELD ARE COMING FROM.
>> SO WE'VE HAD CHALLENGES WITH
DO ENCOURAGE THEM TO EVALUATE
THE STUDENTS THAT COME INTO
THEIR EDUCATIONAL PROGRAMS.
THERE ARE SOME CHALLENGE WITH
TRACKING THEM BECAUSE THESE ARE
4 YEAR GRANT ANDS THEY'RE NOT AS
WAS NOTED THEY'RE NOT AS LARGE
OF GRANTS AS SOME GRANTS OR SO
IT'S HARD TO ACTUALLY FOLLOW UP
WITH THE STUDENTS OF THESE
PROGRAMS OVER BEYOND THE 4 YEARS
OF THE PROGRAM.
BUT I COULD CERTAINLY GO BACK
CAN COMPILE THAT INFORMATION.
IT DEPENDS ON THE--IT REALLY
DEPENDS ON THE FOCUS OF THE
PROGRAM AS WELL EMPLOY SO
SOMEBODY WHO TAKES FOR EXAMPLE,
A POWER CALCULATIONS 1, THAT
MIGHT NOT HAVE QUITE AS LARGE OF
AN IMPACT ON, IT WOULD BE USEFUL
AND REALLY IMPORTANT BUT NOT
QUITE AS LARGE OF AN IMPACT ON
1'S CAREER AS SOMEBODY WHO GUESS
INTO THE CBPR 1 AND LEARNING
THESE METHODS FOR OVERALL
RESEARCH THAT MIGHT YOU KNOW
REALLY IMPACT THE TRAJECTORY OF
THE CAREER.
BUT THAT'S AN INTERESTING POINT
AND I SHOULD GO BACK AND TAKE A
LOOK AT SOME THESE THINGS.
>> YEAH, TRACKING JUST IN
GENERAL OF TRAINEES, WE WERE
TALKING ABOUT WHEN THEY'RE
TAKING COURSES, IS IT
CHALLENGING AND SOMETHING WE'RE
ALWAYS TRYING TO REFINE AND ARE
STRUGGLING WITH ACROSS THE
BOARD, NOT JUST NIH, BUT YOU
KNOW SNF IS OTHER AGENCIES THAT
SUPPORT TRAINEES NAND THERE ARE
ALSO SOME COURSES THAT WANT TO
TRACK TRAINEES AND COULDN'T
BECAUSE OF FRFA, SO THERE ARE
MANY CHALLENGES TO LOOKING AT
THE IMPACT OF THESE.
NTHERE ARE SOME SOLUTIONS THOUGH
THAT PEOPLE ARE DEVELOPING
THOUGH SO I DON'T WANT TO SOUND
LIKE IT'S IMPOSSIBLE BUT IT IS A
LITTLE BIT HARDER EACH WHEN
WE'RE TALKING ABOUT THESE KIND
OF COURSES INSTEAD OF DIRECT
AWARDS.
THAT SORT OF THING.
RAFAEL?
>> HOW LONG ARE YOU'RE THESE
COURSES USUALLY BECAUSE I'M
SEEING SOME PRETTY ADVANCED
COURSES, SOME OF THESE WHICH ARE
Ph.D. COURSES AND ARE FULL
SEMESTER Ph.D. COURSES IN OUR
PROGRAM.
NIT REALLY DEPENDS ON THE
PROGRAM.
SO ALL OF THEM ARE 4 YEAR AWARD
BUT I DON'T THINK THAT'S YOUR
QUESTION.
SOME OF THEM ARE SO FOR EXAMPLE
THE POWER CALCULATION 1 WAS A 3
DAY COURSE AND THAT WAS IT.
SOME OF OF THE OTHER 1S FOR
EXAMPLE THE CBPR WAS A 1 OR 2
DAYS PER WE'RE IN-PERSON COURSE
AND THEN THEY WERE ASSIGNED A
MENTOR THEY INTERACTED WITH
DURING THE NEXT YEAR OR 2, THE
SAME WITH THE MIXED METHODS 1
DID A SIMILAR THING.
A LOT OF THEM CREATE KIND OF
ONLINE GROUPS LIKE PEER GROUPS
THAT THEY CONTINUE ON WITH
THROUGH THE NEXT NUMBER OF YEARS
OR INDEFINITELY SO IT REALLY
DOES VARY.
>> OKAY, SO YEAH, 1 THING I WILL
BE CAREFUL ABOUT IS THAT COURSES
THAT JUST GIVE YOU RECIPES AS
OPPOSE TO UNDERSTANDING WHAT
YOU'RE DOING, THAT COULD LEAD TO
MISUSE OF THE METHODS.
>> ABSOLUTELY.
AND THAT'S SOMETHING THAT THUS
FAR REVIEW AS BEEN VERY GOOD AT,
I THINK, AT KIND OF EVALUATING
IN THE APPLICATION.
>> GENE, I THINK YOU'RE NEXT.
>> I KNOW IT'S PROBABLY SPOKEN
ABOUT BEFORE BUT WHAT WE TRY TO
DO IS OFFER GRANTS FOR THE
COURSE FOR SEVERAL YEARS AND
WHAT WE TRY TO DO IS OFFER THAT
OPPORTUNITY TO AT A AS A COHORT
AND HAVE WHOEVER TO THE COURSE
ONCE A YEAR MEET WITH PEOPLE AND
KNOW THAT EVERYTHING IS ONLINE
JUST TO CHECK-IN WITH THEM AND
HAVING THAT PART OF THE GRANT WE
WOULD LIKE THIS TO CONTINUE IN
SOME FORM OR FASHION THAT'S NOT
TOO TIMELY AND DIDN'T TAKE A LOT
OF TIME BUT I THINK ENCOURAGING
PEOPLE TO DO THAT BECAUSE THEN
WE LOOSE, HOW THAT INFORMATION
COULD HELP US SAY WELL THESE
TRAINEES MOVE ON TO THE
FOLLOWING PLACES.
WE TALKED ABOUT THE PIPELINE
LAST NIGHT WHICH YOU DIDN'T
QUALIFY FOR BUT I LOVE, BUT WE
KEEP PEOPLE IN SCIENCE, WHERE
ARE THEY?
OUTSIDE OF THE COURSES, I WANT
TO KNOW IF WE DO ALL THE THINGS
WE DO ARE THEY HELPFUL TO
PEOPLE.
THEY MAY NOT END UP EXACTLY
WHERE WE THINK THEY ARE ENDING
UP BUT ARE THEY STAYING IN
SCIENCE, RESEARCH, WHATEVER IT
IS.
IT'S MORE THAN JUST A COURSE.
HOW DO WE MAKE SURE THAT WHAT
WE'RE DOING IS BEING BENEFICIAL
ANDIME SURE IT IS BUT IS IT
GETTING TO THE PLACE WE WANT
THEM TO GET TO.
DO WE NEED TO DO MORE, SHOULD
THEY GO FROM 1 COURSE TO THE
NEXT, YOU WE WANT DISCOURSE, WE
WANT TO ENCOURAGE YOU TO GO TO
THAT SO THAT WE SORT OF THINK
ABOUT IT PERSPECTIVELY AND
STUDENTS ARE CHOOSING BASED ON
WHAT THEY NEED AT A PARTICULAR
MOMENT ARE NOT REALIZING THAT
THIS NEED WILL PROBABLY
TRANSLATE TO THIS OTHER THING
WE'RE DOING SO HOW DO WE HELP
THEM CONNECT THE DOTS.
>> I'M NOT SEEING ANY OTHER
QUESTIONS SO WHY DON'T WE MOVE
FORWARD WITH A VOTE.
NSO I VOTE DISCUSSIONS BUT I
THINK THEY CAN PRETTY MUCH
STRAIGHT FORWARD MOVE TO A
REQUEST.
MAY I HAVE A MOTION FOR
APRIEWLAL OF THE OBSSR CONCEPT
ENTITLED SHORT COURSES ON
INNOVATIVE METHODOLOGIES IN AND
APPROACHES IN THE BEHAVIORIAL
AND SOCIAL SCIENCES.
IS THERE SUCH A MOTION?
SECOND.
THANK YOU.
ANYMORE DISCUSSION?
ALL THOSE IN FAVOR SAY AYE.
ALL OPPOSED SAY NAY, NOT
HEARING, ANY.
ANY ABSTENTIONS?
THANK YOU ALL.
THE MOTION CARRIES.
>> THANK YOU ERICA.
>> THANK YOU.
WELL, NOW WE HAVE MAGICALLY GOT
ARK HEAD OF SCHEDULE BY A COUPLE
MINUTES NOW SO THAT'S GREAT.
NEXT WE HAVE A PRESENTATION FROM
THE OFFICE OF STRATEGIC
COORDINATION OR THE COMMON FUND
OFFICE, DR. DOUG SHEELEY WHO IS
THE ACTING DIRECTOR WILL PRESENT
A--BITS UPDATE ON THE COMMON
FUND VENTURE PROGRAM WHICH WE
HEARD ABOUT EARLIER THIS YEAR.
SO WE HAD MENTIONED THAT WE
WOULD CIRCLE BACK TO YOU ALL ON
KIND OF WHERE THINGS STAND WITH
THIS PROGRAM, SO DOUG?
NTHANKS TARA.
IT'S GREAT TO BE WITH YOU TODAY
TO GIVE YOU AN UPDATE ON THE
VENTURE PROGRAM BEFORE I BEGIN I
WANT TO ADD MY WELCOME TO OUR
INCOME DIRECTOR CAROLYN
HUTTER,IME LOOKING FORWARD TO
WORKING WITH YOU CAROLYN AND I
ALSO WANT TO ACKNOWLEDGE SOME OF
OUR IC COLLEAGUES WHO HAVE BEEN
IMPORTANT IN THE DEVELOPMENT OR
WHO ARE LEADING THE DEVELOPMENT
UP TO THE INITIATIVES WHY WILL
INTRODUCE TO YOU TODAY, JONATHAN
[INDISCERNIBLE] IN NIDA, AND
[INDISCERNIBLE] ANDERSON FROM
NIBIB, AND DOMINIC AND PY JUDGE
MCATS AND THEY WILL BE HERE TO
CORRECT ME WHEN I
MISCHARACTERIZE THE SLIDES OF
WHATY WOO WILL BE TALKING ABOUT.
NEXT SLIDE PLEASE.
SO THE IDEA OF THE VENTURE
PROGRAM GREW OUT OF DISCUSSIONS
WITH THE NIH LEADERSHIP AND THAT
IS TO HARKEN BACK TO THE NIH
ROADMAP AND THINK ABOUT HOW WE
CAN DO AMAZING THINGS WITH
MODEST FUNDING AND THAT'S A
QUOTE FROM ELIAS
[INDISCERNIBLE].
SO THE COMMON FUND IS THE IDEA
IS TO ABLE TO DO SMALLER FOCUSED
BUT STILL BOLD INITIATIVES TO
TRY TO ACCOMPLISH AN UPSIZED
IMPACT WITH A MODEL LEVEL OF
FUNDING FOR A SHORT PERIOD OF
TIME.
THESE INITIATIVES WOULD GO FOR 3
YEARS, AND THEY RECEIVE ABOUT
$5 MILLION A CAREER FOR THAT
TIME.
AND FY24 WE LAWRCHED OUR FIRST 2
AND I WILL GIVE YOU AN UPDATE ON
THE STATUS OF THOSE 2.
NEXT SLIDE.
THOSE INITIATIVES, ALL NEED TO
STILL MEET THE PROGRAM CRITERIA
THAT WE HAVE FOR COMMON FUND AS
A WHOLE.
AND THOSE CRITERIA HAVEN'T
CHANGED EMPLOY , WEEK EXPECT THE
WORK TO BEING TRANSFORMATIVE
WE'RE SHOOTING FOR EXCEPTIONAL
HIGH IMPACT TO THE INVESTMENT
WE'RE MAKING WE ALSO WANT THOSE
INVESTMENTS TO BE CATALYTIC SO
THAT IT STIMMULING OTHER
RACIVITY OUTSIDE IN THE RESEARCH
COMMUNITY.
THEY'RE DPOAL DRIVEN.
WE'RE VERY CAREFUL TO AMRI, TO
TEAB MILESTONES AND TO APPLY
THOSE MILESTONES AS WE MONITOR
PROGRESS OF THE PROGRAMS AND WE
WILL DO THAT WHETHER IT'S A
FULLON COMMON FUND PROGRAM OR A
MODEST FUND PROGRAM.
WE EXPECT THOSE TO BE SINNER
GESTIC EMPLOY WE WANT TO SEE AN
IMPACT THAT GOES ACROSS THE NIH
AND ACROSS THE VARIETIES OF THE
DIFFERENT COMPONENTS OF NIH AND
IF--AND WE EXPECT THAT WORK TO
BE INNOVATIVE.
TO BE A VENTURE INITIATIVE, WE
EXPECT THOSE TO BE BOLD, TO
MAKERS AND A DARING INVESTMENT
THAT HAS POETIC TEBTIAL FOR
SIGNIFICANT UPSIZED IMPACT BUT
WE ALSO WANT TO IMPLEMENT THEM
RAPIDLY, WE STREAMLINE THE
APPROACH, ALTHOUGH WE ADHERE TO
THE SAME PROGRAM TWEPMENT AND
SELECTION APPROACH THAT WE DO
FOR OTHER COMMON FUND PROGRAM
ANDS AGAIN 3 YEARS UP TO
$5 MILLION A YEAR.
NEXT SLIDE.
SO THE FIRST 2 INITIATIVES, THE
GOAL OF THE [INDISCERNIBLE]
IMAGE IS TO TAKE ADVANTAGE OF
THE TECHNOLOGY TO LOOK BEYOND
EYE DISEASE AND WHETHER WE CAN
FIND SPECIFIC HIGH VALUE
BIOMARKERS FOR DECS THAT ARE
SYSTEMIC AND BEING ABLE TO USE
THE EYE AS A WINDOW FOR THOSE
OTHER ILLNESSES.
AND SO WE HAD ISSUED A RESEARCH
OPPORTUNITY ANNOUNCE AM IN
MARCH, WE RECEIVED APPLICATIONS
IN MAY AND WE EXEC TO MAKE 3 ARK
WARDS BY THE END OF THIS MONTH.
NEXT SLIDE.
THE SYSTEMS BIOLOGY DAILY BASIS
THEA PLATFORM IS A PROJECT THAT
WILL TAKE DATA THAT'S COME IN
UNDER THE ACCELERATING
MEDICINE'S INITIATIVE AND
INTEGRATE THAT ACROSS THE
DIFFERENT DISEASE AREAS AND
SYSTEMS THAT ARE BEING STUDIED
IN THOSE INITIATIVES TO TRY TO
HELP US TO DRAW OUT AND
EMPHASIZE MODEL CITIZEN LEAKULAR
PHENOTYPES THAT ARE IN COMMON
ACROSS THOSE DIFFERENT SYSTEMS
AND DECS, SO FOR EXAMPLE, SEE
COMMONALITIES THAT HAVE TO DO
WITH INFLAMMATION ACROSS SEVERAL
DISEASES THE BRAIN STUDIED
THERE.
AND A XON PLATFORM TO DO THAT
DATA INQUIRY AND WE ISSUED AN
ASHES NOUNS WANT IN MARCH, HAD
THE APPLICATIONS AND REVIEWED
OVER THIS SUMMER AND THERE WILL
BE 1 OR 2,A WARDS MADE THIS
MONTH.
NEXT SLIDE.
SO WE'VE BEEN THINKING THROUGH
HOW WE IMPROVE VENTURE AND HOW
DO WE IMPROVE IT?
AND WE WANT TO MAKE SURE WE'RE
CONSISTENTLY LEVERAGING PUBLIC
INPUT SO PUBLIC CALL THAT WE
MAKE FOR INPUT FOR IDEAS FOR
COMMON FUND AS HAS BEEN
REGULARIZED TO BE ISSUED EVERY
YEAR NOW, THIS IS--THIS YEAR WAS
THE THIRD YEAR IN A ROW THAT WE
DID THE REQUEST FOR INFORMATION
AND THAT INFORMATION GOES TO THE
SCIENTISTS ACROSS THE ICs FOR
THE IC DIRECTORS TO BE ABLE TO
FEED THE PROCESS OF DEVELOPING
THE PROGRAMS AND WE WANT TO COME
BACK TO YOU WITH REGULAR UPDATES
EVERY YEAR ABOUT THE STATUS OF
THE PROGRAM AND WHAT THE
INITIATIVES ARE THAT WE'RE
PUTTING FORWARD AND APPLY THE
SAME KIND OF TRANSPARENCY THAT
WE DO WITH ALL OF OUR OTHER
PROGRAMS WHERE THERE'S A PROGRAM
WEBSITE, ALL THE MILESTONES ARE
THERE, THE PROGRESS THAT'S BEING
MADE IS THERE, AND WE CAN SHOW
HOW WE'RE DOING OR COORDINATING
AND HOW WE'RE JUDGING PROGRESS
ON THOSE INITIATIVES.
NEXT SLIDE.
WE ALSO WANT TO MAKE SURE WE'RE
CLEAR ABOUT WAWE'RE TALKING
ABOUT IN VENTURE, WE WANT TO
BE--BECAUSE UNLIKE SOME OF THE
OTHER PROGRAMS IN COMMON FUND
WHERE THERE'S A SPECIFIC
SCIENTIFIC AREA THAT'S BEING
ADDRESSED THIS IS MUCH MORE WIDE
OPEN, WE WANT TO BE CLEAR THAT
IT INCLUDES BIOMEDICAL AND
BEHAVIORIAL SCIENCE, THE FULL
SPECTRUM OF WORK THAT NIH
SUPPORTS AND ACROSS THE BASIC
TRANSLATIONAL AND CLINICAL
FRAMEWORK TO INCLUDE COMMUNITY
BASED RESEARCH.
I WANT TO BE CLEAR THAT EVERYONE
WHO'S INTERESTED IN DEVELOPING
PROGRAMS, DEVELOPING INITIATIVES
UNDER VENTURE KNOWS THAT AND WE
WANT TO EMPHASIZE THAT WE'RE
INTERESTED IN OLD APREACHES THAT
HAVE THE POTENTIAL FOR OUTSIDE
IMPACT THAT WE'RE HOPING TO
ACCOMPLISH GREAT THINGS IN A
SHORT PERIOD OF TIME WITH THESE
INIAATIVES.
WE WANT TO MAKE SURE WE'RE
ACTIVELY ENCOURAGING INCLUSION
OF DIVERSE, SCIENTIFIC AND
CULTURAL PERSPECTIVES AS WE HAVE
THE TEAMS ON THESE PROGRAMS.
EVERYTHING WE DO IN COMMON FUND
IS PREDICATED ON COLLABORATION.
THE TEAMS THAT ARE ASSEMBLED TO
DO THE WORK, THE TGF BETA WORK
AND ALSO THE TEAMS THAT ARE
ASSEMBLED INSIDE NIH TO DO THAT
WORK AND WE WANT TO MAKE SURE
WE'RE AS EBSPLICIT AS POSSIBLE
ABOUT MAKING SURE WE'RE DOING A
GOOD JOB OF PUTTING OUR VALUES
TO WORK IN THE STUDIES PROGRAM.
AND SO WE'RE MAKING SURE WITH
THIS INITIATIVE AND ALSO WITH
OUR OTHER COMMON FUND ACTIVITIES
THAT WE'RE ACTIVELY LOOKING
INSIDE THE OFFICE OF HOW TO DO
BETTER WITH THAT AND APPLYING
THOSE PRINCIPLES THAT ARE BEING
ARRIVED AT BY THE COMMITTEE WORK
IN OUR GROUP.
AND ALSO MAKING SURE THAT WE'RE
DOING THE KIND OF OUTREACH WE
NEED TO TO REACH ALL THE
POTENTIAL VERY LONGS THAT IT
PARTICIPATE IN THESE
INITIATIVES.
NEXT SLIDE.
SO I WILL TELL YOU TODAY ABOUT 2
NEW INITIATIVES THAT ARE MOVING
FORWARD FOR DEVELOPMENT FOR FY25
AND 26.
AND THE FIRST 1 IS AN EFFORT TO
IMPROVE NEW BORN SCREENING BY
USING WHOLE GERONTOLOGYSTS NEM
SEQUENCING.
AND THE IDEA HERE IS TO
DEMONSTRATE THAT WE CAN BUILD A
COLLABORATIVE EFFORT THAT WOULD
INCLUDE SEVERAL STATES TO TAKE A
DIFFERENT APPROACH RATHER THAN
BEING CONFINED TO BIOCHEMICAL
ASSAYS, TO SCREEN NEWBORNS FOR
GENETIC DECS, WE CAN USE
SEQUENCING TO TRY TO SCREEN FOR
MORE DISEASES AND TO DO SO MORE
WITH GREATER EFFICIENCY AND
BETTER ACCESS AND KEEP PACE WITH
THE THERAPEUTIC DEVELOPMENTS
THAT MAKE IT WORTH WHILE TO
KREEN FOR NEW DECS.
NEXT SLIDE.
SO RIGHT NOW MOST NEWBORNS IN
THE UNITED STATES ARE SCREENED
BY PUBLIC HEALTH LABS FOR A
VARIETY OF GENETIC DISORDERS,
AND SO YOU MIGHT TAKE A BLOOD
SAMPLE AND LOOK FOR A MASS
SPECTROMETER AND LOOK FOR PEAKS
IN THE METABOLITES.
MANY STATES KREEN FOR A NUMBER
OF DISEASES CAN THOSE ARE
RECOMMENDED ON THE TANNED ARD
ROSTER OF DECS TO KREEN FOR BUT
THERE ARE THOUSANDS OF RARE DECS
THAT AREN'T SCREENED FOR AND AS
CAPABILITIES IMPROVE, AND
INTERVENTIONS BECOME AVAILABLE,
WE WANT TO MAKE SURE THAT
FAMILIES AND CHILDREN HAVE
ACCESS TO THE SCREEN THAT WOULD
ENABLE TREATMENT OR INTERVENTION
AT AN EARLY TAIJ AS POBLG AND TO
SIMPLIFY IT, THE PROCESS OF IAT
THE PRESENT TIMIFYING AN ILLNESS
AND BEING ABLE TO SEEK
TREATMENT.
SO NEXT SLIDE, PLEASE.
SO THE GOALS HERE ARE TO SUPPORT
A CENTRALIZED LAB FOR ANALYSIS
AND INTERPRETATION OF RESULTS.
FOCUS ON A LIMITED GENE PANEL OF
THINGS THAT ARE SERIOUS, OF
CHILDHOOD OR INFANCY AND TO BE
ABLE TO PROVIDE ACCESS TO THAT
INFORMATION FOR PARENTS AND
ACHIEVE EQUITABLE ACCESS TO THAT
GENOME SEQUENCING ACTIVITY AND
IN THAT PERIOD AND BIBLE TO ASK
QUESTIONS AS WE'RE DOING THIS ON
A LIMITED SCALE IN THESE
FEASIBILITY STUDY ABOUT HOW TO
DO THIS THE RIGHT WAY AND WHAT
ARE THE--WHAT ARE THE QUESTIONS
THAT WILL COME UP IN TERMS OF
ETHICS AND LEGAL AND SOCIAL
IMPLICATIONS TO BE ABLE TO TAKE
FULL ADVANTAGE OF THIS
TECHNOLOGY.
NEXT SLIDE.
SO PROGRAM TO BE ABLE TO KNOW
WE'RE DOING THESE THINGS RIGHT
WILL ESTABLISH AN ADVISORY BOARD
THAT WILL LOOK FOR INFORMATION
ON HOW TO DO THIS WELL AND
CONSIDER THE NEEDS OF ALL THE
COMMUNITIES THAT CAN BENEFIT
FROM IT.
AND ADVISE ON HOW TO ENGAGE
COMMUNITIES, HOW TO DEAL WITH
CONSENT ISSUES, HOW TO SHARE
DATA AND HOW TO DESIGN THE
RESEARCH THAT'S GOES ON IN THIS
PROGRAM OVER THE PERIOD OF 3
YEARS.
WE WANT TO TRY TO BRING IN NEW
EXPERTISE TO THE FIELD, TO NEW
BORN SCREENING WE ARE GOING TO
TRY TO TRY TO IMPROVE THE
SCIENTIFIC PERSPECTIVE THAT WE
HAVE AND TRY TO UNDERSTAND WHEN
IT'S APPROPRIATE TO MOVE INTO A
GENETIC SCREEN AND WHEN IT'S
APPROPRIATE TO CONTINUE TO LOOK
AT METABOLITE AND IT IS BE ABLE
TO LOOK AT COMPLEX METABOLIC
PHENOMENON.
NEXT SLIDE.
I LOOKED THROUGH THE COMMON FUND
CRITERIA, AND THE VENTURE FUND
CRITERIA AND PICKED OUT A FEW
AREAS OF EXAMPLES OF WAYS THAT
THIS INITIATIVE IS RESPONSIVE TO
OUR CRITERIA.
CERTAINLY THIS WILL BE
TRANSFORMATIVE.
THE OPPORTUNITY TO CHANGE
FUNDAMENTALLY IS HOW WE DO NEW
BORN SCREENING TO PROVIDE FAR
GREATER ACCESS AND FAR MORE
EQUITABLE ACCESS WILL BE A BIG
STEP FORWARD EMPLOY WE THINK
THAT BY DOING THIS IT WOULD HAVE
A CATALYTIC IMPROVEMENT ON A
BROADER SCALE THAN THE INITIAL
PROJECT FOR A WHILE AND IN TERPS
OF THE VENTURE CRITERIA,
CERTAINLY IT'S A BOLD INIT
WHYATIVE BECAUSE OF THE PRANS
FORMATIVE NATURE AND THEY WILL
PROVIDE ACTIONABLE INTERVENTION
AND THOSE THAT ARE ALREADY
AVAILABLE AND BE ABLE TO MOVE
FORWARD QUICKLY WITH A SMALL
NUMBER OF STATES PARTICIPATING
IN A FOCUSED PROGRAM TO SHOW
FEASIBILITY FOR A LARGER
PROGRAM.
NEXT SLIDE.
SO I'VE ALREADY TALKED I THINK
ABOUT ALL OF THIS.
WE HOPE THAT WHAT WILL HAPPEN IS
THAT WE WILL BABLY TO SHOW WE
CAN DO THIS EFFECTIVELY FROM A
TGF -
-SCIENTIFIC AND ETHICAL
PERSPECTIVE AND PROVIDES A MODEL
FOR EXPANDED NEW BORN KREENING
AND DISEASES WHERE INTERVENTIONS
ARE AVAILABLE AND WE CAN MAKE IT
MORE STRAIGHT FORWARD FOR
FAMILIES TO FIND THE HELP THAT
THEY NEED FOR SERIOUS GENETIC
DISEASES.
NEXT SLIDE.
THE SECOND INITIATIVE I WANT TO
TALK TO YOU ABOUT IS A BROAD
EFFORT TO ADVANCE NONINN VASIVE
OPTIMAL APPROACHES FOR
BIOLOGICAL SYSTEMS AND THIS IS
REALLY PREDICATED ON THE SIMPLE
IDEA THAT THE RESOLUTION AND
SENSITIVITY WE CAN GET ON
OPTICAL IMANNUALING TECHNOLOGIES
IS INADEQUATE TO DO EVERYTHING
WE WANT TO DO BUT CLINICALLY,
YOU KNOWION THAN GAVE ME A
FLASHLIGHT WHEN I CAME IN AFTER
THE BREAK TO REMIND US ALL OF
THE THINGS WE USED TO DO WITH WE
WERE KIDS.
YOU KNOW YOU PUT YOUR HAND UP
OVER YOUR LIGHT, I REMEMBER
DOING THIS IN THE BACK OF THE
DAD'S CAR, AND YOU CAN SEE A
GREAT EXAMPLE OF LIGHT SCATTER.
THE LIGHT WE SHINE THROUGH
TISSUES IN OUR BODIES THEY GET
PICKED UP AND SCATTERED AND
ABSORBED AND IT'S HARD TO GET
GOOD PENETRATION INTO THE BODY
WITHOUT THE GOLD SPECTROCOPPIC
TEAKNIQUE EMPLOY AND WE END UP
USING OTHER THINGS THAT ARE MUCH
MORE INVASIVE AND WHAT WE WANT
TO BE ABLE TO DO IS TO ON
MULTIPLE SCALES FOR MULTIPLE
APPLICATIONS BE ABLE TO SUPPORT
THE DEVELOPMENT OF NEW
TECHNOLOGIES WHICH CAN GROW INTO
HAVING CLINICAL APPLICATIONS IN
THIS SPACE.
NEXT SLIDE, PLEASE.
SO THE BASIC PROBLEM, THE BASIC
CHALLENGE IS WHAT I JUST TALKED
ABOUT.
THE STRAYED OFF ABOUT WHETHER
YOU CAN GO DEEPLY INTO A TISSUE
OR GET GOOD SENSITIVITY OR GET
GOOD RESOLUTION EMPLOY I WAS
THINKING TOO OF ANOTHER REAL
LOAF EXAMPLE AS A PERSON WHO'S
HAD A LITTLE TROUBLE WITH 1 OF
MY RETINAS, I'VE BEEN ABLE TO
WITNESS THE IMPACT OF OPTICAL
[INDISCERNIBLE] OF GATHERING
THAT INFORMATION AND THEN THE
CLINICAL USE BY MY DOCTOR.
BUT YOU KNOW THAT'S 1 TECHNIQUE
OUT OF A BIG SPACE AND IT HAS
LIMITATIONS AND WE WOULD LIKE TO
BE ABLE TO HAVE THAT KIND OF
TRANSFORMATIVE EFFECT ON A WHOLE
RANGE OF DIFFERENT AREAS AND THE
CLINIC AND THEN AND IN RESEARCH
AS WELL.
RIGHT NOW, THE WAY WE TRY TO GET
AT THAT, THERE ARE VARIOUS WAYS
TO TRY TO GET PAST THAT.
ONE INVOLVES JUST TWEPPING NEW
TECHNOLOGIES THAT CAN DO THINGS
THAT WE CAN'T DO NOW.
BUT THERE ARE LIMITATIONS
ASSOCIATE WIDE SOME OF THESE
THINGS, FOR EXAMPLE, YOU CAN SAY
WELL WE CAN'T PENETRATE WITH
LIGHT SO LET'S GENERATE THE
LIGHT AND THE TISSUE BUT THAT
REQUIRES OF COURSE GENETIC
MANIPULATION.
WE CAN TRY TO FIND NEW WAYS TO
ACCOUNT FOR SCATTERING BY
TRACKING PHOTONS THAT ARE
SCATTERED IN TISSUES AND BE ABLE
TO DETECT THEM AND THERE ARE
LIMITATIONS WITH THAT.
WE TRY TO DO THINGS LIKE WAVE
FRONT SHAPING OR PHOTO ACOUSTIC
IMAGING THAT HELP US TO MAKE
PROGRESS IN THAT WRAIR AND WE
WOULD LIKE TO BE ABLE TO SUPPORT
THAT KIND OF EFFORT SO THAT WE
CAN DEVELOP CAPABILITIES THAT
HAVE A BROAD RANGE OF
APPLICATIONS AND MUCH MORE
SIGNIFICANT CAPABILITIES ACROSS
THE BOARD THAN WE HAVE RIGHT
NOW.
NEXT SLIDE.
SO PROGRAM GOALS ARE TO ENABLE
DEVELOP AM OF NEXT GENERATION
NONINVASIVE IMAGING PLATFORM
ANDS TO INCORPORATE APPROACHES
THAT PUSH THE OPTICAL IMAGESERAL
INTERFACES TO BE ABLE TO DO
THOSE THINGS.
SO LARNL PART TECHNOLOGY
TWEPMENT PROGRAM.
TALKING ABOUT BEING ABLE TO
DESIGN WITH HARDWARE, BEING ABLE
TO PROTOTYPE, AND BEING ABLE TO
OPTIMIZE THEM .
NEXT SLIDE.
THIS WILL REQUIRE DIVERSE TEAMS
INCLUDING FIZZISTS, BIOLOGIST,
ENGINEERS.
WE WANT TO ENCOURAGE
PARTNERSHIPS ACROSS INSTITUTION
ANDS ACROSS RESEARCH
ORGANIZATIONS AND TO PROVIDE
RESEARCH AND TRAINING
OPPORTUNITIES TO ENCOURAGE
EVERYBODY WHO CAN CONTRIBUTE TO
THIS WORK TO DO SO.
AND MAKE SURE WE'RE ADVERTISING
AGAIN, THE OPPORTUNITIES, THE
FUNDING OPPORTUNITIES CREATED TO
BRING IN A DIVERSITY OF IDEAS
AND PERSPECTIVES.
NEXT SLIDE.
SO LOOKING AT COMMON FUND
VENTURE CRITERIA, CLEARLY THIS
WILL HAVE A CATALYTIC CENTER FOR
EXCELLENCE ON AGING, IT'S
CLEARLY SUCCESSFUL AND FOLLOW ON
BEINGAIST ITS THAT ARE WERE THED
BY A NUMBER OF NIH INSTITUTES
AND CENTERS, IT'S GOAL DRIVEN,
WE WANT TO HAVE CLEAR METRICS
FOR HOW WELL THESE IDEAS ARE
WORKING AND WHETHER WE NEED TO
MAKE ADAPTATIONS AS WE GO
THROUGH THE PROGRAM.
WE SEE THOSE AS AN OPPORTUNITY
TO LIFT ACTIVITIES THAT ARE
IMPORTANT TO A LOT OF DIFFERENT
NIH INSTITUTES AND CENTERS.
THE FUNDAMENTAL PRINCIPLES AND
MICROSCOPY AND OPTICS THAT WILL
BE LEVERAGED TO DO THIS HAVE TO
BE COMBINED IN BOLD WAYS THAT
ARE NOT NECESSARILY APPARENT AT
THE MOMENT AND WE HOPE THAT BY
COMBINING SOME OF THOSE KEY
ELEMENTS OF CURRENT RESEARCH,
THEY WILL GEPERATE TECHNOLS THAT
WILL HAVE A SIGNIFICANT IMPACT.
NEXT SLIDE.
SO WE HOPE THAT WHAT WILL HAPPEN
EVENTUALLY THROUGH THE CATALYTIC
EFFECT OF THE WORK WE WOULD
SUPPORT IN THIS PROGRAM IS THAT
WE WOULD BE ABLE TO SEE
PHYSIOLOGIC PROCESSES DIRECTLY
ON A MUCH MORE IMMEDIATE TIME
SCALE AND REALTIME EMPLOY BE
ABLE TO USE IT TO FOLLOW
CLINICAL PROCESSES INCLUDING
PROGRESS AND TREATMENT OF DECS
AND SO WE'LL BE ABLE TO USE THIS
FOR EVERYTHING FROM BASIC TO
TRANSLATIONAL AND CLINICAL
SCIENCES AND SO WE'RE HAVING
EXCITED ABOUT THE POSSIBILITY OF
WHAT THESE 2 INITTIAIVE ITS ARE
ABLE TO ACCOMPLISH.
THE NEXT SLIDE.
HAPPY TO TAKE YOUR QUESTIONS OR
HEAR COMMENTS ABOUT HOW WE DO
THINGS.
>> THANK YOU.
I SEE A COUPLE TENTS UP, I DID
NOT SEE THE ORDER.
SO I AM GOING TO START WITH
RAFAEL AND THEN MAYBE WE'LL JUST
WORK ARK ROUND THE TABLE THAT
WAY.
THAT MAKES SENSE.
>> I DO--
>> A LEGACY TENT UP.
>> IT'S A GENERAL QUESTION, SO
IF THERE'S NO TIME WE CAN KIP IT
BUTIME CURIOUS ABOUT THE
PROCESS, MORE DETAILS ON THE
PROCESS ON HOW YOU DECIDE ON
WHAT THESE INITIATIVES ARE?
NI CAN GO THROUGH THAT VERY
QUICKLY.
SO WHAT--THE PROCESS THAT WE USE
AT NIH FOR SELECTING COMMON FUND
PROGRAMS IS TO TRY TO IMAGHTER
INFORMATION FROM THE COMMUNITY
AT LARGE, WHICH INCLUDES THE
STAFF WHO WORK HERE BUT EVERYONE
IN THE COMMUNITY.
AND THEN TO PROVIDE AN
OPPORTUNITY, SOME FRAMEWORK FOR
THE FOLKS HERE AT NIH TO WORK ON
DEVELOPING IDEAS FOR PROGRAMS
THAT COME OUT THAT.
HA'S WHAT YOU WOULD DO FOR ANY
OTHER NIH DEVELOPMENT PROCESS
BUT THEY DO IT COLLABORATIVELY
ACROSS INSTITUTES, CENTERS AND
OFFICES AND WHEREAS FOR A FULL
PROGRAM WHERE WE'RE TALKING
ABOUT SPENDING 30, $40 MILLION A
YEAR, FOR UP TO 10 YEARS ALL THE
IC DIRECTORS WILL TALK TOGETHER
ABOUT THOSE.
FOR VENTURE WE HAVE A SOMEWHAT
STREAMLINED PROCESS WHERE A
SUBSET OF THE ICR DIRECTORS LOOK
AT PROPOSAL ANDS DO THE SAME
KIND OF EVALUATATIVE WORK THAT
THEY WOULD FOR THE FULL
PROPOSALS BUT THEY DO IT IN A
BIT MORE STREAMLINED FAG.
IT'S INTERNATIONAL
CLASSIFICATION GRITTED WITH AND
THAT'S FINAL EVALUATIVE PROCESS
PARALLEL TO THE WAY WE DO IT FOR
EVERY OTHER PROGRAM.
>> OKAY, SO, WE WILL START
AROUND AND GO THAT WAY IF IT
MAYBES SENSE SO THEN RUSS,
LAUREN, ANAA MARIA, THEN KEVIN,
RHONDA AND LINDA NTHANK YOU FOR
THE UPDATE.
I WAS 1 OF THE DISCUSSANTS WHEN
THIS CAME FORWARD AND SOME OF
THE THINGS I DON'T THINK WERE
FULLY ADDRESSED IN THIS UPDATE,
THERE WERE SOME ISSUES WITH
LANGUAGE AND YOU ACTUALLY CALLED
OUT LANGUAGE IS AN ISSUE HERE
BUT I TILL DON'T UNDERSTAND THE
DEFINITION OF OLD OR NIMBLE AND
HOW 1 DECIDES THAT'S BOLD OR NOT
BOLD.
AUTOQUESTION 1.
NUMBER 2, IN ANY--I KNOW WE
WANTED TO,A VOID HIGH RISK, HIGH
GAIN AND THAT'S WHERE THE
AMAZING THINGS WITH MODEL
FUNDING CAME FORWARD BUT AS WAS
POINTED OUT AT THE PREVIOUS
COUNCIL MEETING THAT IMPLIES
THAT THE NIH IS DOING A LOT OF
MODEST THINGS WITH,A MAZING
FUNDING WHICH IS PROBABLY NOT
THE MESSAGE WE WANT TO SEND
INTERNALLY THAT THEY'RE CLONING
FRUIT AND IGNORING AND WE COULD
BE PLUCKING THIS OFF WITH
RELATIVELY SMALL GRANTS SO
LANGUAGE DID MATTER HERE AND I'M
CONCERNED ABOUT HOW THIS PROGRAM
IS POSITIONING ITSELF RELATIVE
TO THE BULK OF NIH RESEARCH
ACTIVITIES.
THE QUESTION I THINK I ASKED
WHEN I WAS A DISCUSSANT IS
WHAT'S THE ANTICIPATED FAILURE
RATE ON THIS BECAUSE IF YOU'RE
GOING TO DO BOLD THINGS, YOU ARE
GOING TO SWING FOR THE FENCES,
YOU WILL GOING TO STRIKE OUT
MORE THAN YOU WOULD OTHERWISE.
AND I LOOK AT THE OCULOMMICS
PROGEC AND THINKING ABOUT
NIMBLENESS.
BETWEEN WHEN THE RFA WENT OUT
AND NOW WHEN YOU'RE ABOUT TO
AWARD GRANTS, NATURE PAPER CAME
OUT IN NATURE, FROM A GROUP IN
ENGLAND SHOWING THE FOUNDATIONAL
AI MODELS CAN DO PRETTY MUCH ALL
THE THINGS THAT THE RFP WAS
LOOKING FOR, THAT IS HIGH
ACCURACY PREDICTION OF SYSTEMIC
DEC FROM RETINAL IMAGING AND
REDUCTION ANALYSIS TO DETERMINE
WHAT THE AI WAS USING TO MAKE
THOSE PREDICTIONS.
VERY IMPRESSIVE WORK THAT
LARMINGLY PRESUMES THIS BECAUSE
YOU'RE IN AN AREA THAT IS NIMBLE
AND IT'S DIFFICULT TO SAY AHEAD
OF THE CURVE IN THAT AREA.
SO I GUESS MY SPECIFIC QUESTION
IS, YOU KNOW WHAT IS THE
ANTICIPATED FAILURE RATE HERE
AND HOW DOES 1 PROTECT THIS
PROGRAM FROM THE COMPETITION
THAT IS OUT THERE, PARTICULARLY
IT'S VERY HIGH PROFILE PROGRAM
WITHIN THE DIRECTOR'S OFFICE.
>> I CAN'T GIVE YOU A FAILURE
RATE OF WHAT WE EXPECT TO SEE.
I THINK WE HAVE TO BE OKAY OF
SOMETHING FAILURE, NOT BE
PROTECTIVE OF IT, NOT TAKE IT
PERSONALLY WHEN SOMETHING FAILS.
>> WELL, I GUESS I'M LOOKING AT
THE FUTURE, I WON'T BE ON THIS
COUNCIL WHEN IT COMES UP FOR
REUPS BUT WHEN IT DOES WHAT
LEVEL DO YOU THINK IT SHOULD BE
RIA AUTHORIZED.
I REALIZE WE'RE NOT DOING THE
REAUTHORIZE RISATION NOW, BUT
GOING FORWARD WHAT ARE THE
CRITERIA FOR SUCCESS FOR THIS
PROGRAM IN TERPS OF THE SUCCESS
OF THESE INDIVIDUAL PROJECTS?
>> THE THINGS I'M INTERESTED IN
SEEING TO UNDERSTAND WHETHER
IT'S WORTH CONTINUING TO DO, IS
WHETHER WE CAN--WHAT ARE THE
INITIATIVES THAT ARE PROPOSED AT
$5 MILLION AIER FOR 3 YEARS
ACTUALLY CAN RESULT IN SOMETHING
WORTH WHILE AFTER THAT TIME AND
IS IT THE THING THAT WE SET OUT
TO DO.
ARE WE SEEING WORK PRODUCTS THAT
HAVE AN IMPACT ON BIOMEDICAL
RESEARCH AND ON CARE BUT WHAT
HAPPENS AFTERWARDS ESSENTIALLY.
OKAY, WE MAKE THIS INVESTMENT
AND WHAT HAPPENED?
AND IF SOMETHING HAPPENS WHERE
THE LANDSCAPE CHANGES HOW DO WE
RESPOND TO THAT?
WERE WE ABLE TO RESPOND TO IT
AND THIS CAN COME UP WITH OTHER
PROGRAMS, TOO, RIGHT IN A LARGER
PROGRAM THAT WE SUPPORT, THERE
COULD BE MAJOR RESULTS THAT
CHANGE THE WAY WE THINK ABOUT
THAT FIELD AND WHERE WE NEED TO
BE ABLE TO PIVOT AND 1 OF THE
REASONS THAT WOO WE HAVE MILE
TONES AND SPECIFIC CLOSE
MANAGEMENT OF THIS INITIATIVE IS
SO THAT WE CAN DO THAT SO WE CAN
PIVOT BUT I'M--IT'S EASIER TO
TALK ABOUT THAT THAN TO ACTUALLY
DO IT RIGHT IN SO WHAT I WANT TO
SEE IS WHEN WE CAN PULL THAT
OFF, OR LOOK AT IT AND SAY, YOU
KNOW, THE INVESTIGATORS ISSUES
THE PROGRAM THROW A FOOTBALL WHO
ARE MANAGING THE PROGRAM, CAN
SEE WHO'S HAPPENING IN THE
COMMUNITY AND THEN WE CAN MOVE
TO BABLY TO TAKE ADVANTAGE OF
THE NEW INFORMATION THAT'S
AVAILABLE, TO REINVEST IN
SOMETHING ELSE BECAUSE IT'S NOT
WORTH WHILE ANYMORE, PROBLEM'S
BEEN SOLVED.
NFIELD FUNCTIONS COULD JUST ADD
1 THING, RUSS, 1 OF THE THINGS
IN MY EXPERIENCE I HAVE SEEN IS
IF YOU SET AND I'M NOT
NECESSARILY SAYING YOU'RE
ADVOCATING FOR THIS, I'M JUST
PUTTING THIS OUT THERE BUT IF
YOU SET A FAILURE RATE, YOU WILL
AIM FOR THAT FAILURE RATE AND I
DON'T THINK WE WANT TO AIM FOR A
PARTICULAR FAILURE RATE BUT
RATHER I THINK THE QUESTION YOU
ASK LATER RIGHT WAS LIKE WHAT
ARE YOUR METRICS OF SUCCESS IS
REALLY CRITICAL TO OUTLINE SO I
JUST WANT TO POINT THAT OUT.
>> PARTICULARLY FOR THIS, IN
STANDARD NIH RESEARCH, WE HAVE
OUR PEER REVIEW PROCESS THAT WE
HAVE AN ORGANIC PROCESS FOR
DOING PRIORITIZATION AMONG THE
GROUP OF EX PERS AND WE HAVE
VERY CLEAR SPECIFIC AIMS WHICH
EITHER NEED TO BE MET OR NOT MET
FOR A GRANT TO BE SUCCESSFUL
EMPLOY THE SUCCESS CRITERIA HERE
ARE MUCH MORE NEBULOUS, AND WE
CAN'T ANSWER THE TRUE QUESTION
IS WHAT HAPPENS TO THIS FIELD IF
THE PROGRAM DOES NOT EXIST IN
BECAUSE I KNOW THERE'S ACTIVE
WORK GOING ON IN ALL OF THESE
DOMAINS, WHAT ARE WE
SPECIFICALLY CATALYZING HERE
THAT'S UNIQUE AND HAS HIGH VALUE
ARE THE COMMUNITY.
IT'S HARD TO QUAWBTIFY AND
THAT'S MY WORRY FOR THIS PROGRAM
IS AT THE END OF ALL OF IT, IT'S
A FAIR AMOUNT OF MONEY IT'S
$5 MILLION PER YEAR FOR PROJECT,
IS HOW DO YOU SHOW THE REST OF
THE NIH AND THE TAXPAYER THAT
THIS PROGRAM HAS HAD REAL ADD
THE VALUE TO WHAT WE HAVE IN
PLACE.
>> THAT'S A FORWARD QUESTION WE
CAN ASK ABOUT ALL OF OW
PROGRAMS.
IT IS HARD TO ANSWER.
YOU CAN'T DO THE CONTROL
EXPERIMENT, RIGHT.
YOU LOOK AND SAY DID WE HAVE AN
INFLUENCE ON IT IN WE'RE
GENERALLY NOT THE ONLY
INVISITMENT IN A FIELD.
SO IF I GO BACK TO SOMETHING
LIKE, THERE ARE SOME WAYS TO TRY
TO PUSH THAT, I DOPE KNOW IF I'M
USING UP MY TIME.
FOR EXAMPLE WITH THE GLYCOMICS
PROGRAM, WOO WE HAD A GOAL TO
MAKE IT UNSPECIAL FOR ALL THE
SPECIALISTS, WE WANTED TO HIT A
SPECIFIC LINE UPON PEOPLE WHO
WERE NOT GOING TO BE IN THAT
FIELD OTHERWISE WHO WERE GOING
TO WALK AWAY BECAUSE THEY
WEREN'T ANYTHING TO DO IT SO HOW
DO WE DEAL WITH THAT SPECIFIC
THING.
SO THAT'S 1 WAY TO DEAL WITH,
THE ANOTHER IS TO TRY TO
UNDERSTAND WHETHER THE THINGS
THE, SPECIFIC THINGS THAT CAME
OUT OF THE PROGRAM, THE WORK
PROD UBTS THAT CAME OUT OF IT,
YOU CAN TRACE HAVING HAD AN
IMPACT, VERSUS THE OTHER
INVESTMENTS IN THAT SPACE.
WHETHER THEY BLEW RIGHT PAST US,
DIDN'T MATTER WE INVESTED OR
WHETHER WE ACTUALLY CHANGED THE
TRAJECTORY, CHANGED THE SLOPE
AND THAT'S WHAT WE NEED TO TO K
AT AND WHETHER WE WERE
RESPONSIVE TO THE CHANGES THAT
WERE OCCURRING SO SOMETHING LIKE
THE PAPER YOU JUST TALKED ABOUT
COMES UP, ARE WE PIVOTING OR ARE
WE JUST IGNORING AND AND JUST
TRYING TO DO OUR BUSINESS.
>> I HAD A SOMEWHAT SIMILAR
REACTIONOT SEQUEPSING PROJECT
WHICH IS HOW ARE YOU ACCOUNTING
FOR OTHER THINGS IN THIS SPACE,
THE BROAD IS LOOKING AT IT, AND
HOW ARE YOU DISTINGUISHING WHAT
THEY'RE DOING FROM WHAT YOU'RE
DOING AND ALSO HOW ARE INSURING
THAT, AND EVERYONE'S CREATING
THEIR OWN DATA SET BECAUSE THIS
IS A POPULATION LEVEL ISSUE
IDEALLY AND I KNOW YOU MENTIONED
DATA SHARING BUT YOU KNOW IF
EVERYBODY'S CREATING THEIR OWN
SEQUENCING SET, LIKE HOW ARE WE
MOVING THIS OVERALL ISSUE
FORWARD.
>> SO I THINK THAT I WOULD MAYBE
WANT TO ASK PJ OR DOMINIQUE TO
TALK ABOUT THIS FOR A MINUTE BUT
BASICALLY, I THINK WE'RE
COMPLETELY AWARE OF THOSE OTHER
THINGS THAT ARE HAPPENING AND
TRYING TO TRY TO PUT THAT
TOGETHER IN A WAY THAT SHOWS
THAT IT'S POSSIBLE FOR THAT TO
FLOURISH.
SO DOMINIQUE, YOU WANT TO TALK
ABOUT THAT FOR A MOMENT?
>> HI, I'M DOMINIQUE--OKAY, I'M
DOMINIQUE PICARD, THERE ARE A
LOT OF PROGRAMS,--IT'S A GREAT
QUESTION--WHICH ALL ADDRESS THE
QUESTION OF IS IT FEASIBLE, AND
IS IT A GOOD IDEA TO BE
SEQUENCING NEWBORNS THAT ARE
ASYMPTOMATIC AT THE TIME AND
WHAT CAN WE DO WITH THAT DATA IN
THE NEXT STEP WHICH WE'RE TRYING
TO ADDRESS IS HOW CAN WE
EQUITABLY INSTITUTE THIS.
SO RATHER THAN IT BEING IF YOU
DELIVERED YOUR BABY OR YOUR BABY
HAD TO GO TO MAJOR CITY X FOR AN
INTERVENTION, THAT HAS THIS
PROGRAM, THERE HAY GET IT.
WE WANT TO SAY THERE IS THIS
EXISTING NEW BORN SCREENING
INFRASTRUCTURE THAT CANNOT DO
THE SEQUENCING HOW CAN WE CREATE
A COLLABORATIVE MODEL WHERE WE
HAVE A CONSOLIDATED SEQUEPSING
AND ANALYSIS THAT WORKS FOR
MULTIPLE STATES AT ONCE TO THEN
PROVIDE INFORMATION TO THE
STATES.
SO USING A NEW BORN SCREENING
THAT IS POPULATION WIDE WHICH IS
ONLY A ZIP CODE WITHIN THE
STATE'S POPULATION THAT HAS
ACCESS TO THIS DATA THAT CAN
PROVIDE REALLY IMPORTANT
DIAGNOSTIC INFORMATION FOR THESE
FAMILIES.
>> HI, DOUG, FIRST OF ALL GREAT
PRESENTITION EMPLOY REALLY
INTERESTING PROGECS, I THINK THE
LARGER WE CAN'T ADDRESS
OURSELVES HAS A LOT TO DO WITH
THIS HISTORY OF PRIORITIZATION
AND OTHER POTENTIAL FUNDING.
BUT I HAVE A QUESTION ABOUT THE
MBS PROJECT WHICH IS THAT AS
LISTED, I JUST HAVE 2 QUESTIONS,
AS LISTED THE THOUSANDS OF RARE
GENETIC DECS THAT COULD
POTENTIALLY BE IERK DENTIFIED, I
IMAGINE MOST OF THEM WE CAN'T DO
ANYTHING WITH THEM SO THERE'S NO
APPROPRIATE KREENING BUT I WAS
JUST WONDERING ABOUT THAT
DIALOGUE IN MOVING IN PARTICULAR
VENTURE FORWARD?
>> SO PJ?
>> HI, SO PJ [INDISCERNIBLE]
DEPUTY TRECTOR OF DECKER RDRI,
WHAT WE'RE REALIZING IS IN THE
AREA OF GENOME EDITING THROUGH
ANOTHER COMMON FUND PROGRAM AND
INVOLVED WITH THIS, THE NUMBER
OF DECS THAT WE CAN POTENTIALLY
DO SOMETHING ABOUT IS INCREASING
RAPIDLY.
AND SO THAT'S KIND OF WHAT'S
ONGOING HERE AND WE ARE TRYING
TO INTERNATIONAL CLASSIFICATION
IMRAIT THIS EFFORT WITH THOSE
IMPROVEMENTS IN EDITING
TECHNOLOGY BECAUSE IME NOAM
EDITING REALLY IS A THERAPEUTIC
PLATFORM TO TREAT MONOGENIC
DISEASE.
IN A SENSE YOU CAN DESIGN AT
LEAST IN PRINCIPAL AN EFFECTIVE
THERAPEUTIC BASED JUST ON THE
SEQUENCE.
SO IT ELEMINATES FACTORS OFTEN
BECOME THE ABILITY TO DELIVER TO
THE RIGHT NUMBER OF CELLS SO I
THINK IT'S PARTLY THE
ACCELERATION IN THESE KIND OF
THERAPEUTICS THAT MAKE THIS
PROJECT MAKE SENSE NOW.
IF WE DIDN'T HAVE THOSE, I WOULD
ABSOLUTELY AGREEN CELLS WITH
YOU.
I DON'T THINK IT WOULD MAKE
SENSE.
>> THAT'S GREAT.
THANK YOU VERY MUCH.
SO MY SECOND PART IS YOU KNOW
PUTTING ON MY [INDISCERNIBLE] IN
CASE, [INDISCERNIBLE], I WONDER
HOW MUCH EFFORT AS A PART OF
THIS VENTURE SHOULD BE FOCUSED
ON THE COMMUNITY OF FAMILIES WHO
MAY HAVE REAL CONCERNS ABOUT
WHOLE GENOME SEQUENCING OF
OTHERWISE UNKNOWN CHILDREN SO
HAVE YOU THOT ABOUT THE SCICOM,
SCIENCE COMMUNICATIONS OF THIS
AND SHOULD BE SOMETHING TO BE
ADDED TO THIS?
>> I THINK I CAN SAY CONFIDENTLY
THAT THE GROUP THAT'S DEVELOPING
THE INITIATIVE AND THINKING HARD
ABOUT THAT.
THAT'S 1 OF THE THINGS WE ASKED
ABOUT AND TALKS ABOUTERING FROM
WHAT HAPPENS TO THE DAILY BASIS
THEA AFTER THE SCREENINGS
OVERWITH, IS IT EVEN STRATEGY
AND FINANCIAL INNOVATIONED
BECAUSE THE FOCUS HERE IS ON
IMPROVING THE KREENING NOT
GIVING EVERYBODY A CARD WITH
THEIR SEQUENCE ON IT, RIGHT IN
SO THE IDEA OF BEING ABLE TO DO
RAPID DEEP SEQUENCING TO BE ABLE
TO GET AT THAT DYNAMICALLY
EVOLVING LIST OF THINGS THAT
NEED THAT CAN BE INTERVENED FOR
X. HOW DO WE TALK TO PEOPLE.
THAT WILL BE AN IMPORTANT PART
OF THIS.
THAT'S A REALLY IMPORTANT PART
OF THE IMP LIAISONNATION SCIENCE
PART OF THIS PROGRAM THAT--IT
WON'T DO ANYONE ANY GOOD IF IT
TURNS OUT TO CONFUSE AND HARM
PEOPLE.
>> OR TO END UP WITH HEALTHCARE
DISPARITIES WITH GROUPS OF
PEOPLE WHO SIMPLY CHOOSE NOT TO
PARTICIPATE--NYEAH, WELL IF
SOMEBODY CAME UP TO ME AND SAID
ARE YOU GOING TO DO THIS FOR
YOUR KID, I WOULD HAVE A WHOLE
BUNCH OF QUESTIONS ABOUT IT.
>> YEAH, GREAT, THANK YOU.
>> AND PART OF THE ADVISORY
REPORT IS INTENDED TO GUIDE THE
WORK AND CREATE THOSE LOCAL
CONNECTIONS WITH MANY OF THE
COMMUNITIES WE INTEND TO SERVE
REGARDLESS OF, YOU KNOW WHAT
SKIP CODE OR NATIONALITY OR YOU
KNOW COLOR OR PLEEFS OR THEIR
CONCERNS, I WANT TO HEAR FROM
THEM AND MAKE SURE WE'RE IMP
LEMMING THIS IN A WAY THAT WE
ARE THEN SERVING THE ENTIRE
POPULATION.
NGREAT.
THANK YOU EMPLOY.
>> GREAT.
RHONDA AND THEN LINDA AND
BARBARA WE WILL HAVE YOU CLOSE
THINGS OUT.
>> OKAY.
THANK YOU SO MUCH, I HAVE 2
QUESTIONS.
ONE I WASN'T CLEAR, MAYBE I JUST
MISSED IT, IS THIS--IT WAS OPEN
TO ACADEMIC ORGANIZATIONS AND
OTHER ORGANIZATIONS DOES THAT
INCLUDE PRIVATE SECTOR?
>> SIEM SORRY I DIDN'T HEAR THE
LAST--
>> DOES THAT INCLUDE PRIVATE
SECTOR?
>> SO EVERY INITIATIVE, SO WHAT
WE DID HERE IS WE DECIDED THE
NIH AND STAFF DECIDED WHICH
INITIATIVES TO DEVELOP, RIGHT
AND WHEN THOSE ARE COMPETED,
THEY'RE GOING TO HAVE
ELIGIBILITY RITERRIA WITH THEM
FOR THE APPLICATION PROCESS FOR
THE NOFOs OR THE RESEARCH
OPPORTUNITIES ANNOUNCE UPONS
THAT ARE ISSUED FOR OT, BUT
YEAH, OUR INTENTION LIKE WITH
PRETTY MUCH EVERYTHING ELSE WE
DO IN COMMON FUND IS FOR THE
ELIGIBILITY TO BE AS BROAD AS
POSSIBLE SO THERE'S ELIGIBILITY
FOR ACADEMIC AND COMMERCIAL AND
OTHER ENTITIES, YES.
>> I ASKED THAT QUESTION BECAUSE
I'M ON THE BLUEPRINT MED TICK
ADVISORY BOARD AND THEY HAVE
FIGURED OUT A WAY TO INVOLVE
COMMERCIAL AND PRIVATE SECTOR IN
COLLABORATION WITH--ALSO A WAY
TO TAKE IT A STEP FURTHER--IN
LOOKING AT THE FEDERAL
GOVERNMENT AS BEING AN INVESTOR
WITH AN INTEREST IN THE
TECHNOLOGY WITH THE POTENTIAL
REVENUE TREME AFTER THAT.
SO I PRINCIPLE IT UP AS A
BUSINESS APPROACH AND 1 THAT
COULD, I DON'T KNOW ALL THE
RULES BECAUSE I KNOW THERE'S A
LOT OF THEM POTENTIALLY COULD BE
A REVENUE GENERATOR FOR THE
MONEY THAT NIH IS PUTTING INTO
THE VENTURE.
MY LAST QUESTION IS YOU KEEP
USING THE TERM COMMUNITY WHO. IS
THE COMMUNITY SOME WHAT MAKES UP
THE COMMUNITY?
YOU GO OUT TO THE COMMUNITY AND
YOU FIND OUT WHAT THEY WANT.
WHO ARE YOU TALKING TO?
WHAT TYPE OF PEOPLE ARE YOU
TALKING TO IN.
>> WELL, IF WE'RE TALKING ABOUT
SOLICITING IDEAS FOR NEW
INITTIAIVE ITS FOR EXAMPLE,
WE'RE TALKING ABOUT THE RESEARCH
COMMUNITY BUT WE'RE NOT PUTTING
CONTRAINTS ON THAT.
IT CAN BE AN INDIVIDUAL WRITING
TO US TELLING US THIS IS THE
WHYED I THINK YOU SHOULD IT
COULD BE, PEOPLE IN ACADEMIC
ORGANIZATIONS NIEGZATION AND
COMMERCIAL ORGANIZATION,
PRIVATE, NONPROFIT.
I KNOW THIS LATEST ROUND WE HAD
PEOPLE FROM FOUNDATIONS, FROM
UNIVERSITIES, FROM CUTCHES AND
FROM INSIDE NIH WHAT WE SHOULD
BE WORKING ON.
>> I APPRECIATE THAT BUT I WOULD
ADVIS TO TO EXPAND YOUR
COMMUNICATION AS IT RELATES TO
THAT AS I MENTIONED BEFORE,
THERE'S ANOTHER PERRA DIME,A
ROUND WHAT IS HIGH PRIORITY AND
THAT PRIORITY HAS TO DO WITH I
RECALL THE TYPE OF MONETARY
WASTE OR GAPS IN THE MEDICAL
FIELD THAT HIT ALL OF US AS IT
RELATES TO THE RISING MEDICAL
COST AND YOUR PREMIUMS THAT
YOU'RE PAYING.
SO IF THOSE ENTITIES DON'T KNOW
THAT THIS IS AN AVENUE FOR THEM
TO BRENG THAT INFORMATION TO
YOU, I THINK IT NEEDS TO BE
BECAUSE I THINK WE NEED TO HOLD
HANDS ON THIS BECAUSE WE'RE ALL
AFFECTED BY THIS AND THE
DYNAMICS ARE DIFFERENT.
WHAT 1 LOOKS FOR AS IT RELATES
TO MEDICAL LOSS COST IS
DIFFERENT THAN THE DEATH RATE OR
PREVALENCE OF DISEASE, IT HAS TO
DO WITH HOW MUCH WASTE WE HAVE
AS IT RELATES TO DIAGNOSE AS
WELL AS TO TREAT VARIOUS
ENTITIES, RISING NUMBERS ON
AGAIN, I KEEP USING THIS
AUTOIMMUNE DISEASES, 10 YEARS
AGO WE DIDN'T KNOW WHAT THOSE
WERE AND NOW WE HAVE 21
DIAGNOSIS THAT KIND OF FIT INTO
THAT BUT WE DON'T KNOW HOW TO
TREAT IT WE DON'T KNOW HOW TO
DIAGNOSIS AND THERE'S MILLIONS
OF DOLLARS THAT ARE BEING AND I
SO I BRING THAT UP AS AIAN WAY
OF THINKING ABOUT YOUR
DEFINITION OF COMMUNITY.
NTHANKS FOR BRINGING THAT UP.
>> AND JUST NOTING THE TIME,
WE'RE ALMOST OUT OF TIME SO IF
WE--FOR YOU AND BARBARA IF WE
CAN BE JUST CONCISE.
>> YEAH I JUST WANT
CLARIFICATION OF THE MECHANISM
SO IT'S A VENTURE THING SO ARE
YOU THINKING OF FUNDING SOMEONE
LIKE A VENTURE CAPITAL
INVESTMENT INTO A NEW APPROACH
BECAUSE LIKE THE 3 EXAMPLES YOU
GAVE, THE FIRST 1 WITH THE
[INDISCERNIBLE] MAKE--MY FIRST
IMPRESSION IS WELL WHY ISN'T
THIS BEING FUNDED BY THE
NATIONAL EYE INSTITUTE LIKE THEY
DO THIS EYE RESEARCH AND THEY
ARE EXPLORATORY GRANT PROPOSALS,
TOO, EVEN IF YOU WANT TO FUND
SOMEBODY WHO DOESN'T HAVE--WHO
JUST HAS THE IDEA BUT DON'T HAVE
THE PRELIMINARY DATA YET AND
THEN SAME THING WITH THE
KREENING THE BABIES, THAT'S
EXACTLY WHAT ALL OF US YESTERDAY
TALKED ABOUT, THEY'VE ALREADY
KREENED 633,000 ADULT
PARTICIPANTS AND OUT OF THOSE
THEY HAD 3000 CASES THAT WERE
ACTIONABLE AND THEY WERE TALKING
ABOUT ADDING A PEDIATRIC COHORT
TO WHAT THEY'RE DOING INCLUDING
STARTING FROM NEW BORN OR
SOMETHING LIKE THAT SO IT SEEMS
LIKE THERE'S JUST A LOT OF LIKE
OVERLAP AND GIVEN THE LAST 1,
THE OPTICAL IMAGING APPROACH
[INDISCERNIBLE] HAS A WHOLE
DIVISION ON DEVELOPING OPTICAL
IMAGING AND YOU SAID IT WOULD
INVOLVE MULTIDISCIPLINARY
PHYSICISTS, COMPUTER SCIENTISTS
AND BAKE SCIENCE AND THAT'S
EXACTLY WHAT NIDA DOES, EVERY
IMAGING TECHNOLOGY, WAS FORMED
BY DR. [INDISCERNIBLE], YOU
CITED HIM AND IT'S FOR THAT
PURPOSE BECAUSE ALL THE IMAGING
TECHNIQUES THEY DEVELOP REQUIRE
MULTIDISCIPLINARY APPROACH SO
I'M JUST GETTING CONFUSED ABOUT
HOW SOME OF THIS IDEAS COME UP
BY HOW--WHY WOULDN'T THEY BE
FUNDED BY THE CORRESPONDING
EN--STRATEGIESITUTE ANDS LIKE
WHO'S THE LUCKY 1 THAT GETS THIS
BIG POT OF VEPTURE CAPITAL MONEY
TO TART THEIR PROMULGATEEC AND
NOT OTHERS?
I JUST NEED CLARIFICATION ABOUT
THAT.
>> SO WE'RE USING THE WORD
VENTURE WITH RESPECT TO A BOLD
VENTURE NOT IN TERMS OF VENTURE
CAPITAL INVESTING, THE PRIMARY
DEFINITION OF THE WORD THAT
PREDATES VENTURE CAPITAL.
YOU KNOW EVERY 1 OF THESE
EXAMPLES THAT YOU CITE, I CAN
UNDERSTAND WHY YOU WOULD SAY
THERE'S RELATIONSHIPS WEAN OTHER
EXISTING INVESTMENTS OR AREAS OF
NIH THAT WORK IN THESE AREAS AND
EVERY CASE THERE'S A COALITION
OF INSTITUTES AND CENTERS THAT
HAVE COME TOGETHER TO TRY TO
PROPOSE A JOINT ACTIVITY THEY
FEEL CROSSES THOSE BOWPPEDRYS SO
WE ARE TO BE CAREFUL AS THEY'RE
BEING DEVELOPED THAT IT'S NOT A
WHOLLY OWNED SUBSIDIARY OF AN IC
THAT THERE REALLY IS REFLECTING
THE [INDISCERNIBLE] THAT THE
PROPOSERS INTENDED AND FOR THAT
SITUATION, THE EYE INSTITUTE IS
1 OF THE LEAD FOR THE OCULOMMICS
AND OTHERS THAT ARE
PARTICIPATING IN THE LEAD
INSTITUTE AND THE SAME IS TRUE
FOR NONINVASIVE IMAGING SO WE
HAVE TO--WE HAVE TO BE MINDFUL
JUST LIKE WE WOULD WITH ANY OF
OUR OTHER PROJECTS BUT IT'S AN
IMPORTANT CONSIDERATION.
>> BARBARA?
NTHANK YOU.
I WANT TO EMPLIFY KEVINS COMMENT
ABOUT THE PARENTS AND I'M GOING
TO USE THE ANALOGY OF THE NEW
BORN HEARING STREENING WHICH IS
LAW AND WHEN PARENTS FIND OUT
THEIR BABY HAS A HEARING LOSS
AND PROGRAMS IN EACH OF THE
STATES TO EDUCATE THESE PARENTS
AND ALL OF THEIR OPTIONS AND IT
IS FRAUGHT WITH BIAS AS WELL SO
WHEN PARENTS GET THE INFORMATION
THAT THEIR BABIES MIGHT HAVE A
GENETIC DEC, EDUCATING THESE
PARENT ANDS I'M THINKING OF
HEALTH LITERACY LEVEL ANDS
UNDERSERVED COMMUNITIES AND WHAT
PARENTS DO WITH THIS
INFORMATION, I THINK IS REALLY
IMPORTANT AND HOW IT'S DEALT
WITH AT THAT POINT NETWORK THANK
YOU FOR POINTING THAT OUT.
NALL RIGHT, WELL, GREAT THIS HAS
BEEN A REALLY GREAT DISCUSSION
EMPLOY AS WE SAID IT WILL
CONTINUE TO BRENG UPDATES ON
THIS EFFORT AS IT MOVES ALONG.
I DO NOW WANT TO SWITCH OVER TO
THE NEXT AND FINAL REALLY ITEM
THAT WE HAVE TO DISCUSS WHICH IS
OUR LAST CONCEPT CLEARANCE FOR
SURE.
WE HAVE JOINING WITH US
DR. BRUCE TROMBERG, WHO IS THE
DIRECTOR OF NIBIB, SO LINDA YOU
MAY WANT TO SNAG HIM LATER AFTER
THAT LAST TALK, AND KATHLEEN
NEUZIL WHO IS THE NEW DIRECTOR
OF THE FOGARTY INTERNATIONAL
CENTER CENTER.
THEY WILL TALK ABOUT A NEW
CONCEPT ENTILINGED HARNESSING
DATA SCIENCE FOR HEALTH DORPHY
INMODEL CITIZENIVATION IN AFRICA
AND THIS IS THE SECOND STAGE OF
DS-I AFRICA WHICH HAS BEEN
ONGOING FOR SEVERAL YEARS HOW
AND THE PRESENTATION WILL BE
FOLLOWED BY COMMENTS FROM
DOCTORS KRISTIN AND RAFAEL.
SO I GUESS I WILL TURN IT OVER
TO BRUCE AND KATHLEEN WHO NEED
NO FURTHER INTRODUCTION BASED ON
THEIR TITLE AND THEY HAVE A
WEALTH OF EXPERIENCE IN LEADING
VARIOUS DIFFERENT PROGRAMS SO I
GUESS, BRUCE YOU'RE GOING TO
KICK US OFF.
NTHANK YOU TARA.
THANKS TO ALL OF YOU.
IT'S BRAIT TO BE HERE.
THANK YOU FOR THE OPPORTUNITY.
SO AS TARA MENTIONED I'M THE
DIRECTOR OF THE NIBIB, IT'S
ALWAYS GOOD TO HEAR OUR NAME, WE
DON'T HEAR IT OFTEN, IT'S HARD
TO PRONOUNCE SO WE'RE THE NERDY
ENGINEERING INSTITUTE AT THE NIH
AND I'M DELIGHTED TO BE HERE
WITH EYE COLLEAGUE CATHY, IT WAS
2019 WHEN I WAS A DIRECTOR AND
CATHY IS A NEW DIRECTOR AND I
WAS STANDING HERE WITH ROGER
GLASS WHO THE LONG TIME DIRECTOR
OF THE FOGARTY CENTER PRESENTING
THIS CONCEPT WHICH WE WERE JUST
SO EXCITED ABOUT ROGER WAS THE
FIRST PERSON WHO VISITED ME WHEN
I JOINED NIH, ON MOY SECOND OR
THIRD DAY, HE POPPED INTO MY
OFFICE AND SAID WE LOVE
BIOMEDICAL ENGINEERING SO LET'S
TALK AND THIS IS 1 OF THEORY
SULTS OF THAT CONVERSATION.
IT'S BEEN PRETTY SPECTACULAR.
NEXT SLIDE, DO I HAVE CONTROL?
OKAY.
LET'S GO TO THE NEXT SLIDE.
OKAY, SO, YOU KNOW FROM THOSE
EARLY DAYS, WE HAD INVOLVEMENT
OF 4 KEY INSTITUTES, THE FOGARTY
TRUSTEES, NIBIB, NIMH, AND THANK
TO YOU SHELLLY [INDISCERNIBLE]
WHO IS THE ACTING DIRECTOR OF
NIERK MH, AND TO STEVE SHERRY
WHO IS THE DIRECTOR OF NCBI, AND
HAD 12 ICs AT THE COUNCIL OF
COUNCILS WE NOW HAVE 21 ICOs,
AMAZING ENTHUSIASM ALL ACROSS
THE NIH AND THEY'RE NOT JUST
CONTRIBUTING PEOPLE AND PROGRAM
DIRECTORS BUT THERE ARE 12
ICOs THAT ARE CONTRIBUTING
MONEY TO THE ENTERPRISE, SO YOU
KNOW I THINK THAT REALLY SPEAKS
TO THE ENTHUSIASM AND THE CROSS
CUTTING NATURE OF THE PROGRAM.
HERE'S A PICTURE AT A WORKSHOP
IN SOUTH AFRICA, TO PROGRAM
DIRECTORS I HAVE TO BRUCE YOU
TO, SO LAURA [INDISCERNIBLE] AND
TIFFANY LASH FROM FOAG ART EXPE
FROM NBIBRESPECTIVELY, THEY'RE
RESPONSIBLE FOR PUTTING
EVERYTHING TOGETHER AND MAKING
SURE THAT WE'RE HERE ON TIME SO
THANK YOU VERY MUCH YOU GUYS AND
I ALSO NOTE THEY'RE BOTH
BIOMEDICAL ENGINEERS SO EXCITING
TO HAVE THAT COLLABORATION
COLLABORATION.
NEXT SLIDE.
OUR ORIGINAL MOTIVATION WAS TO
GET A COORDINATED EFFORT TO
CONNECT DISPARATE GROUPS IN
HEALTH SCIENCE AND ININIVATION
ALL ACROSS AFRICA THAT COULD
HAVE AN SIGNIFICANT IMPACT ON
HELT CHALLENGES AND THAT WAS
SUPER COMPELLING IN 2019.
WE THOUGHT, YOU KNOW WHEN I
ARRIVED AT THE MIH, I THOUGHT
WOW, THE NIH JUST DISCOVERED
MATH.
EVERYBODY'S GOING CRAZY OVER
DAILY BASIS THEA SENTENCE AND
ARTIFICIAL INTELIENCE AND IT WAS
A CONSTANT COMMUNICATION AND
CONVERSATION.
WELL, HERE WE WE ARE IN 2024 AND
THAT'S ACTUALLY AN
UNDERSTATEMENT.
I MEAN TALK ABOUT EXPLOSION AND
EXPANSION OF ACTIVITIES,
EVERYTHING HAS CHANGED.
THE PANDEMIC AND THE TECHNOLOGY.
SO WITH ARTIFICIAL INTELLIGENCE
IT WAS JUST A YEAR AGO IN AUGUST
THAT THERE WERE BRISE LEVEL
GENERATIVE AI TECHNIQUES THAT
WERE RELEASED AND SUDDENLY ALL
FORTINE 500 COMPANIES ARE USING
THESE THINGS SO THE
TRANSFORMATION IN THE NEED, THE
PUBLIC HEALTH COP OPPOSITE
BEHAVIORIAL PHENOTYPENTS AS WELL
AS THE TECHNOLOGY ELEMENTS HAVE
BEEN EVEN MORE COMPELLING.
SO NEXT SLIDE.
AND A LITTLE BIT SO WE LOOK TO
REALLY LOOK TO OUR COLLEAGUES IN
AFRICA FOR THEIR WRITINGS AND
THOUGHTS, THIS IS 1 THAT GRABBED
ME FROM THE WORLD ECONOMIC
FORUM, 2 LEADERS, THOUGHT
LEADERS IN IN AREA WHO
UNDERSCORE THAT BY 2035 THERE
WILL BE MORE YOUNG AFRICANS
ENTERING THE WORKFORCE EACH YEAR
THAN IN THE WEST OF THE WORLD
COMBINED AND THERE ARE SO MANY
OF THOSE YOUNG AFRICAN
STATISTICS, YOUNG UNIVERSITIES,
ENORMOUS GROWTH, SO THEY REALLY
PUT OUT YOU KNOW A STRONG
ARGUMENT FOR IN THE
DIMINISHITTAL AGE TECHNOLOGY HAS
THE POWER TO REVOLUTIONIZE THE
SOCIOECONOMIC LANDSCAPE,
PROVIDING YOUNG AFRICANS WITH
THE OPPORTUNITIES TO ACQUIRE
KNOWLEDGE, INNOVATIVE IDEA ANDS
CONNECK THE GLOBAL COMMUNITY.
SO THAT'S THE UNDERLYING GOAL OF
THIS PROGRAM AND IT MESHES
REALLY, REALLY NICELY WITH
WHAT'S BEING CALLED FOR ALL
AROUND THE WORLD EMPLOY SO NEXT
SLIDE.
WHAT ARE SOME OF OUR
ACCOMPLISHMENTS AND I WILL
BRIEFLY SUMMARIZE
ACCOMPLISHMENTS AND TURN IT OVER
TO CATHY WHO WILL TALK ABOUT THE
VISION FOR THE FUTURE.
SO CONTHERE'S JUST BEEN ENORMOUS
INVESTMENT COVERING MOST OF THE
MAP AND I HAD NO IDEA WHEN WE
STARTED THAT WE COULD REALLY
EFFECTIVELY MOVE INTO ALL OF
THESE SITES, ALL OVER AFRICA,
$88 MILLION, SO THAT'S THE
EXPENTINE REGIMENITTURE THAT'S
EXCEEDED APPROPRIATION OR
ALLOCATION FOR THE PROGRAM.
THIRTY-EIGHT AWARDS, 22
DIFFERENT COUNTRIES.
SO WE'VE ESTABLISHED MULTIPLE
RESEARCH HUBS, 7 DIFFERENT
RESEARCH HUBS THAT BRINGS ALL
THE PARTNERS TOGETHER ACROSS
ACADEMIA, GOVERNMENT AND
INDUSTRY AND REALLY, YOU KNOW
VERY INNOVATIVE PARTNERSHIP
PROGRAM ANDS PROJECTS.
I'LL SUMMARIZE A FEW IN A
MINUTE.
IN EMERGING ITS OF CAPACITY
BUILDING.
WE LIKE TO THINK OF THIS IN
TERMS OF TRAINING AND EDUCATION,
SO YOU CAN'T DO DATA SCIENCE
WITHOUT PEOPLE WHO REALLY
UNDERSTAND AND ARE PASSIONATE
ABOUT DATA SCIENCE.
SO THERE'S 7 RESEARCH TRAINING
PROGRAM, 6 EDUCATION PROGRAMS,
RESEARCH TRAINING ARE BOTH
FACULTY TRAINING AS WELL AS
INDIVIDUALS IN NEW MASTERS AND
Ph.D. PROGRAMS, THE EDUCATION
PROGRAMS ARE SHORT-TERM
TECHNOLOGY TRAINING PROGRAMS, TO
MEET URGENT NEEDS THAT ARE
THROUGHOUT AFRICA.
LCD ETHICAL, LEGAL AND SOCIAL
IMPLICATIONS, THERE ARE 4
DIFFERENT PROJECTS HERE AND THEY
ENDPAIJ THE TECHNICAL COMMUNITY,
RESEARCH HUBSAs WELL AS
COMMUNITY STAKEHOLDERS AND AS
YOU KNOW THESE ARE REALLY
COMPLICATED PROGEC ANDS CATHY
WILL TALK A LITTLE BIT ABOUT HOW
TRANSFORMATION OF ELSI INTO
MAYBE DROPPING THE L WILL BE
MORE POWERFUL FOR US GOING
FORWARD AND THEN IN TERMS OF THE
OVERALL ECOSYSTEM, WE ARE A
COORDINATING CENTER THAT HELPS
FACILITATE COMMUNICATION AMONGST
ALL THE GROUPS WHICH IS
ABSOLUTELY CRITTAL AND THEN THAT
COORDINATING CENTER AND ALL THE
PROJECTS NEED A PLACE TO WORK SO
PROBABLY 1 OF THE MORE TECH
PACKULAR DEVELOPS IS THE ELWAZI
OPEN DAILY BASIS THEA SCIENCE
PLATFORM IT'S CONNECTED TO THE
GEN 3 PLATFORM THAT HAS OVER 26
DATABASES, MANY OF THEM
SUPPORTED BY THE NIH AND ALSO
TARA AND THEY'RE IN THE MIDDLE
OF DEVELOPING ALL THIS NEW TOOLS
HELPING PEOPLE SIGN ON, PUT
THEIR DATA, HAVE A DATA
REPOSITOR EXPE DEVELOP AND
DISCOVER NEW THINGS FROM THAT
WORK.
SO NEXT SLIDE PLEASE SO RESEARCH
EXAMPLES AND AND I WILL HAVE TO
DPLOSES OVER A LOT OF THESE AND
RESONATE MANY OF YOU THERE'S
LOTS OF EXCITING DETAIL THAT IN
TERMS OF PRECISION AND PUBLIC
HEALTH MULTIMORBIDITY IS
INCREASINGLY AROUND THE WORLD
AND AFRICA, BUT NOT THAT MUCH IS
KNOWN ABOUT HOW TO COLLECT THAT
INFORMATION AND HOW TO MANAGE IT
SO THERE ARE DATA SCIENCE TOOLS
CLICKING BOTH EPIDEMIOLOGIC DATA
LABORATORY DATA, GENOMIC DATA SO
LOTS OF INTERESTING SPECS OF
INFORMATION AND THIS HELPING
FACILITATE BOTH RESEARCH AND
PRACTICAL TOOLS FOR CLINICAL
MANAGE AM, PATIENTS ACROSS
AFRICA.
WE HEAR A LOT ABOUT SURVEILLANCE
TRACKING AND MODELS AND THIS IS
OBVIOUSLY SOMETHING THAT ESI
AFRICA AND A DEEP HOLDER IN AND
THESE TOOLS ARE DEVELOPED ALL
ACROSS THE CONTINENT AND THEY'RE
DESIGNED TO REALLY PREPARE FOR
NEXT PANDEMICS BUT ALSO HELP
REALLY FOCUS ON SARS-COV-2 AND
HIV, YOU ARE HEARING
INCREASINGLY ABOUT MPOX SO THESE
KINDS OF PROGRAMS ARE DEEPLY
ENGAGED IN THAT.
IN TERMS OF DIAGNOSTIC ANDS
DECISION SUPPORT, WE'RE HOPING
THAT AI CAN HELP FACILITATE MORE
POWERFUL FORMS OF INICAL
ANALYSIS, DIAGNOSTICS AND
PREDICTIONS FOR INDIVIDUALS,
THERE'S AN MHEALTH TOOL THAT'S
BEEN A MOBILE HEALTH TOOL FOR
RAPID ID AND TRIAGE.
ONE OF THE MORE EXCITING
PROGGENTS FOR ME IS IN THE AREA
OF RETINAL IMAGING SO WE ALL
KNOW THAT RETINAL IMAGES MAY
CONTAIN INFORMATION IN THE EYE,
ABOUT TBLAW COMA, DIABETIC
RETINAL LOCATION NUMBER OF
PATIENTSATHYS, SOPHISTICATED
MUCH POTENTIAL TO USE THAT USING
LEARNING BASED APPROACHES
FACILITATING DIAGNOSIS AND
MOVING ON TO THERAPEUTIC
STRATEGIES VERY QUICKLY BUT
THERE'S ALSO A CONNECTION
BETWEEN THAT OPPORTUNITY AND
UNDERLYING SYSTEMIC DEC WHICH IS
SOMETHING THAT WE'RE VERY ACTIVE
HERE IN THE U.S. BUT THERE ARE
NO DATABASES IN AFRICA SO IT'S
REALLY ESSENTIAL TO USE
PLATFORMS THAT ARE IN AFRICA AND
DATA FROM AFRICANS ALL ACROSS
THE CONTINENT TO DEVELOP THOSE
MODELS SO THEY'RE NOT BIASED
POTENTIALLY BIASED BY ALL THE
LEARNING THAT'S GONE ON IN OTHER
NATIONS, THIS IS AN EXCITING AND
CRITICAL AREA FOR US IN NIBIB.
IN TERMS OF MENTAL HEALTH
THERE'S INTEGRATION FROM THE
TRACK RECORDS AND PHONES REALLY
THE CONSTRUCTION OF NEW
DIMINISHIT AT HEALTH PLATFORMS
USING MOBILE TOOL WHICH IS IS SO
POWERFUL AND THIS IS REALLY 1 OF
THE FIRST TEAMS TO DO THAT AND
THEN, MODELS THAT POTENTIALLY
UNDERSTAND DEPRESSION RISK AND
PREDICTED AND POSSIBLY INTERVENE
EARLY AND FINALLY IN THE AREA OF
CLIMATE CHANGE AND HEALTH, REAL
FOCUS HERE UNDERSTANDINGNYONATAL
AND CHILD HEALTH IMPACS SO OUR
CLIMB AT HEALTH, TEMPERATURE
FLUCTUATIONS, DOES AN
INSTANTANEOUS FLUCTUATION FOR A
SHORT PERIOD OF TIME HOW IS THAT
IMPACING HEALTH OUTCOMES AS
COMPARED TO CUMULATIVE EXPOSURES
OVER TIME SO THERE ARE
FUNDAMENTAL QUESTIONS THAT ARE
BEING ASKED BETWEEN THE
RELATIONSHIPS BETWEEN LIMATE
HEALTH AND OUTCOMES FOR
INDIVIDUALS WITH THIS PARTICULAR
FOCUS ON MATERNAL FETAL AND
CHILD HEALTH.
SO NEXT SLIDE.
SO REALLY, YOU KNOW THOSE
PROJECTS EMBODY MANY OF THE
PROPOSED AND HOPED FOR OUTCOMES
THAT YOU KNOW WE WOULD LIKE TO
HAVE SEEN.
WE HAVE APPLIED DATA SCIENCE
APPROACHES TO DEVELOP NEW
SOLUTIONS FOR HEALTHCARE
PROBLEMS.
THE CONSORTIUM DEVELOPED NEW
DATA SCIENCE AND HEALTH
INNOVATIONS THAT COME FROM ALL
OF THESE.
THERE'S THE SORT OF THIRD MAJOR
ACCOMPLISHMENT IS ADVANCES IN
SYNTHETIC VARIATIONS FOR GENETIC
SHARING AND YOU WILL HEAR MORE
ABOUT THAT FROM CATHY AS WE DROP
THE LEGAL IMPLICATIONS THIS IS A
BARRIER AND THIS IS A CLEVER
WORK ARK ROUND, THERE ARE A FEW
OTHERS IN SCIENCE THAT BE
ACHIEVED TO OVERCOME SOME OF
THESE HARD PROBLEM ANDS
DEVELOPED NEW AFRICAN
INSTITUTIONAL CAPACITY TO TORE,
MANAGE AND ANALYZE DATA AND
RIGHT AT THE CORE OF THAT ARE
THE PEOPLE, THE TRAINING
PROGRAMS, ENORMOUS DEMAND FOR
THESE PROGRAMS AND THAT'S REALLY
A CRITICAL COMPONENT OF
CAPACITY.
SO NEXT SLIDE.
>> SO IN KIND OF OUR MAJOR
SECTORS IN OUR HOPED FOR
ACHIEVEMENTS IN AND MORE THAN
150 PUBLICATION HAVE COME OUT IN
A VARIETY OF TOPICS COVERED IN
THESE RESEARCH PROJECTS I JUST
MENTIONED, THERE IS THIS ELWSI
DATA SHARING AND TOOL
DEVELOPMENT GATEWAY OR PATH TO
FACILITATE ALL THESE TYPES OF
COLLABORATIVE INTERACTIONS WHIH
IS FROM KRACH AND MY EXPERIENCE
IN DEVELOPING DATABASES AND THE
TOOLS TO ANALYZE THAT
INFORMATION, I REALLY THINK
THAT'S QUITE A SPECTACULAR
ACCOMPLISHMENT AND FOUNDATION
FOR ENORMOUS FUTURE GROWTH.
THEY'RE AHEAD OF US IN CREATING
AN AI CHAT BOT THAT HELPS WITH
RESEARCHERS, NAVIGATING DATA
SHARING AND SO OTHER ON, AND WE
HOPE TO DO THAT IN SOME PLACES
IN NIH AND IT'S A POWERFUL WAY
TO HELP MOVE IDEAS QUICKLY
THROUGH THE PIPELINE.
IN TERPS OF EDUCATION, THERE ARE
NEW HEALTH SCIENCE ADVANCE
DEGREE PROGRAMS AT 8 AFRICAN
UNIVERSITIES AND ENORMOUS
INTEREST IN THIS, 120 STUDENTS,
46 FACULTY, 11 POST DOCS AND
INCLUDING THE MINISTRY OF HELT
STAFF, THIS IS A TANGIBLE
OUTCOME, I UNDERSTAND THE DEMAND
EXCEEDS THE SUPPLY.
IN RWANDA THERE MAY HAVE BEEN 75
APPLICATIONS FOR 4 Ph.D.
APPLICATIONS, 125 HAP
MRIIDATIONS FOR 7 MASTERS
POSITIONS SO THIS IS CLEARLY AN
URIENT NEED AND SOMETHING WE CAN
REALLY HELP WITH.
IN TERMS OF COLLABORATION, MORE
THAN 200 PARTNERSHIPS HAVE BEEN
DEVELOPED TO MAINTAIN HUNDREDS
OF DATA SCIENTISTS, COMPANIES,
NG Os AND GOVERNMENT STAFF
HAVE BEEN ENGAGED, MANY EXAMPLES
OF NETWORKS, PRESENTATIONS,
WORKSHOPS AND A LATE BREAKING
NEWS ITEM THE UNITED NATIONS
GENERAL ASSEM MYELIN HAS INVITED
2 DS-I AFRICA PRESENTATIONS IN 1
OF THEIR MEETING COMING UP.
LAURA CAN TBIF YOU MORE DETAILS
ON THAT BUT IT'S A REAL
TESTAMENT TO THE POWER AND
VISIBILITY OF THIS PROGRAM.
NOW WHERE'S IT GOING IN THE
FUTURE?
CATHY, THE FUTURE IS ALL YOURS.
>> I WAS HOPING THERE WERE
SLIDES UP HERE, I WAS THINKING
HOW IS HE SO MAGICAL?
THANK YOU BRUCE AND I MEAN WE
ALREADY I HOPE YOU HAVE THE IDEA
THAT S&P A DPRAIT EXAMPLE OF
WORKING BETTER TOGETHER AND NIH
WORKING ACROSS DISCIPLINES AND
NOT BEING VACCINE SPECIFIC.
BRUCE, I APPRECIATE YOUR
DISCLAIMER, PERHAPS, TOO, ON MY
BEHALF THAT I AM NOT THE
ENGINEER IN THE GROUP AND THAT I
AM NEW.
SO, THANK YOU FOR THAT.
BUT EQUALLY EXCITED ABOUT THIS
PROGRAM, GOING FORWARD, AS
SOMEONE WHO HAS SPENT A COUPLE
DECADES DOING GLOBAL HEALTH
WORKING IN AFRICA, I HAVE TO SAY
THAT MAP THAT BRUCE SHOWED AND
JUST SO IMPRESSIVE AND I CAN'T
EMPHASIZE THAT ENOUGH.
USUALLY PROGRAMS I HAVE BEEN
INVOLVED IN, YOU KNOW THERE ARE
4 COUNTRIES COLORED IN AND MAYBE
IT'S SOUTH AFROMMICCA AND KENYA
OR UGANDA, MAYBE GUANA THAT'S
DIFFICULT COUNTRIES TO WORK IN
WEST AFRICA, SUDAN, ET CETERA,
REALLY, REALLY IMPRESSIVE EMPLOY
NEXT SLIDE.
SO LOOKING FORWARD TO INFORM
THIS, WE DID GO THROUGH A PORT
PORTFOLIO AND LANDSCAPE ANALYSIS
AND CAN YOU SEE THERE AND THE
NIH WILL REPORT OTHER FUNDER
ACTIVITIES, SPECIFIC DISCUSSIONS
WITH AWARDEES, CONSORTIUM
MEETINGS, OTHER PEOPLE AT NIH
AND THEN CONSULTATIONS WITH
OTHER IMPORTANT FUNDERS AND THE
PRIVATE SECTOR.
NEXT SLIDE.
AND SO, GENERAL FINDINGS HERE,
IS THAT NIH IS THE LEADING
FUNDER OF DATA SCIENCE AND
HEALTH RESEARCH AND AFRICA.
THERE ARE OTHERS INCREASING
INVESTMENTS IN DATA SCIENCE AND
THOSE INCLUDE AFRICAN
GOVERNMENTS WHO ARE SUPPORTING
DATABASES FOR EXAMPLE, THE
PRIVATE SECTOR AND OTHER
FOUNDATIONS PARTICULARLY, THE
WELCOME TRUST AND THE GATES
FOUNDATION ARE SUPPORTIVE IN
THIS AREA.
AND THEN YOU SEE THE
OPPORTUNITIES THAT WE IESHES
DENTIFIED FOR STAGE 2 AND THE
PRIVATE SECTOR AGAIN, LOOKING AT
THAT SUSTAINABILITY IN THE NEXT
STAGE, COLLABORATIONS WITH OTHER
FUNDERS.
ENGAGING WITH THE AFRICAN
SCIENCE COUNCILS AND AFRICAN
OPEN SCIENCE PLATFORM AND THEN
AGAIN THE IMPORTANT
IDENTIFICATION OF OTHER
PARTNERSHIPS WITH
SUSTAINABILITY.
NEXT SLIDE.
SO WE SEE HERE SOME OF THE
FINDINGS THAT BRUCE TALKED ABOUT
AND THEN WERE TYING THEM TO
PLANS AND OPPORTUNITIES FOR
STAGE 2.
I MEAN CLEARLY, MORE TIME IS
NEEDED TO TRANSLATE SOME OF
THESE RESEARCH INTO HEALTH
OUTCOMES THAT THE DEMAND FOR
RESEARCH TRAINING YOU GAVE THE
PERSPECT EXAMPLES.
I DON'T THINK I NEED TO REPEAT
THEM, WAS FAR GREATER THAN THE
AVAILABLE DEGREE TRAINEES, SO
SCALING UP TRAINING ACTIVITIES
AND ALSO TRAINING OF THE TRAINER
TYPES ACTIVITIES, SO MORE PEOPLE
CAN BE REACHED.
THE ETHICS RESEARCH IS CRITICAL
FOR THE FIELD, WE HAVE A PACIFIC
SLIDE ON THAT AND I WILL TALK
ABOUT THAT.
THE IDEA THAT THIS FIELD AND
MOVING FOR FAST AND THAT FUNDING
MODELS REALLY CAN'T KEEP UP WITH
ADVANCES IN THIS FAST PACED
FIELD AND YOU WILL SEE OUR
PROPOSAL FOR A FLEXIBLE AND
ADAPTABLE STRATEGIC INVESTMENT
FUND AND THEN THE DAILY BASIS AT
ACCESS, OWNERSHIP AND MANAGEMENT
REMAIN CHALLENGING AND WE WILL
LIKE TO LOOK AT FUNDING FOR
EARLY STAGE DATA REPOSITORIES.
NEXT SLIDE.
SO LOOKING HERE AT PROGRAM GOALS
AND INITIATIVES, I WON'T SPEND A
LOT OF TIME ON THIS SLIDE, WE
WILL GO INTO SPECIFICALLY MAIN
LYE WHERE THINGS HAVE CHANGED.
WE HAVE HIGHLIGHTED IN PURPLE
WHERE THERE ARE CHANGES FROM
STAGE 1 AND AGAIN I'LL POINT
THESE OUT IN THE NEXT COUPLE
SLIDES.
NEXT SLIDE.
SO IN TERMS OF THE STAGE 2
INITIATIVES, THESE FIRST 2 WILL
REMAIN VERY SIMILAR TO WHAT YOU
SAW FOR STAGE 1.
IN TERMS OF RESEARCH, WE WILL
MAINTAIN THOSE RESEARCH HUBS AND
THOSE PARTNERSHIPS FOR
INNOVATION PROJECTS.
THERE WILL BE RECOMPETITIONS OR
CONTINUATION OF THESE THE
EMPHASIZE WILL BE ON TRANSLATION
OF THE DATA SCIENCE AND
SUSTAINABILITY THROUGH
PARTNERSHIPS AND EXPANDING
POSSIBLE RESEARCH AREAS TO
INCLUDE TECHNOLOGIES AND
APPROACHES.
AND THEN AGAIN THE CAPACITY
BUILDING WHICH I FEEL LIKE WE'VE
ALREADY EMPHASIZED AND TARGETING
A WIDER AUDIENCE AND SCALE THE
TRAINING.
NOW IN TERMS OF STAGE 2 WHERE WE
HAVE THE ETHICAL AND SOCIAL
IMPLICATIONS, WE'RE REALLY
FOCUSING ON THOSE 2 AREAS AND
LESS ON THE LEGAL IMPLICATIONS
OF THIS RESEARCH AND WE KNOW
THAT AGAIN, THERE ARE A LOT OF
HOT AREAS IN TERMS OF THE
ETHICAL AND SOCIAL IMPLICATIONS
OF AI FOR EXAMPLE.
WE THINK THIS WILL PROVIDE MORE
FLEXIBILITY, WE'RE GOING TO
DEEMPHASIZE THE LESS
GENERALIZABLE LEGAL IMPLICATIONS
RESEARCH, AND THEN THE RESEARCH
HUBS CAN INCORPORATE ACTIVITIES
TO UNDERSTAND PROJECTS SPECIFIC
LEGAL IMPLICATIONS.
NEXT SLIDE.
AND THEN IN TERMS OF THE
ECOSYSTEM, WE WOULD LIKE TO
EXPAND THE ELWASI OPEN DATA
SCIENCE PLATFORM BEYOND THE
RESEARCH HUB ANDS WORK MORE
TOWARDS A NETWORK.
AGAIN WE WOULD LIKE TO SCALE THE
OUTPUTS OF THE TRAINING PROGRAMS
AND AS I MENTIONED LOOK AT
TRAINING THE TRAINER PROGRAMS
AND BROADER DISSEMINATION OF THE
CURRICULUM.
AND THEN THIS IDEA ABOUT EARLY
STAGE DATA REPOSITORIES WE THINK
IS QUITE IMPORTANT.
THESE WILL BE MULTIDISCIPLINARY
RESOURCES, REEL RELEVANT TO MON
1 DISEASE OR SCIENTIFIC FOCUS
AND THERE WILL BE COUNTRY
SPECIFIC REGIONAL AND AFRICA LED
AND I THINK AGAIN, PRODUCE YOU
ECHICIZED NICELY THAT THE
RESEARCH COMMUNITY THERE IS
REALLY VERY ANXIOUS FOR DATA
FROM AFRICA, ON A LARGER SCALE
TO BE AVAILABLE TO THEM TO
ANSWER SPECIFIC QUESTIONS.
NEXT SLIDE.
IN TERMS OF THE STRATEGIC
INNOVATION FUND THIS, IS AGAIN
TO HELP WITH DAILY BASIS THEA
SCIENCE AND INNOVATIVE
TECHNOLOGIES, AGAIN, WE KNOW HOW
FAST THIS FIELD IS MOVING.
WHEN WE LOOK AT THE FUTURE AND
TRY TO BUILD A RESILIENT FUTURE
WE NEED TO BE ABLE TO ADAPT
QUICKLY EVEN IN AN ORGANIZATION
LIKE NIH.
WE WANT TO TACKLE EMERGING
ISSUES IN AFRICA WITH AFRICAN
ORGANIZATIONS, OTHER GLOBAL
FUNDERS, COMMERCIAL PARTNERS AND
PLANS WILL BE INFORMED BY
EXTERNAL CONSULTANTS AND WE'VE
JUST GIVEN A FEW EXAMPLES THERE,
PERHAPS A SERIES OF YOINT
CONVENINGS BETWEEN DATA SCIENCE
GROUPS FUNDERS, WORKSHOPS THAT
ADDRESS TRANSLATIONAL NEED ANDS
SUPPLEMENTAL FUNDING TO GRANTEES
TO NEW INNOVATIVE RESOURCES AND
TECHNOLOGIES AND I THINK THE
GENERATIVE AI WAS A GOOD EXAMPLE
OF SOMETHING THAT COULD POP UP
AND WE WOULD BE ABLE TO RESPOND
TO QUICKLY.
NEXT SLIDE.
I THINK I'M GETTING VERY NEAR
THE END BUT HERE ARE SOME OF OUR
ANTICIPATED IMPACTS.
I WON'T READ ALL THE WORDS ON
THIS SLIDE BUT REALLY LOOKING
FOR, YOU KNOW THESE RECK NASSED
CENTERS OF
EXCELLENCE--RECOGNIZED TRUSTEESS
OF EXCELLENCE, ADVANCES IN
POLICY, THIS WILL BE A
NIEWRKSNIQUE CONTINENTAL
NETWORK, WE'RE VERY PROUD OF
THAT.
AGAIN A SUSTAINABLE PLATFORM OF
INTERDISCIPLINARY AND SECTORAL
CLARERATIONS.
A DEMONITRATION OF FEASIBILITY
OF DATA CONSCIENCE INNOVATION TO
IMPROVE HEALTH IN AFRICA,
INCREASE CAPACITY FOR AFRICAN
APPROPRIATE TOOLS AND
APPLICATIONS.
PRODUCTS AND AGAIN LIKE THE
FIRST TIME AROUND, YOU KNOW
THERE ARE REQUIREMENTS ON MANY
OF THESE GRANTS FOR THE PRIVATE
SECTOR COLLABORATION AND THEN
NEW SCIENTIFIC KNOWLEDGE THAT
IMPROVES CLINICAL PRACTICE AND
HEALTH.
NEXT SLIDE.
SO HERE'S A LITTLE BIT ABOUT THE
OVERALL BUDGET AND TIMELINE.
WE'RE ASKING JUST OVER
95 MILLION OVER 5 YEARS.
THE TAIJ CONCOMMON FUND BUDGET
WAS ABOUT 73 MILL WHEREON AND
THEN 88 MILLION TOTAL WHEN WE
LOOK AT CONTRIBUTIONS FROM OTHER
INSTITUTES AND CENTERS, THE
INCREASE COST STEM FROM REQUESTS
FOR AN ADDITIONAL RESEARCH HUB,
AN ADDITIONAL TRAINING PROGRAM,
THE EXTENSION OF PARTNERSHIP AND
THE RESEARCH EDUCATION PROGRAMS
FROM 3-5 YEARS.
THE 4 EARLY STAGE DATA
REPOSITORIES AND THEN THIS
STRATEGE INCREASE IN BODY
INNOVATION FUND.
AND THEN IF YOU LOOK THERE, AT
THE TIMELINE OF WHEN STAGE 1
ENDS AND STAGE 2 BEGINS, THERE
COULD BE A GAP OF 3-4 MONTHS AND
WE WOULD DEAL WITH THIS THROUGH
NO COST EXTENSIONS AS ABLE AND
NECESSARY.
NEXT SLIDE.
SO I THINK IN THE INTEREST OF
TIME, WE WOULD RATHER HEAR FROM
YOU, BUT THIS IS JUST TO SHOW
YOU THE COMMON FUND CRITERIA,
AND WE BELIEVE THAT THIS PROJECT
REALLY ADDRESSES IN A VERY
GRANULAR WAY EACH OF THESE
CRITERIA, BEING GOAL DRIVEN AND
NOVEL AND TRANSFORMATIVE.
WE'VE SHOWN YOU HOW IT'S BEEN
CATALYTIC AND SYNERGISTIC EMPLOY
NEXT SLIDE.
SO WE WOULD LIKE TO STOP HERE,
ADDRESS ANY QUESTIONS AND
HOPEFULLY VOTE FOR APPROVAL OF
THE CONCEPT.
THANK YOU FOR YOUR ATTENTION.
>> GREAT.
THANK YOU VERY MUCH CATHY AND TO
YOU BRUCE, TOO.
I WILL ADD BEFORE WE TURN IT
OVER TO KRISTIN AND RAFAEL, I
HAPPEN TO BE IN CAPE TOWN FOR A
MEETING A FEW MONTHS AGO OR LATE
LAST YEAR AND WAS ABLE TO KIND
OF AS A SIDE DO A SITE VISIT
WITH THE UNIVERSITY OF CAPE TOWN
AND GOT TO LEARN ALL ABOUT THE
WORK THEY'RE DOING AT DS-I
AFRICA AND IT WAS SO IMPRESSIVE
AND THE AMOUNT OF COORDINATION
AND COLLABORATION THEY HAVE
GARNERED ACROSS THE CONTINENT
HAS BEEN I THINK IMMENSELY
IMPACTFUL FOR THE DATA SCIENCE
COMMUNITY THERE.
AND I JUST FELT LIKE THERE WAS
SO MUCH I COULD LEARN FROM THEM
BECAUSE THEY'RE DOING THIS
ACROSS SO MANY DIFFERENT
COUNTRIES AND WE'RE STRUGGLING
WITH SOME OF THE SAME ISSUES
ACROSS THE UNITED STATES WITH
OUR DIFFERENTITATES AND
DIFFERENT--SOME OF THE SAME BUT
DIFFERENT CHALLENGES SO I JUST
WANTED TO ECHO THAT SORT OF
PERSONAL EXPERIENCE I HAVE AND
INTERACTING WITH THEM BUT LET ME
TURN IT OVER TO KRISTIN FIRST TO
SAY A FEW WORDS AND LEAD
DISCUSSION AND THEN RAFAEL.
>> THANK YOU.
I KNOW THAT OUR GOAL HERE IS TO
SORT OF MAKE STATEMENTS AS TO
WHETHER WE'RE GOING TO APPROVE
THE CONCEPT AND I WILL START AT
THE END AND SAY, YES OF COURSE I
APPROVE IT BECAUSE I CAN'T SEE
THAT THERE'S NO POINT STOPPING
IT NOW.
IT'S DOING GREAT WORK.
IT'S THE RIGHT THING TO BE DOING
BUT WITH THAT IN MIND AND I FIND
THOSE HARD TO ADDRESS AND I'VE
BEEN LOOKING AT THE VARIOUS
WEBSITES, MY BIG CONCERNS ARE 3,
BY BIGGEST 1 IS SUSTAINABILITY,
LARRY BROUGHT THAT UP AS A BIG
NIH GOAL AND I REALLY, REALLY
WORRIED ABOUT IT HERE.
I'M PARTICULARLY WORRIED WHEN
YOU NOTE THAT THE NIH IS THE
BIGGEST FUNDER AND THAT CAN'T
CONTINUE IN PERPETUITY BUT I
DON'T KNOW THE STRUCTURALLY ARE
OF THESE ASHES WARDS BUT I THINK
IT'S IMPORTANT THEY WORK ON
LONG-TERM AND I'M PARTICULARRED
WORRIED ABOUT SUSTAINABILITY OF
THESE DATA THAT YOU KNOW THE BIG
DATA, OPEN DATA PORTAL OR EACH
THE NEW DATA THAT THIS, WE'RE
HAVING 4 NEW DATA REPOSITORIES,
I DON'T KNOW WHAT THEY WILL BE
BUT I KNOW THAT WE'RE ALREADY
STRUGGLING WITH THESE THINGS
OURSELVES, THE ELWASI DATA
PORTAL, YOU PROUDLY SAID HAS
CONNECTIONS TO 2 BIG DATA PLACES
THAT I KNOW FIRST HAND OR
STRUGGLING RIGHT NOW THEMSELVES.
SO THIS IS A BIG ISSUE.
HOW DO WE KEEP THESE GOING?
AND HOW DO WE KEEP IT GOING IN
MULTIPLE COUNTRIES WITHIN THE
SUSTAINED FUNDING THAT THE NIH
CAN'T AFFORD TO PUT IN FOREVER
AND EVER.
I DO THINK THAT THE TRAINING
ASSPEBT IS KEY AND YOU
HIGHLIGHTED THAT THE DEMAND IS
THERE AND I THINK THAT IS VERY,
VERY VALUABLE PART OF THE
PROGRAM.
I THINK THE LONGER TERM TRAINING
OF INDIVIDUALS IS PROBABLY MORE
FRUITFUL BECAUSE IT GIVES THEP
BETTER INSIGHTS THEMSELVES INTO
WHAT IS NEEDED WITH DATA, WHAT
THE INFRASTRUCTURE IS, I THINK
THE SHORT-TERM COSTS ARE FEIGN
BUT I THINK THE LONGER TERM 1S
ARE THE BETTER INVESTMENT IN
LONGER TOMORROW SUSTAINABILITY
AND UNDERSTAND BEING OF
REQUIREMENTS.
I THINK THE SHORT COURSE IS
ACTUALLY A PERFECT PLACE FOR THE
OPEN DATA SCIENCE PLATFORM.
I'M A LITTLE BIT CRITICAL OF
THAT IN THAT I SEE IT'S SIMILAR
TO 1S THAT I'M CRITICAL THAT I'M
ENGAINLED WITH MYSELF.
FIRSTLY CAN I CAN THAT IF WE'RE
GOING TO MAKE SOMETHING FAIR,
FINDABLE, EXESESSIBLE,
INTEROPERABLE AND SO ON, THAT WE
STOP USING ACRONYMS, I'VE BEEN
PLAYING ON ELWASI AND THERE ARE
16 DIFFERENT ACONKRIMS FOR THESE
PROGEC ANDS I DON'T KNOW WHAT
THEY ARE.
HONEST LOAMACYY I'M ENGAGED IN
THE COMMON FUND ECOSYSTEM AND MY
BIGGEST COMPLAINT IN THE MY
OPENING REMARKS ENGAGEMENT THERE
CAN THAT THE COMMON FUND IS
SIMILAR BUT VERY DIVERSE,
DIFFERENT PRONL ECTOMYOSINS AND
IT'S HARD TO FIND OUT WHAT THEY
ARE AND MA THEY DO.
AND PLAYING AROUND WITH SOME OF
THESE IDEALLY IT SHOULD BE A
PLACE WHERE SOME OF THOSE
TRAINING COURSES CAN BE ASA
OPPOSE TO BIG KNOWLEDGE
DEVELOPMENT BECAUSE PEOPLE NEED
TO DEVELOP THEIR OWN KNOWLEDGE
AND NEED ACCESS TO THE DATA SO
AS A PLACE WHERE THEY CAN GO AND
FIND OUT WHAT THESE PROJECTS
DID, WHAT THE DATA ARE AND WHERE
IS IT?
I DID CLICK THROUGH SEVERAL
DOWNLOADS, SEVERAL--I DID FIND 1
SET OF DATA THAT SAID IT WAS
AVAILABLE AND THE LOCATION IT
GAVE WAS AZURE.
I THOUGHT THAT DOESN'T HELP ME
IF I'M A SCIENTISTS WHO WANTS TO
GET TO THAT DAT. DATA.
SO I THINK THATIA A REALLY
IMPORTANT INFORMATION OF THAT
PLATFORM ABOVE AND BEYOND
ANYTHING ELSE SO PEOPLE CAN
UNDERSTAND WHAT'S THERE AND
WHERE TO GO AND FIND IT.
AND AS I SAID I WOULD LIKE TO
KNOW MORE ABOUT WHAT THESE 4 AT
THAT TIMA PLATFORMS ARE, WHERE
THEY'RE GOING TO BE, HOW THEY'RE
SUSTAINED, WHAT I THAT ARE,
BECAUSE I THINK THEREYA A REAL
PROBLEM WITH SUSTAINABILITY IN
GENERAL.
>> I DON'T KNOW HOW MUCH TIME WE
HAVE FOR SPECIFIC RESPONSE SO
YOU CAN TELL ME, I KNOW SOME
PEOPLE ARE CATCHING PLANES, I
CAN MAKE A COUPLE QUICK
COMMENTS.
FIRST OF ALL, THANK YOU.
I MEAN WE REALLY APPRECIATE YOUR
CLOSE REVIEW, WE REALLY
APPRECIATE YOUR VERY SPECIFIC,
SOME OF WHICH ARE ACTIONABLE,
SOME OF WHICH ARE GOING TO BE
HARDER AND LAURA I'M TRUSTING
YOU AND OTHERS HAVE REALLY TAKEN
THESE DOWN.
YOU KNOW THE ISSUE OF
SUSTAINABILITY IS A VERY
DIFFICULT 1.
AND PARTICULARLY IN AFRICA AND
THERE IS GOING TO HAVE TO BE
AFRICAN OWNERSHIP AND THERE WILL
HAVE TO BE COOPERATION EMPLOY
YOU KNOW WE DEAL WITH EVERY DAY
EMPLOY I SPENT THE FIRST 2 HOURS
OF MY MORNING ON CALLS WITH
PEOPLE ACROSS THE WORLD ON MPOX,
RIGHT?
AFRICA'S DEALING WITH RECORD
POPULATION DISPLACEMENT.
THEY ARE DEALING WITH CONFLICT.
THEY ARE DEALING WITH 1 OUTBREAK
AFTER THE OTHER AND THE
SOLUTIONS ARE GOING TO BE THESE
MEDIUM AND LONG-TERM INVEST AMS,
THEY HAVE TO BE.
US REACTING TO EVERY PROBLEM IN
AFRICA WILL NOT SOLVE THE
PROBLEM.
SO I THINK THERE HAS TO BE A LOT
OF POLITICAL WILL INVOLVED HERE,
RIGHT?
IN ENSURING THERE IS
SUSTAINABILITY AND IT WILL HAVE
TO BE GOVERNMENTS AND
MULTILATERAL DONORS AND MANY
OTHER BIG FUNDERS THAT WE TALKED
ABOUT.
AND IT'S GOING TO BE TOUGH.
RIGHT BEFORE I CAME HERE MEANT
WITH SENATOR REED FROM ROAD
ISLAND AND I TOLD HIM THE SAME
THING, I SAID WE CANNOT KEEP
MAKING SHORT-TERM INVESTMENTS IN
AFRICA OR WE WILL NOT GET
ANYWHERE.
>> SO ADDING TO THAT, FIRST,
YOUR COMMENTS ARE SPOT-ON.
THANK YOU AND WE FEEL THAT
GRAPPLING WITH THESE ISSUES NOW
AS WE ARE ALL A GLOBAL COMMUNITY
ARE GRAPPLING WITH THE SAME
ISSUE ANDS PROVIDING TRAINING
AND EDUCATION PROGRAMS AND
BUILDING STAKEHOLDERS THROUGHOUT
AFRICA, WE OF COURSE WE DON'T
HAVE THE SOLUTION, THE ANSWERS
BUT WE'RE COLLECTIVELY GOING
THROUGH THIS PROCESS AND TRYING
OUT DIFFERENT APPROACHES AND
DIFFERENT COMMUNITIES.
SO WE CAN INTRODUCE SOME OF
THOSE MORE OR LESS SUCCESSFUL
APPROACHES.
PEOPLE CAN LEARN AND APPRECIATE
NOT JUST THE TECHNOLOGY
INNOVATION ASPECTS BUT THE
PROCESS, THE STRUCTURAL
INNOVATION THATNYS TO TAKE PLACE
BECAUSE WE DON'T HAVE THE
ANSWERS, SO IT'S KIND OF LIKE
DERIVING THAT TOGETHER.
BUT FOR SURE, YOU KNOW THESE ARE
REALLY THE PRIMARY CONCERNS THAT
WE HAVE, YOU KNOW SUBSEQUENT AND
GOING FORWARD.
ON THE EDUCATION, THERE'S JUST 1
QUICK THOUGHT, YOU KNOW AS WE IN
THE TECHNICAL FIELDS, YOU KNOW
THOSE OF US WHO KNOW LINEAR
ALGEBRA LOOK AT AI DIFFERENTLY
THAN PEOPLE WHO DON'T, BUT MOST
PEOPLE DON'T KNOW LEANIAR
ALGEBRA, THEY'RE THE USERS OF
AI, HOW DO WE DEAL WITH PEOPLE
WHO WANT TO USE IT AND APPLY IT
RESPONSIBLY AND ETHICALLY AND
THAT'S 1 SORT OF NEARBY FOR
THESE EDUCATIONAL APPROACHES.
WE DON'T HAVE TO TEACH EVERYONE
INIAR ALIME BRACHYTHERAPY BUT WE
DO NEED TO UNDERSTAND PIT PAULS,
ADVANTAGES AND CONNECT WITH THE
COMMUNITY TO MAKE SURE YOUR AI
APPROACHES ARE ETHICAL, USEFUL
AND GETTING TO TRUE SOLUTIONS
RATHER THAN FALSE OR
HALLUCINATIONS IN AI THAT CAN
LEAD TOCCATA STROPHIC CONQUENCES
DEPENDING ON THE RISK, SO I
THINK THERE'S A LITTLE NEECH FOR
SOME OF THOSE BUT NOT ALL THE
VERGS ARE AS GOOD.
>> RAFAEL?
>> THANKS.
SO I HAD THE SAME CONCERN, MAYBE
BIGGER.
I THINK--SO I READ THROUGH THE
PROGRAMS AND THERE'S SOME REALLY
GOOD PROJECTS THERE THAT ARE
LIKE THE SPECIFIC 1S, THE
TRAINING 1S ARE BY FAR THE 1S I
WOULD MOST SUPPORT OF THE THE
SPECIFIC PROGECS THAT
INVESTIGATORS ARE DEVELOPING,
SAME THING BUT THE COORDINATIO,
BUILDING OF DATABASES, I THOUGHT
THAT WAS NOT WELL DEFENDED AND
IT DOESN'T--IT CONCERNS ME THAT
WE'RE GOING TO FUND, THERE'S
VERY, VERY LITTLE FUNDING WITH A
CONTINENT WITH 1.4 BILLION
PEOPLE AND 54 COUNTRIES, I DON'T
THINK IT'S GOING TO WORK SO I
DON'T KNOW IF THAT'S THE BEST
USE OF FUNDING.
I THINK IT WOULD BE MUCH BETTER
TO PUT IT IN TRAINING PROGRAM
ANDS SPECIFIC PI-DRIVEN
PROGGENTS.
NOW MAYBE THERE COULD BE PEOPLE
SHARE AND LEARN FROM EACH OTHER
BUT THAT DATABASE, I WENT
THROUGH IT FOR SEVERAL MINUTES I
COULDN'T FIND A SINGLE USEFUL
DATA SET.
SO AGAIN, THERE'S LIKE 2 KINDS
OF PARTNERS TO THIS AND THE
SPECIFIC--SAY IT AGAIN, THE
SPECIFIC TRAINING PROGRAMS, THE
SPECIFIC PROJECTS THAT ARE
ATTACKING SPECIFIC PROBLEMS,
THEY ALL SEEM GREAT AND WE
SHOULD FUND THEM BUT THE BIGGER
THINGS ARE THE CORDINATION AND
COMBIN AGZ OF AT THAT TIMA BASE
AND CREATING ECHO WHATEVER THIS
OR THAT AND EVEN THE USE OF THE
TERM DATA SCIENCE.
I MEAN THIS CASE DOESN'T SEEM
APPROPRIATE.
IT LOOKS LIKE WE SHOULD BE
FUNDING BIOAT THAT TIMISTICS
TRAINING, EPIDEMIOLOGY, COHORT
STUDIES, DEVELOPING OF PUBLIC
HEALTH DATABASES, THIS IS A VERY
SPECIFIC THING THAT THEY WILL BE
FUNDING.
USING THE TERM DATA SCIENCE
MAKES IT VAGUE AND HARD TO
UNDERSTAND EXACTLY WHAT THE BIG
PICTURE IS, SO MY SUGGESTION
WOULD BE TO COME BACK WITH
A--WITH A NEW PROPOSAL THAT JUST
GOES AND IS VERY SPECIFIC AND
TELLS US ABOUT HOW WE'RE GOING
TO FUND SPECIFIC PROJECTS AND
MAYBE NOT EITHER ABANDON THE
IDEA OF HAVING THESE BIG
COORDINATION INIAATIVE OR
JUSTIFYING A LITTLE BIT BETTER.
THAT'S MY SUGGESTION.
NAGAIN, I CAN COMMENT MORE FROM
MY EXPERIENCE WITH WORKING ON
LARGE PROJECTS AND AFRICA AND
YOU CAN PROBABLY COMMENT MORE ON
THE CAPACITY OF SO MANY
COUNTRIES IN AFRICA, IS SO LOW,
THAT WE'RE NOT GOING TO GET
THERE IN 5 YEARS.
SO CREATING THESE HUBS, AND
CREATING THESE NETWORKS AND
CREATING THESE SOUTH TO SOUTH
COLLABORATIONS IS GOING TO GIVE
US A BETTER CHANCE AT
SUSTAINABILITY AND WE SEE SOUTH
AFRICA IN PARTICULAR AS HAVING
BEEN A LEADER IN AFRICA ON OTHER
FRONTS WITH RECOGNITION OF
COVID, THE GENOMIC SURVEILLANCE
FOR COVID, ET CETERA.
SO, AGAIN, THAT IS MY VIEW
ALTHOUGH I TAKE VERY SERIOUSLY
YOUR SPECIFIC SUGGESTIONS AND I
THINK THERE ARE ABSOLUTELY WAYS
THAT WE CAN LOOK TO IMPROVE THIS
BUT I SEE THE NETWORKS AND THE
COORDINATION AS ACTUALLY BEING
QUITE IMPORTANT FOR AFRICA.
NTHANKS, CATHY AND I WOULD ADD
FROM A DATA SCIENCE PERSPECTIVE,
IT CERTAINLY LOOKS DIFFERENTLY
THROUGH DIFFERENT PEOPLE'S EYES
OF COURSE AND IT'S VERY HARD TO
DRIVE FORWARD AN INITIATIVE
THAT'S TRAINING FOLKS IN THESE
TECHNICAL AREAS WITHOUT GIVING
THEM AN AREA TO CONSTRUCT
DATABASES AND QUERY THEM AND
DEVELOP TOOLS SO WE SEE THAT
ASENTIOUS SENTIAL AND CERTAINLY
ELWASI IS UNFINISHED PRODUCT BUT
THIS IS SORT OF A CRITICAL
MOMENT TO PUT THE PRESSURE ON IT
TO MAKE DATA REPOSITORY AND AI
DEVELOPMENT DISCOVERY VALIDATION
METHODS REAL WORKING FOR PEOPLE
ON AFRICAN DATA SETS.
SO HAVING THAT ASPIRATIONAL GOAL
OVER THE NEXT 5 YEARS IS REALLY
CRITICAL AND IF WE DON'T HAVE
THE PATHWAYS FOR PEOPLE TO
REALLY ENGAGE IN THAT, I MEAN,
MY VIEW OF THE DATA SET THAT IS
A PERFECT REPOSITORY AND IS
STRUCTURED TO GIVE REALLY HIGH
PERFORMING ALGORITHMS AS AN
OUTPUT IS REALLY DIFFERENT FROM
MY COLLEAGUES ALL ACROSS THE
NIH, SO, YOU KNOW THERE IS
DIVERSITY IN THE IMPRESSION AND
UNDERSTANDING OF THESE.
I ATBREE WITH YOU AND YOUR
CRITICISMS ABOUT THEIR STRUCTURE
CURRENTLY BUT WE HOPE TO REALLY
PUT A LOT OF RESOURCES, THOUGHT,
DISCUSSION AND PRESSURE AND
PEOPLE INTO MAKING IT X, SO
THAT'S KIND OF--
>> SO LET ME GIVE YOU A SPECIFIC
EXAMPLE, SO YOU CAN FIND THE
DATA, CREATION OF A DATABASE FOR
STORING DENATIONAL LIBRARY OF
MEDICINICS OF COVID OR SOME
OTHER INFECTIOUS DEC, RIGHT?
THAT'S VERY SPECIFIC.
IT CAN KEEP GOING AFTER WE STOP
FUNDING IT BECAUSE IT'S BUILT.
YOU COULD BUILD THE DATABASE FOR
HOSPITALS TO REPORT INFECTIOUS
DISEASE CASES THAT WOULD BE
BUILT GOING FORWARD BUT LIKE A
DATA REPOSITORY WHERE EVERYBODY
COME MISS AND THERE HAS TO BE
ALL THIS ACTIVITY, IF NIH STOPS
FUNDING THAT, THAT'S IT, IT
DOESN'T EXIST ANYMORE, SO THAT'S
WHY I'M VERY CONCERNED ABOUT
THESE BIG, BIG PICTURE PROJECTS
THAT IF THE FUNDING GOES AWAY,
IT JUST DISAPPEARS AND PEOPLE
THAT DEPEND ON IT NOW CAN'T USE
IT ANYMORE AS OPPOSE TO TRAINING
PROGRAMS ONCE YOU HAVE THEM, YOU
CAP THEM, SCIENTIFIC DISCOVERIES
ONCE YOU MAKE THEM, YOU'VE MADE
THEM, THEY AT A--THEY AT A WITH
US.
THATYA MY MAIN SUGGESTION.
>> I THINK THE SUSTAINABILITY
QUESTION IS A BIG ISSUE IS
SOMETHING WE DISCUSSED WHEN
THEY'RE PRESENTING THIS TO ME A
WHILE BACK.
I KNOW THAT AND I THINK CATHY
MIGHT HAVE TOUCHED ON THIS A BIT
AND I KNOW THEY'VE BEEN IN
DISCUSSIONS WITH VARIOUS FOLKS
ACROSS THE CONTINENT TO TRY TO
ENCOURAGE ADDITIONAL INVESTMENT
AND I'LL USE THAT WORD LOOSELY,
SO IT'S NOT JUST MONEY BUT
INVESTMENT BY THE VARIOUS
DIFFERENT COUNTRIES TO MAKE SURE
THERE IS STILL SOME
SUSTAINABILITY HERE GOING
FORWARD AND THEN SOMETHING THAT
THEY'RE GOING TO SPEND SOMETIME
ON OVER THE NEXT SEVERAL YEARS,
MOVING FORWARD INTO STAGE 2,
THAT'S THE PLAN TO REALLY WORK
AND BUILD THAT OUT FURTHER SO
THERE AREN'T THOSE CLIFFS THAT
BOTH OF YOU HAVE MENTIONED.
LAURA?
>> I JUST WANT TO MENTION REAL
QUICKLY, SO THE ELWASI TEAM IS
WORKING IN CLOSE COLLABORATION
WITH THE AFRICAN OPEN SCIENCE
PLATFORM WHICH IS A INITIATIVE
OUT OF THE THE SOUTH AFRICA AN
GOVERNMENT, BUT IN COLLABORATION
WITH OTHER COUNTRIES ACROSS THE
CONTINENT AND IT MEETS THEIR
GOALS TO MAKE AFRICAN DATA SETS
MORE FINDABLE AND ACCESSIBLE AND
FINDING OUT HOW THEY CAN
INTEGRATE THE PLATFORM TO WHAT
THEY'RE WORKING ON EVEN BEYOND
OUR DSI AFRICA PROGRAM.
SO 1 EXAMPLE OF HOW OUR GRANTEES
THEMSELVES ARE WORK THINKING
ABOUT THE SUSTAINABILITY ISSUE
THAT THE SOUTH AFRICAN TEAM THAT
MEANS THAT PLATFORM IS ON THEIR
SCIENTIFIC ADVISORY BOARD.
SO, JUST WANTED TO MENTION THAT.
THANK YOU.
NGREAT.
THANKS.
ANYTHING ELSE OR CAN WE OPEN IT
UP FOR--
>> THIS IS UNRELATED THE
SCHEDULE BUT I PLANNED MY
SCHEDULE BASED ON THE 12:35
AYOWRN AM.
>> SO MARIA YOUR QUESTION
QUICKLY AND THEN I WILL RUN
THROUGH SOME STUFF FOR THE VOTE.
>> SO I WAS VERY INTERESTED IN
UNDERSTANDING THE GENDER BREAK
DOWN FOR THOSE INDIVIDUALS WHO
HAVE BEEN TRAINED AND I WOULD
LIKE TO UNDERSTAND WHAT'S--WHAT
THE DEMOGRAPH ICsS OF THE
TRAINING PROGRAM.
>> YEAH, SO I ACTUALLY MANAGE
ALL THE TRAINING PROGRAMS IN DSI
AFRICA AND GENDER--INCLUES OF
WOMEN IN DATA SCIENCE, I THINK
IS SOMETHING THAT I CARE ABOUT
AND SOMETHING THAT ALL OF THE
PIs LEADING THESE PROGRAMS
ALSO CARE ABOUT AND SO, WE SEE,
I DON'T HAVE A SPECIFIC
PERCENTAGE FOR YOU BUT ALL OF
THE PROGRAMS HAVE SATISFILY MET
LIKE OUR CRITERIA OF MAKING SURE
THEY HAVE RECRUITMENT STRATEGIES
THAT TARGET BOTH GENDERS AND
THAT THEY ARE SERIOUS ABOUT
HAVING GENDER EQUITY WITHIN
THEIR PROGRAMS.
IN CERTAIN COUNTRIES, IT'S
HARDER THAN OTHERS BUT IT'S
SOMETHING THAT THEY'RE ALL
WORKING ON.
NYEAH, I THINK THAT WAS
PURPOSELY COVERED.
I MEAN NOT PRESENTED BECAUSE I
WOULD IMAGINE THERE'S PROBABLY
LESS WOMEN BEING TRAINED RIGHT
NOW WHILE YOU MIGHT HAVE
RECRUITMENT EFFORTS, I WOULD
LOVE IT TO BE MORE COGNIZANT AND
TRANSPARENT ON ACTUALLY WHO'S
GETTING, BECAUSE WE'RE CLEARLY
DEALING WITH A SOCIETY THAT
DOESN'T VALUE WOMEN TO BE
EDUCATED AND ALL OF NIH HAS BEEN
TRYING TO INCREASE DIVERSITY
ESPECIALLY IN NEEZ FIELDS AND I
THINK WE NEED TO BE SUPPORTIVE
OF THAT NAND WE COULD CERTAINLY
MAKE SURE STATISTICS WITH YOU
AFTER THIS, IF YOU WOULD BE
INTERESTED.
THANKS.
NGENE, MONICA AND KENT BUT I
KNOW WE HAVE LIKE 92ndS LEFT.
>> QUICK.
NIBASHING IB, I WANT TO SAY
THAT'S [INDISCERNIBLE], I SAY IT
ALL THE TIME, BUT LINEAR
ALGERONTOLOGYSTS IS A GOOD THING
TO DO MY POINT IS THERE ARE LOTS
OF PEOPLE THAT WILL HELP YOU
WITH THIS.
SO SOCIETY OF NEUROSCIENCE AND
AFRICA, SONNA, INTERNATIONAL
BRAIN RESEARCH ORGANIZATION, AND
IT STARTED NEUROSCIENCE AROUND
THE WORLD MAINLY IN AFRICA, WE
CAN'T HELP IT AND LOOK TO
ORGANIZATIONS TO HELP YOU GET
THIS GOING.
ONE OF THE THINGS YOU SAID AND I
WANT TO SAY IT OUTLOUD AGAIN AND
HIGHLIGHT IT THAT THEY WERE
AHEAD OF US ON CHAT BOXES.
LET ME JUST SAY, I AM TOTALLY
IMPRESSED AND EXCITED WHEN WE GO
TO AFRICA AND THINK THEY DON'T
ANYONE ANYTHING ABOUT THIS FIELD
AND THEY COME UP WITH SOMETHING
THAT WE HAVEN'T COME UP AND
THEY'RE LIKE WE'RE DOING THIS,
SO TRAINING FOR THEM THEY TAKE
IT SO SERIOUSLY AND THAT'S WHY
YOU HAVE SO MANY APPLICATIONS
AND IF WE EDUCATE THEM INSTEAD
OF GIVING THEM A FISH, WE ARE
TEACHING THEM HOW TO MAKE A
FISH, CATCH THE FISH, WE'RE ON
THE RIGHT PATH AND I UNDERSTAND
SUSTAINABILITY, I AM TOTALLY
THERE BUTIME SAYING THERE ARE
LOTS OF ORGANIZATIONS THAT ARE
WILLING TO HELP YOU, WORK IN
AFRICA, GOING BACK THERE IN
2025, HAVING OUR MEET NOTHING
MOROCCO O IN APRIL, COME, ASK
US, TELL US WHAT YOU NEED FROM
US.
>> YEAH, THANK YOU SO MUCH FOR
COMMENTS, I AM ASTOUNDED BY THE
THINGS DONE FIRST IN AFRICA AND
WE CAN'T GET OUR--WE CAN'T
AGREE.
WE JUST KEEP ARGUING FOR SOME OF
THOSE L-ISSUES IN THE ELSWASI,
AND THANK YOU FOR THE OFFER OF
PARTNERS.
NMONICA QUICKLY.
>> I WANT TO SAY I THINK
SUSTAINABILITY BECAUSE HIV WORKS
A LOT IN AFFRIC ATHERE IS SOME
FUNDAMENTAL SYSTEM THAT COMES
WITH INVESTMENT THERE,
ESPECIALLY IN SOUTH AFRICA WHICH
IS, YOU KNOW MITTS INCOME AND
DOES CONTINUE INITIATIVES SO I'M
NOT AS WORRIED ABOUT THAT AND I
WOULD SAY THAT TRAINING IS, LIKE
YOU SAID IT'S THE FOGARTY
TRAINING CENTER THAT ALLOWS FOR
SUSTAINABILITY BECAUSE WITH VERY
LITTLE YOU CAN DO A LOT AFTER
YOU'VE BEEN TRAINED SO LIKE ANY
AFRICA BASED INITIATIVE, THANK
YOU.
>> KENT, FINAL WORD.
>> IF THIS CONCEPT IS NOT
APPROVED AT THIS MEETING CHA IS
THE LATEST TO BE APPROVED AND
INSURE IT DID NOT DISRUPT
FUNDING INTO STAGE 2 SO THERE'S
NOENTIOUS RUPGZ IN FUNDING?
>> I THINK THAT'S A GOOD
QUESTION AND GREAT SEGUE
SPONTANEOUS ACTIVITY WHAT WE
WERE TRYING TO DISCUSS HERE
BEHIND THE SCENES.
WE ARE GOING TO--I'M GOING TO
PROPOSE WE BRING THIS BACK IN
FEBRUARY BECAUSE I DON'T WANT
THE DISQUUGZ OF THIS TO BE
RUSHED AND GIIVE THAT YOU YOU
KNOW WE'RE AT THE END OF THE
DAY.
SO I THINK WE WILL PLAN TO BRING
IT BACK AND WE WILL DO THE VOTE
THEN AND I'VE BEEN ASSURED THAT
THE TIMING OF THAT SHOULD BE
FINE FOR THE PROGRAM.
SO THAT'S JUST 1 THING
N[INDISCERNIBLE].
NGREAT.
YEAH.
THAT WOULD BE GREAT.
IF YOU COULD SEND THAT.
OKAY, JUST VERY, VERY QUICKLY IF
WE REQUEST GO TO THE NEXT SLIDE.
THANK YOU SO MUCH CATHY AND
BRUCE.
WE WILL MAYBE SEE YOU OR AT
LEAST YOUR COLLEAGUES BACK IN
FEBRUARY.
WE WILL BE IN TOUCH AGAIN ON
THAT.
ALL RIGHT, SO JUST QUICKLY
BECAUSE THERE WAS 1 THING WE
WANTED TO GET TOO BEFORE THE
END, JUST VERY BRIEFLY, WE'LL
SEND THE SLIDE AROUND, I WAS
GOING TO GO THROUGH SOME OF
THINGS WE'VE HEARD AND HAD
DISCUSSIONS ON TODAY BUT I DON'T
WANT TO BE THE REASON THAT SOME
FOLKS ARE HAVING TO RUN THROUGH
THE AIRPORT.
SO, WE'LL SEND THIS AROUND TO
YOU ALL FOR FURTHER REVIEW, BUT
JUST NOTE THAT WE'VE HEARD THE
DISCUSSION, IT'S BEEN REALLY,
REALLY FRUITFUL AND WE HAVE A
FEW ACTION ITEMS THAT WE WILL
TAKE AWAY.
AND A REMINDER THE NEXT COUNCIL
MEETING IS IN FEBRUARY, IF WE
CAN GO TO THE NEXT SLIDE QUICKLY
BECAUSE WE HAD YOU ALL VOTE ON
WHAT YOU WANTED TO DO IN TERPS
OF MEETINGS IN PERSON-VERSUS
NOT, CAN WE GO TO THE NEXT
SLIDE, PLEASE.
THERE WE GO, CAN WE SEE THE
RESULTS SO WHETHER OR NOT WE
WANT TO HAVE THESE IN PERSON
TWICE A YEAR, THE ANSWER IS
DEFINITELY YES, SOPHISTICATED IF
YOU CAN GO TO THE NEXT SLIDE AND
IT LOOKS LIKE SEPTEMBER AND MAY
WERE THE TIME PERIODS YOU VOTED
ON SO WE WILL MAKE PLANS
ACCORDING 3 SO NOTE THAT
FEBRUARY WILL BE VIRTUAL, AND
THEN WE WILL HAVE THE NEXT 1 IN
MAY IN PERSON AND WE WILL KEEP
THAT CADENCE, THAT SORT OF, I IT
THE 2/3RDS RULE, 2/3RDS IN
PERSON, 1 VIRTUAL.
AND RAFAEL IF YOU WANT TO OUT,
YOU ARE WELCOME, YOU MIGHT LIKE
TO SEE THE PICTURE, WE WILL POST
THIS ON THE WEBSITE, THIS IS
KNOW WOOF THE GREAT VALUES OF
BEING IN PERSON AND OF COURSE,
WE PROBABLY WON'T BE POSTING
THIS 1 BUT I WANTED YOU TO SEE
IT.
SO, WITH THAT,--[LAUGHTER]
RIGHT.
WELL WITH THAT THANK YOU ALL SO,
SO, MUCH AGAIN WE HAD SUCH A--I
THINK REALLY, REALLY RICH
DISCUSSIONS FOR THIS TIME
PERIOD.
HAVE A SAFE TRIP BACK FOR
EVERYONE AND OH YES, OH THANK
YOU ALL SO MUCH FOR THOSE WHO
ARE ROTATING OFF, WE APPRECIATED
YOUR SERVICE!
AND I WILL GAVEL US OUT.
SO THANK YOU ALL.
THANKS KENT AND KAREN FOR BEING
ONLINE.